<data>
<row _id="1"><id>1</id><FinancialYear>2011/12</FinancialYear><HBT>S92000003</HBT><HBTQF>d</HBTQF><Laboratory>Scotland</Laboratory><LaboratoryQF>d</LaboratoryQF><Results>Total number of smears</Results><ResultsQF>d</ResultsQF><NumberResult>408838</NumberResult><PercentageResult>100</PercentageResult></row>
<row _id="2"><id>2</id><FinancialYear>2011/12</FinancialYear><HBT>S92000003</HBT><HBTQF>d</HBTQF><Laboratory>Scotland</Laboratory><LaboratoryQF>d</LaboratoryQF><Results>Unsatisfactory</Results><ResultsQF /><NumberResult>9980</NumberResult><PercentageResult>2.4</PercentageResult></row>
<row _id="3"><id>3</id><FinancialYear>2011/12</FinancialYear><HBT>S92000003</HBT><HBTQF>d</HBTQF><Laboratory>Scotland</Laboratory><LaboratoryQF>d</LaboratoryQF><Results>Negative</Results><ResultsQF /><NumberResult>362664</NumberResult><PercentageResult>90.9</PercentageResult></row>
<row _id="4"><id>4</id><FinancialYear>2011/12</FinancialYear><HBT>S92000003</HBT><HBTQF>d</HBTQF><Laboratory>Scotland</Laboratory><LaboratoryQF>d</LaboratoryQF><Results>Borderline Squamous Changes</Results><ResultsQF /><NumberResult>22272</NumberResult><PercentageResult>5.6</PercentageResult></row>
<row _id="5"><id>5</id><FinancialYear>2011/12</FinancialYear><HBT>S92000003</HBT><HBTQF>d</HBTQF><Laboratory>Scotland</Laboratory><LaboratoryQF>d</LaboratoryQF><Results>Borderline Glandular Changes</Results><ResultsQF /><NumberResult>320</NumberResult><PercentageResult>0.1</PercentageResult></row>
<row _id="6"><id>6</id><FinancialYear>2011/12</FinancialYear><HBT>S92000003</HBT><HBTQF>d</HBTQF><Laboratory>Scotland</Laboratory><LaboratoryQF>d</LaboratoryQF><Results>Mild Dyskaryosis</Results><ResultsQF /><NumberResult>8391</NumberResult><PercentageResult>2.1</PercentageResult></row>
<row _id="7"><id>7</id><FinancialYear>2011/12</FinancialYear><HBT>S92000003</HBT><HBTQF>d</HBTQF><Laboratory>Scotland</Laboratory><LaboratoryQF>d</LaboratoryQF><Results>Moderate Dyskaryosis</Results><ResultsQF /><NumberResult>2685</NumberResult><PercentageResult>0.7</PercentageResult></row>
<row _id="8"><id>8</id><FinancialYear>2011/12</FinancialYear><HBT>S92000003</HBT><HBTQF>d</HBTQF><Laboratory>Scotland</Laboratory><LaboratoryQF>d</LaboratoryQF><Results>Severe Dyskaryosis</Results><ResultsQF /><NumberResult>2278</NumberResult><PercentageResult>0.6</PercentageResult></row>
<row _id="9"><id>9</id><FinancialYear>2011/12</FinancialYear><HBT>S92000003</HBT><HBTQF>d</HBTQF><Laboratory>Scotland</Laboratory><LaboratoryQF>d</LaboratoryQF><Results>Severe Dyskaryosis (Invasive)</Results><ResultsQF /><NumberResult>70</NumberResult><PercentageResult>0</PercentageResult></row>
<row _id="10"><id>10</id><FinancialYear>2011/12</FinancialYear><HBT>S92000003</HBT><HBTQF>d</HBTQF><Laboratory>Scotland</Laboratory><LaboratoryQF>d</LaboratoryQF><Results>Glandular Abnormality</Results><ResultsQF /><NumberResult>152</NumberResult><PercentageResult>0</PercentageResult></row>
<row _id="11"><id>11</id><FinancialYear>2011/12</FinancialYear><HBT>S92000003</HBT><HBTQF>d</HBTQF><Laboratory>Scotland</Laboratory><LaboratoryQF>d</LaboratoryQF><Results>Endocervical Adenocarcinoma</Results><ResultsQF /><NumberResult>6</NumberResult><PercentageResult>0</PercentageResult></row>
<row _id="12"><id>12</id><FinancialYear>2011/12</FinancialYear><HBT>S92000003</HBT><HBTQF>d</HBTQF><Laboratory>Scotland</Laboratory><LaboratoryQF>d</LaboratoryQF><Results>Endometrial or other cancer</Results><ResultsQF /><NumberResult>20</NumberResult><PercentageResult>0</PercentageResult></row>
<row _id="13"><id>13</id><FinancialYear>2011/12</FinancialYear><HBT>8</HBT><HBTQF /><Laboratory>Inverclyde</Laboratory><LaboratoryQF /><Results>Total number of smears</Results><ResultsQF>d</ResultsQF><NumberResult>31120</NumberResult><PercentageResult>100</PercentageResult></row>
<row _id="14"><id>14</id><FinancialYear>2011/12</FinancialYear><HBT>8</HBT><HBTQF /><Laboratory>Inverclyde</Laboratory><LaboratoryQF /><Results>Unsatisfactory</Results><ResultsQF /><NumberResult>795</NumberResult><PercentageResult>2.6</PercentageResult></row>
<row _id="15"><id>15</id><FinancialYear>2011/12</FinancialYear><HBT>8</HBT><HBTQF /><Laboratory>Inverclyde</Laboratory><LaboratoryQF /><Results>Negative</Results><ResultsQF /><NumberResult>27655</NumberResult><PercentageResult>91.2</PercentageResult></row>
<row _id="16"><id>16</id><FinancialYear>2011/12</FinancialYear><HBT>8</HBT><HBTQF /><Laboratory>Inverclyde</Laboratory><LaboratoryQF /><Results>Borderline Squamous Changes</Results><ResultsQF /><NumberResult>2081</NumberResult><PercentageResult>6.9</PercentageResult></row>
<row _id="17"><id>17</id><FinancialYear>2011/12</FinancialYear><HBT>8</HBT><HBTQF /><Laboratory>Inverclyde</Laboratory><LaboratoryQF /><Results>Borderline Glandular Changes</Results><ResultsQF /><NumberResult>14</NumberResult><PercentageResult>0</PercentageResult></row>
<row _id="18"><id>18</id><FinancialYear>2011/12</FinancialYear><HBT>8</HBT><HBTQF /><Laboratory>Inverclyde</Laboratory><LaboratoryQF /><Results>Mild Dyskaryosis</Results><ResultsQF /><NumberResult>294</NumberResult><PercentageResult>1</PercentageResult></row>
<row _id="19"><id>19</id><FinancialYear>2011/12</FinancialYear><HBT>8</HBT><HBTQF /><Laboratory>Inverclyde</Laboratory><LaboratoryQF /><Results>Moderate Dyskaryosis</Results><ResultsQF /><NumberResult>141</NumberResult><PercentageResult>0.5</PercentageResult></row>
<row _id="20"><id>20</id><FinancialYear>2011/12</FinancialYear><HBT>8</HBT><HBTQF /><Laboratory>Inverclyde</Laboratory><LaboratoryQF /><Results>Severe Dyskaryosis</Results><ResultsQF /><NumberResult>131</NumberResult><PercentageResult>0.4</PercentageResult></row>
<row _id="21"><id>21</id><FinancialYear>2011/12</FinancialYear><HBT>8</HBT><HBTQF /><Laboratory>Inverclyde</Laboratory><LaboratoryQF /><Results>Severe Dyskaryosis (Invasive)</Results><ResultsQF /><NumberResult>2</NumberResult><PercentageResult>0</PercentageResult></row>
<row _id="22"><id>22</id><FinancialYear>2011/12</FinancialYear><HBT>8</HBT><HBTQF /><Laboratory>Inverclyde</Laboratory><LaboratoryQF /><Results>Glandular Abnormality</Results><ResultsQF /><NumberResult>6</NumberResult><PercentageResult>0</PercentageResult></row>
<row _id="23"><id>23</id><FinancialYear>2011/12</FinancialYear><HBT>8</HBT><HBTQF /><Laboratory>Inverclyde</Laboratory><LaboratoryQF /><Results>Endocervical Adenocarcinoma</Results><ResultsQF /><NumberResult>0</NumberResult><PercentageResult>0</PercentageResult></row>
<row _id="24"><id>24</id><FinancialYear>2011/12</FinancialYear><HBT>8</HBT><HBTQF /><Laboratory>Inverclyde</Laboratory><LaboratoryQF /><Results>Endometrial or other cancer</Results><ResultsQF /><NumberResult>1</NumberResult><PercentageResult>0</PercentageResult></row>
<row _id="25"><id>25</id><FinancialYear>2011/12</FinancialYear><HBT>11</HBT><HBTQF /><Laboratory>Cross House</Laboratory><LaboratoryQF /><Results>Total number of smears</Results><ResultsQF>d</ResultsQF><NumberResult>26790</NumberResult><PercentageResult>100</PercentageResult></row>
<row _id="26"><id>26</id><FinancialYear>2011/12</FinancialYear><HBT>11</HBT><HBTQF /><Laboratory>Cross House</Laboratory><LaboratoryQF /><Results>Unsatisfactory</Results><ResultsQF /><NumberResult>708</NumberResult><PercentageResult>2.6</PercentageResult></row>
<row _id="27"><id>27</id><FinancialYear>2011/12</FinancialYear><HBT>11</HBT><HBTQF /><Laboratory>Cross House</Laboratory><LaboratoryQF /><Results>Negative</Results><ResultsQF /><NumberResult>24504</NumberResult><PercentageResult>93.9</PercentageResult></row>
<row _id="28"><id>28</id><FinancialYear>2011/12</FinancialYear><HBT>11</HBT><HBTQF /><Laboratory>Cross House</Laboratory><LaboratoryQF /><Results>Borderline Squamous Changes</Results><ResultsQF /><NumberResult>1042</NumberResult><PercentageResult>4</PercentageResult></row>
<row _id="29"><id>29</id><FinancialYear>2011/12</FinancialYear><HBT>11</HBT><HBTQF /><Laboratory>Cross House</Laboratory><LaboratoryQF /><Results>Borderline Glandular Changes</Results><ResultsQF /><NumberResult>21</NumberResult><PercentageResult>0.1</PercentageResult></row>
<row _id="30"><id>30</id><FinancialYear>2011/12</FinancialYear><HBT>11</HBT><HBTQF /><Laboratory>Cross House</Laboratory><LaboratoryQF /><Results>Mild Dyskaryosis</Results><ResultsQF /><NumberResult>256</NumberResult><PercentageResult>1</PercentageResult></row>
<row _id="31"><id>31</id><FinancialYear>2011/12</FinancialYear><HBT>11</HBT><HBTQF /><Laboratory>Cross House</Laboratory><LaboratoryQF /><Results>Moderate Dyskaryosis</Results><ResultsQF /><NumberResult>67</NumberResult><PercentageResult>0.3</PercentageResult></row>
<row _id="32"><id>32</id><FinancialYear>2011/12</FinancialYear><HBT>11</HBT><HBTQF /><Laboratory>Cross House</Laboratory><LaboratoryQF /><Results>Severe Dyskaryosis</Results><ResultsQF /><NumberResult>177</NumberResult><PercentageResult>0.7</PercentageResult></row>
<row _id="33"><id>33</id><FinancialYear>2011/12</FinancialYear><HBT>11</HBT><HBTQF /><Laboratory>Cross House</Laboratory><LaboratoryQF /><Results>Severe Dyskaryosis (Invasive)</Results><ResultsQF /><NumberResult>3</NumberResult><PercentageResult>0</PercentageResult></row>
<row _id="34"><id>34</id><FinancialYear>2011/12</FinancialYear><HBT>11</HBT><HBTQF /><Laboratory>Cross House</Laboratory><LaboratoryQF /><Results>Glandular Abnormality</Results><ResultsQF /><NumberResult>11</NumberResult><PercentageResult>0</PercentageResult></row>
<row _id="35"><id>35</id><FinancialYear>2011/12</FinancialYear><HBT>11</HBT><HBTQF /><Laboratory>Cross House</Laboratory><LaboratoryQF /><Results>Endocervical Adenocarcinoma</Results><ResultsQF /><NumberResult>0</NumberResult><PercentageResult>0</PercentageResult></row>
<row _id="36"><id>36</id><FinancialYear>2011/12</FinancialYear><HBT>11</HBT><HBTQF /><Laboratory>Cross House</Laboratory><LaboratoryQF /><Results>Endometrial or other cancer</Results><ResultsQF /><NumberResult>1</NumberResult><PercentageResult>0</PercentageResult></row>
<row _id="37"><id>37</id><FinancialYear>2011/12</FinancialYear><HBT>4</HBT><HBTQF /><Laboratory>Forth Park</Laboratory><LaboratoryQF /><Results>Total number of smears</Results><ResultsQF>d</ResultsQF><NumberResult>26786</NumberResult><PercentageResult>100</PercentageResult></row>
<row _id="38"><id>38</id><FinancialYear>2011/12</FinancialYear><HBT>4</HBT><HBTQF /><Laboratory>Forth Park</Laboratory><LaboratoryQF /><Results>Unsatisfactory</Results><ResultsQF /><NumberResult>552</NumberResult><PercentageResult>2.1</PercentageResult></row>
<row _id="39"><id>39</id><FinancialYear>2011/12</FinancialYear><HBT>4</HBT><HBTQF /><Laboratory>Forth Park</Laboratory><LaboratoryQF /><Results>Negative</Results><ResultsQF /><NumberResult>24078</NumberResult><PercentageResult>91.8</PercentageResult></row>
<row _id="40"><id>40</id><FinancialYear>2011/12</FinancialYear><HBT>4</HBT><HBTQF /><Laboratory>Forth Park</Laboratory><LaboratoryQF /><Results>Borderline Squamous Changes</Results><ResultsQF /><NumberResult>1152</NumberResult><PercentageResult>4.4</PercentageResult></row>
<row _id="41"><id>41</id><FinancialYear>2011/12</FinancialYear><HBT>4</HBT><HBTQF /><Laboratory>Forth Park</Laboratory><LaboratoryQF /><Results>Borderline Glandular Changes</Results><ResultsQF /><NumberResult>15</NumberResult><PercentageResult>0.1</PercentageResult></row>
<row _id="42"><id>42</id><FinancialYear>2011/12</FinancialYear><HBT>4</HBT><HBTQF /><Laboratory>Forth Park</Laboratory><LaboratoryQF /><Results>Mild Dyskaryosis</Results><ResultsQF /><NumberResult>667</NumberResult><PercentageResult>2.5</PercentageResult></row>
<row _id="43"><id>43</id><FinancialYear>2011/12</FinancialYear><HBT>4</HBT><HBTQF /><Laboratory>Forth Park</Laboratory><LaboratoryQF /><Results>Moderate Dyskaryosis</Results><ResultsQF /><NumberResult>184</NumberResult><PercentageResult>0.7</PercentageResult></row>
<row _id="44"><id>44</id><FinancialYear>2011/12</FinancialYear><HBT>4</HBT><HBTQF /><Laboratory>Forth Park</Laboratory><LaboratoryQF /><Results>Severe Dyskaryosis</Results><ResultsQF /><NumberResult>118</NumberResult><PercentageResult>0.4</PercentageResult></row>
<row _id="45"><id>45</id><FinancialYear>2011/12</FinancialYear><HBT>4</HBT><HBTQF /><Laboratory>Forth Park</Laboratory><LaboratoryQF /><Results>Severe Dyskaryosis (Invasive)</Results><ResultsQF /><NumberResult>6</NumberResult><PercentageResult>0</PercentageResult></row>
<row _id="46"><id>46</id><FinancialYear>2011/12</FinancialYear><HBT>4</HBT><HBTQF /><Laboratory>Forth Park</Laboratory><LaboratoryQF /><Results>Glandular Abnormality</Results><ResultsQF /><NumberResult>11</NumberResult><PercentageResult>0</PercentageResult></row>
<row _id="47"><id>47</id><FinancialYear>2011/12</FinancialYear><HBT>4</HBT><HBTQF /><Laboratory>Forth Park</Laboratory><LaboratoryQF /><Results>Endocervical Adenocarcinoma</Results><ResultsQF /><NumberResult>0</NumberResult><PercentageResult>0</PercentageResult></row>
<row _id="48"><id>48</id><FinancialYear>2011/12</FinancialYear><HBT>4</HBT><HBTQF /><Laboratory>Forth Park</Laboratory><LaboratoryQF /><Results>Endometrial or other cancer</Results><ResultsQF /><NumberResult>3</NumberResult><PercentageResult>0</PercentageResult></row>
<row _id="49"><id>49</id><FinancialYear>2011/12</FinancialYear><HBT>7</HBT><HBTQF /><Laboratory>Stirling Royal Infirmary</Laboratory><LaboratoryQF /><Results>Total number of smears</Results><ResultsQF>d</ResultsQF><NumberResult>23442</NumberResult><PercentageResult>100</PercentageResult></row>
<row _id="50"><id>50</id><FinancialYear>2011/12</FinancialYear><HBT>7</HBT><HBTQF /><Laboratory>Stirling Royal Infirmary</Laboratory><LaboratoryQF /><Results>Unsatisfactory</Results><ResultsQF /><NumberResult>519</NumberResult><PercentageResult>2.2</PercentageResult></row>
<row _id="51"><id>51</id><FinancialYear>2011/12</FinancialYear><HBT>7</HBT><HBTQF /><Laboratory>Stirling Royal Infirmary</Laboratory><LaboratoryQF /><Results>Negative</Results><ResultsQF /><NumberResult>20829</NumberResult><PercentageResult>90.9</PercentageResult></row>
<row _id="52"><id>52</id><FinancialYear>2011/12</FinancialYear><HBT>7</HBT><HBTQF /><Laboratory>Stirling Royal Infirmary</Laboratory><LaboratoryQF /><Results>Borderline Squamous Changes</Results><ResultsQF /><NumberResult>1303</NumberResult><PercentageResult>5.7</PercentageResult></row>
<row _id="53"><id>53</id><FinancialYear>2011/12</FinancialYear><HBT>7</HBT><HBTQF /><Laboratory>Stirling Royal Infirmary</Laboratory><LaboratoryQF /><Results>Borderline Glandular Changes</Results><ResultsQF /><NumberResult>49</NumberResult><PercentageResult>0.2</PercentageResult></row>
<row _id="54"><id>54</id><FinancialYear>2011/12</FinancialYear><HBT>7</HBT><HBTQF /><Laboratory>Stirling Royal Infirmary</Laboratory><LaboratoryQF /><Results>Mild Dyskaryosis</Results><ResultsQF /><NumberResult>444</NumberResult><PercentageResult>1.9</PercentageResult></row>
<row _id="55"><id>55</id><FinancialYear>2011/12</FinancialYear><HBT>7</HBT><HBTQF /><Laboratory>Stirling Royal Infirmary</Laboratory><LaboratoryQF /><Results>Moderate Dyskaryosis</Results><ResultsQF /><NumberResult>185</NumberResult><PercentageResult>0.8</PercentageResult></row>
<row _id="56"><id>56</id><FinancialYear>2011/12</FinancialYear><HBT>7</HBT><HBTQF /><Laboratory>Stirling Royal Infirmary</Laboratory><LaboratoryQF /><Results>Severe Dyskaryosis</Results><ResultsQF /><NumberResult>90</NumberResult><PercentageResult>0.4</PercentageResult></row>
<row _id="57"><id>57</id><FinancialYear>2011/12</FinancialYear><HBT>7</HBT><HBTQF /><Laboratory>Stirling Royal Infirmary</Laboratory><LaboratoryQF /><Results>Severe Dyskaryosis (Invasive)</Results><ResultsQF /><NumberResult>7</NumberResult><PercentageResult>0</PercentageResult></row>
<row _id="58"><id>58</id><FinancialYear>2011/12</FinancialYear><HBT>7</HBT><HBTQF /><Laboratory>Stirling Royal Infirmary</Laboratory><LaboratoryQF /><Results>Glandular Abnormality</Results><ResultsQF /><NumberResult>13</NumberResult><PercentageResult>0.1</PercentageResult></row>
<row _id="59"><id>59</id><FinancialYear>2011/12</FinancialYear><HBT>7</HBT><HBTQF /><Laboratory>Stirling Royal Infirmary</Laboratory><LaboratoryQF /><Results>Endocervical Adenocarcinoma</Results><ResultsQF /><NumberResult>0</NumberResult><PercentageResult>0</PercentageResult></row>
<row _id="60"><id>60</id><FinancialYear>2011/12</FinancialYear><HBT>7</HBT><HBTQF /><Laboratory>Stirling Royal Infirmary</Laboratory><LaboratoryQF /><Results>Endometrial or other cancer</Results><ResultsQF /><NumberResult>3</NumberResult><PercentageResult>0</PercentageResult></row>
<row _id="61"><id>61</id><FinancialYear>2011/12</FinancialYear><HBT>2</HBT><HBTQF /><Laboratory>Forester Hill</Laboratory><LaboratoryQF /><Results>Total number of smears</Results><ResultsQF>d</ResultsQF><NumberResult>47536</NumberResult><PercentageResult>100</PercentageResult></row>
<row _id="62"><id>62</id><FinancialYear>2011/12</FinancialYear><HBT>2</HBT><HBTQF /><Laboratory>Forester Hill</Laboratory><LaboratoryQF /><Results>Unsatisfactory</Results><ResultsQF /><NumberResult>1093</NumberResult><PercentageResult>2.3</PercentageResult></row>
<row _id="63"><id>63</id><FinancialYear>2011/12</FinancialYear><HBT>2</HBT><HBTQF /><Laboratory>Forester Hill</Laboratory><LaboratoryQF /><Results>Negative</Results><ResultsQF /><NumberResult>42649</NumberResult><PercentageResult>91.8</PercentageResult></row>
<row _id="64"><id>64</id><FinancialYear>2011/12</FinancialYear><HBT>2</HBT><HBTQF /><Laboratory>Forester Hill</Laboratory><LaboratoryQF /><Results>Borderline Squamous Changes</Results><ResultsQF /><NumberResult>2522</NumberResult><PercentageResult>5.4</PercentageResult></row>
<row _id="65"><id>65</id><FinancialYear>2011/12</FinancialYear><HBT>2</HBT><HBTQF /><Laboratory>Forester Hill</Laboratory><LaboratoryQF /><Results>Borderline Glandular Changes</Results><ResultsQF /><NumberResult>25</NumberResult><PercentageResult>0.1</PercentageResult></row>
<row _id="66"><id>66</id><FinancialYear>2011/12</FinancialYear><HBT>2</HBT><HBTQF /><Laboratory>Forester Hill</Laboratory><LaboratoryQF /><Results>Mild Dyskaryosis</Results><ResultsQF /><NumberResult>757</NumberResult><PercentageResult>1.6</PercentageResult></row>
<row _id="67"><id>67</id><FinancialYear>2011/12</FinancialYear><HBT>2</HBT><HBTQF /><Laboratory>Forester Hill</Laboratory><LaboratoryQF /><Results>Moderate Dyskaryosis</Results><ResultsQF /><NumberResult>224</NumberResult><PercentageResult>0.5</PercentageResult></row>
<row _id="68"><id>68</id><FinancialYear>2011/12</FinancialYear><HBT>2</HBT><HBTQF /><Laboratory>Forester Hill</Laboratory><LaboratoryQF /><Results>Severe Dyskaryosis</Results><ResultsQF /><NumberResult>236</NumberResult><PercentageResult>0.5</PercentageResult></row>
<row _id="69"><id>69</id><FinancialYear>2011/12</FinancialYear><HBT>2</HBT><HBTQF /><Laboratory>Forester Hill</Laboratory><LaboratoryQF /><Results>Severe Dyskaryosis (Invasive)</Results><ResultsQF /><NumberResult>10</NumberResult><PercentageResult>0</PercentageResult></row>
<row _id="70"><id>70</id><FinancialYear>2011/12</FinancialYear><HBT>2</HBT><HBTQF /><Laboratory>Forester Hill</Laboratory><LaboratoryQF /><Results>Glandular Abnormality</Results><ResultsQF /><NumberResult>19</NumberResult><PercentageResult>0</PercentageResult></row>
<row _id="71"><id>71</id><FinancialYear>2011/12</FinancialYear><HBT>2</HBT><HBTQF /><Laboratory>Forester Hill</Laboratory><LaboratoryQF /><Results>Endocervical Adenocarcinoma</Results><ResultsQF /><NumberResult>0</NumberResult><PercentageResult>0</PercentageResult></row>
<row _id="72"><id>72</id><FinancialYear>2011/12</FinancialYear><HBT>2</HBT><HBTQF /><Laboratory>Forester Hill</Laboratory><LaboratoryQF /><Results>Endometrial or other cancer</Results><ResultsQF /><NumberResult>1</NumberResult><PercentageResult>0</PercentageResult></row>
<row _id="73"><id>73</id><FinancialYear>2011/12</FinancialYear><HBT>9</HBT><HBTQF /><Laboratory>Southern General</Laboratory><LaboratoryQF /><Results>Total number of smears</Results><ResultsQF>d</ResultsQF><NumberResult>23460</NumberResult><PercentageResult>100</PercentageResult></row>
<row _id="74"><id>74</id><FinancialYear>2011/12</FinancialYear><HBT>9</HBT><HBTQF /><Laboratory>Southern General</Laboratory><LaboratoryQF /><Results>Unsatisfactory</Results><ResultsQF /><NumberResult>687</NumberResult><PercentageResult>2.9</PercentageResult></row>
<row _id="75"><id>75</id><FinancialYear>2011/12</FinancialYear><HBT>9</HBT><HBTQF /><Laboratory>Southern General</Laboratory><LaboratoryQF /><Results>Negative</Results><ResultsQF /><NumberResult>20914</NumberResult><PercentageResult>91.8</PercentageResult></row>
<row _id="76"><id>76</id><FinancialYear>2011/12</FinancialYear><HBT>9</HBT><HBTQF /><Laboratory>Southern General</Laboratory><LaboratoryQF /><Results>Borderline Squamous Changes</Results><ResultsQF /><NumberResult>1157</NumberResult><PercentageResult>5.1</PercentageResult></row>
<row _id="77"><id>77</id><FinancialYear>2011/12</FinancialYear><HBT>9</HBT><HBTQF /><Laboratory>Southern General</Laboratory><LaboratoryQF /><Results>Borderline Glandular Changes</Results><ResultsQF /><NumberResult>3</NumberResult><PercentageResult>0</PercentageResult></row>
<row _id="78"><id>78</id><FinancialYear>2011/12</FinancialYear><HBT>9</HBT><HBTQF /><Laboratory>Southern General</Laboratory><LaboratoryQF /><Results>Mild Dyskaryosis</Results><ResultsQF /><NumberResult>492</NumberResult><PercentageResult>2.2</PercentageResult></row>
<row _id="79"><id>79</id><FinancialYear>2011/12</FinancialYear><HBT>9</HBT><HBTQF /><Laboratory>Southern General</Laboratory><LaboratoryQF /><Results>Moderate Dyskaryosis</Results><ResultsQF /><NumberResult>92</NumberResult><PercentageResult>0.4</PercentageResult></row>
<row _id="80"><id>80</id><FinancialYear>2011/12</FinancialYear><HBT>9</HBT><HBTQF /><Laboratory>Southern General</Laboratory><LaboratoryQF /><Results>Severe Dyskaryosis</Results><ResultsQF /><NumberResult>109</NumberResult><PercentageResult>0.5</PercentageResult></row>
<row _id="81"><id>81</id><FinancialYear>2011/12</FinancialYear><HBT>9</HBT><HBTQF /><Laboratory>Southern General</Laboratory><LaboratoryQF /><Results>Severe Dyskaryosis (Invasive)</Results><ResultsQF /><NumberResult>3</NumberResult><PercentageResult>0</PercentageResult></row>
<row _id="82"><id>82</id><FinancialYear>2011/12</FinancialYear><HBT>9</HBT><HBTQF /><Laboratory>Southern General</Laboratory><LaboratoryQF /><Results>Glandular Abnormality</Results><ResultsQF /><NumberResult>3</NumberResult><PercentageResult>0</PercentageResult></row>
<row _id="83"><id>83</id><FinancialYear>2011/12</FinancialYear><HBT>9</HBT><HBTQF /><Laboratory>Southern General</Laboratory><LaboratoryQF /><Results>Endocervical Adenocarcinoma</Results><ResultsQF /><NumberResult>0</NumberResult><PercentageResult>0</PercentageResult></row>
<row _id="84"><id>84</id><FinancialYear>2011/12</FinancialYear><HBT>9</HBT><HBTQF /><Laboratory>Southern General</Laboratory><LaboratoryQF /><Results>Endometrial or other cancer</Results><ResultsQF /><NumberResult>0</NumberResult><PercentageResult>0</PercentageResult></row>
<row _id="85"><id>85</id><FinancialYear>2011/12</FinancialYear><HBT>9</HBT><HBTQF /><Laboratory>Glasgow Royal Infirmary</Laboratory><LaboratoryQF /><Results>Total number of smears</Results><ResultsQF>d</ResultsQF><NumberResult>41199</NumberResult><PercentageResult>100</PercentageResult></row>
<row _id="86"><id>86</id><FinancialYear>2011/12</FinancialYear><HBT>9</HBT><HBTQF /><Laboratory>Glasgow Royal Infirmary</Laboratory><LaboratoryQF /><Results>Unsatisfactory</Results><ResultsQF /><NumberResult>1181</NumberResult><PercentageResult>2.9</PercentageResult></row>
<row _id="87"><id>87</id><FinancialYear>2011/12</FinancialYear><HBT>9</HBT><HBTQF /><Laboratory>Glasgow Royal Infirmary</Laboratory><LaboratoryQF /><Results>Negative</Results><ResultsQF /><NumberResult>34495</NumberResult><PercentageResult>86.2</PercentageResult></row>
<row _id="88"><id>88</id><FinancialYear>2011/12</FinancialYear><HBT>9</HBT><HBTQF /><Laboratory>Glasgow Royal Infirmary</Laboratory><LaboratoryQF /><Results>Borderline Squamous Changes</Results><ResultsQF /><NumberResult>3429</NumberResult><PercentageResult>8.6</PercentageResult></row>
<row _id="89"><id>89</id><FinancialYear>2011/12</FinancialYear><HBT>9</HBT><HBTQF /><Laboratory>Glasgow Royal Infirmary</Laboratory><LaboratoryQF /><Results>Borderline Glandular Changes</Results><ResultsQF /><NumberResult>49</NumberResult><PercentageResult>0.1</PercentageResult></row>
<row _id="90"><id>90</id><FinancialYear>2011/12</FinancialYear><HBT>9</HBT><HBTQF /><Laboratory>Glasgow Royal Infirmary</Laboratory><LaboratoryQF /><Results>Mild Dyskaryosis</Results><ResultsQF /><NumberResult>1304</NumberResult><PercentageResult>3.3</PercentageResult></row>
<row _id="91"><id>91</id><FinancialYear>2011/12</FinancialYear><HBT>9</HBT><HBTQF /><Laboratory>Glasgow Royal Infirmary</Laboratory><LaboratoryQF /><Results>Moderate Dyskaryosis</Results><ResultsQF /><NumberResult>438</NumberResult><PercentageResult>1.1</PercentageResult></row>
<row _id="92"><id>92</id><FinancialYear>2011/12</FinancialYear><HBT>9</HBT><HBTQF /><Laboratory>Glasgow Royal Infirmary</Laboratory><LaboratoryQF /><Results>Severe Dyskaryosis</Results><ResultsQF /><NumberResult>273</NumberResult><PercentageResult>0.7</PercentageResult></row>
<row _id="93"><id>93</id><FinancialYear>2011/12</FinancialYear><HBT>9</HBT><HBTQF /><Laboratory>Glasgow Royal Infirmary</Laboratory><LaboratoryQF /><Results>Severe Dyskaryosis (Invasive)</Results><ResultsQF /><NumberResult>7</NumberResult><PercentageResult>0</PercentageResult></row>
<row _id="94"><id>94</id><FinancialYear>2011/12</FinancialYear><HBT>9</HBT><HBTQF /><Laboratory>Glasgow Royal Infirmary</Laboratory><LaboratoryQF /><Results>Glandular Abnormality</Results><ResultsQF /><NumberResult>18</NumberResult><PercentageResult>0</PercentageResult></row>
<row _id="95"><id>95</id><FinancialYear>2011/12</FinancialYear><HBT>9</HBT><HBTQF /><Laboratory>Glasgow Royal Infirmary</Laboratory><LaboratoryQF /><Results>Endocervical Adenocarcinoma</Results><ResultsQF /><NumberResult>0</NumberResult><PercentageResult>0</PercentageResult></row>
<row _id="96"><id>96</id><FinancialYear>2011/12</FinancialYear><HBT>9</HBT><HBTQF /><Laboratory>Glasgow Royal Infirmary</Laboratory><LaboratoryQF /><Results>Endometrial or other cancer</Results><ResultsQF /><NumberResult>5</NumberResult><PercentageResult>0</PercentageResult></row>
<row _id="97"><id>97</id><FinancialYear>2011/12</FinancialYear><HBT>1</HBT><HBTQF /><Laboratory>Raigmore</Laboratory><LaboratoryQF /><Results>Total number of smears</Results><ResultsQF>d</ResultsQF><NumberResult>18889</NumberResult><PercentageResult>100</PercentageResult></row>
<row _id="98"><id>98</id><FinancialYear>2011/12</FinancialYear><HBT>1</HBT><HBTQF /><Laboratory>Raigmore</Laboratory><LaboratoryQF /><Results>Unsatisfactory</Results><ResultsQF /><NumberResult>315</NumberResult><PercentageResult>1.7</PercentageResult></row>
<row _id="99"><id>99</id><FinancialYear>2011/12</FinancialYear><HBT>1</HBT><HBTQF /><Laboratory>Raigmore</Laboratory><LaboratoryQF /><Results>Negative</Results><ResultsQF /><NumberResult>17269</NumberResult><PercentageResult>93</PercentageResult></row>
<row _id="100"><id>100</id><FinancialYear>2011/12</FinancialYear><HBT>1</HBT><HBTQF /><Laboratory>Raigmore</Laboratory><LaboratoryQF /><Results>Borderline Squamous Changes</Results><ResultsQF /><NumberResult>540</NumberResult><PercentageResult>2.9</PercentageResult></row>
<row _id="101"><id>101</id><FinancialYear>2011/12</FinancialYear><HBT>1</HBT><HBTQF /><Laboratory>Raigmore</Laboratory><LaboratoryQF /><Results>Borderline Glandular Changes</Results><ResultsQF /><NumberResult>17</NumberResult><PercentageResult>0.1</PercentageResult></row>
<row _id="102"><id>102</id><FinancialYear>2011/12</FinancialYear><HBT>1</HBT><HBTQF /><Laboratory>Raigmore</Laboratory><LaboratoryQF /><Results>Mild Dyskaryosis</Results><ResultsQF /><NumberResult>412</NumberResult><PercentageResult>2.2</PercentageResult></row>
<row _id="103"><id>103</id><FinancialYear>2011/12</FinancialYear><HBT>1</HBT><HBTQF /><Laboratory>Raigmore</Laboratory><LaboratoryQF /><Results>Moderate Dyskaryosis</Results><ResultsQF /><NumberResult>164</NumberResult><PercentageResult>0.9</PercentageResult></row>
<row _id="104"><id>104</id><FinancialYear>2011/12</FinancialYear><HBT>1</HBT><HBTQF /><Laboratory>Raigmore</Laboratory><LaboratoryQF /><Results>Severe Dyskaryosis</Results><ResultsQF /><NumberResult>151</NumberResult><PercentageResult>0.8</PercentageResult></row>
<row _id="105"><id>105</id><FinancialYear>2011/12</FinancialYear><HBT>1</HBT><HBTQF /><Laboratory>Raigmore</Laboratory><LaboratoryQF /><Results>Severe Dyskaryosis (Invasive)</Results><ResultsQF /><NumberResult>6</NumberResult><PercentageResult>0</PercentageResult></row>
<row _id="106"><id>106</id><FinancialYear>2011/12</FinancialYear><HBT>1</HBT><HBTQF /><Laboratory>Raigmore</Laboratory><LaboratoryQF /><Results>Glandular Abnormality</Results><ResultsQF /><NumberResult>14</NumberResult><PercentageResult>0.1</PercentageResult></row>
<row _id="107"><id>107</id><FinancialYear>2011/12</FinancialYear><HBT>1</HBT><HBTQF /><Laboratory>Raigmore</Laboratory><LaboratoryQF /><Results>Endocervical Adenocarcinoma</Results><ResultsQF /><NumberResult>1</NumberResult><PercentageResult>0</PercentageResult></row>
<row _id="108"><id>108</id><FinancialYear>2011/12</FinancialYear><HBT>1</HBT><HBTQF /><Laboratory>Raigmore</Laboratory><LaboratoryQF /><Results>Endometrial or other cancer</Results><ResultsQF /><NumberResult>0</NumberResult><PercentageResult>0</PercentageResult></row>
<row _id="109"><id>109</id><FinancialYear>2011/12</FinancialYear><HBT>10</HBT><HBTQF /><Laboratory>Monklands</Laboratory><LaboratoryQF /><Results>Total number of smears</Results><ResultsQF>d</ResultsQF><NumberResult>55827</NumberResult><PercentageResult>100</PercentageResult></row>
<row _id="110"><id>110</id><FinancialYear>2011/12</FinancialYear><HBT>10</HBT><HBTQF /><Laboratory>Monklands</Laboratory><LaboratoryQF /><Results>Unsatisfactory</Results><ResultsQF /><NumberResult>1420</NumberResult><PercentageResult>2.5</PercentageResult></row>
<row _id="111"><id>111</id><FinancialYear>2011/12</FinancialYear><HBT>10</HBT><HBTQF /><Laboratory>Monklands</Laboratory><LaboratoryQF /><Results>Negative</Results><ResultsQF /><NumberResult>50367</NumberResult><PercentageResult>92.6</PercentageResult></row>
<row _id="112"><id>112</id><FinancialYear>2011/12</FinancialYear><HBT>10</HBT><HBTQF /><Laboratory>Monklands</Laboratory><LaboratoryQF /><Results>Borderline Squamous Changes</Results><ResultsQF /><NumberResult>2627</NumberResult><PercentageResult>4.8</PercentageResult></row>
<row _id="113"><id>113</id><FinancialYear>2011/12</FinancialYear><HBT>10</HBT><HBTQF /><Laboratory>Monklands</Laboratory><LaboratoryQF /><Results>Borderline Glandular Changes</Results><ResultsQF /><NumberResult>13</NumberResult><PercentageResult>0</PercentageResult></row>
<row _id="114"><id>114</id><FinancialYear>2011/12</FinancialYear><HBT>10</HBT><HBTQF /><Laboratory>Monklands</Laboratory><LaboratoryQF /><Results>Mild Dyskaryosis</Results><ResultsQF /><NumberResult>764</NumberResult><PercentageResult>1.4</PercentageResult></row>
<row _id="115"><id>115</id><FinancialYear>2011/12</FinancialYear><HBT>10</HBT><HBTQF /><Laboratory>Monklands</Laboratory><LaboratoryQF /><Results>Moderate Dyskaryosis</Results><ResultsQF /><NumberResult>300</NumberResult><PercentageResult>0.6</PercentageResult></row>
<row _id="116"><id>116</id><FinancialYear>2011/12</FinancialYear><HBT>10</HBT><HBTQF /><Laboratory>Monklands</Laboratory><LaboratoryQF /><Results>Severe Dyskaryosis</Results><ResultsQF /><NumberResult>290</NumberResult><PercentageResult>0.5</PercentageResult></row>
<row _id="117"><id>117</id><FinancialYear>2011/12</FinancialYear><HBT>10</HBT><HBTQF /><Laboratory>Monklands</Laboratory><LaboratoryQF /><Results>Severe Dyskaryosis (Invasive)</Results><ResultsQF /><NumberResult>13</NumberResult><PercentageResult>0</PercentageResult></row>
<row _id="118"><id>118</id><FinancialYear>2011/12</FinancialYear><HBT>10</HBT><HBTQF /><Laboratory>Monklands</Laboratory><LaboratoryQF /><Results>Glandular Abnormality</Results><ResultsQF /><NumberResult>29</NumberResult><PercentageResult>0.1</PercentageResult></row>
<row _id="119"><id>119</id><FinancialYear>2011/12</FinancialYear><HBT>10</HBT><HBTQF /><Laboratory>Monklands</Laboratory><LaboratoryQF /><Results>Endocervical Adenocarcinoma</Results><ResultsQF /><NumberResult>2</NumberResult><PercentageResult>0</PercentageResult></row>
<row _id="120"><id>120</id><FinancialYear>2011/12</FinancialYear><HBT>10</HBT><HBTQF /><Laboratory>Monklands</Laboratory><LaboratoryQF /><Results>Endometrial or other cancer</Results><ResultsQF /><NumberResult>2</NumberResult><PercentageResult>0</PercentageResult></row>
<row _id="121"><id>121</id><FinancialYear>2011/12</FinancialYear><HBT>5</HBT><HBTQF /><Laboratory>Edinburgh Royal Infirmary</Laboratory><LaboratoryQF /><Results>Total number of smears</Results><ResultsQF>d</ResultsQF><NumberResult>82556</NumberResult><PercentageResult>100</PercentageResult></row>
<row _id="122"><id>122</id><FinancialYear>2011/12</FinancialYear><HBT>5</HBT><HBTQF /><Laboratory>Edinburgh Royal Infirmary</Laboratory><LaboratoryQF /><Results>Unsatisfactory</Results><ResultsQF /><NumberResult>2217</NumberResult><PercentageResult>2.7</PercentageResult></row>
<row _id="123"><id>123</id><FinancialYear>2011/12</FinancialYear><HBT>5</HBT><HBTQF /><Laboratory>Edinburgh Royal Infirmary</Laboratory><LaboratoryQF /><Results>Negative</Results><ResultsQF /><NumberResult>71473</NumberResult><PercentageResult>89</PercentageResult></row>
<row _id="124"><id>124</id><FinancialYear>2011/12</FinancialYear><HBT>5</HBT><HBTQF /><Laboratory>Edinburgh Royal Infirmary</Laboratory><LaboratoryQF /><Results>Borderline Squamous Changes</Results><ResultsQF /><NumberResult>5229</NumberResult><PercentageResult>6.5</PercentageResult></row>
<row _id="125"><id>125</id><FinancialYear>2011/12</FinancialYear><HBT>5</HBT><HBTQF /><Laboratory>Edinburgh Royal Infirmary</Laboratory><LaboratoryQF /><Results>Borderline Glandular Changes</Results><ResultsQF /><NumberResult>99</NumberResult><PercentageResult>0.1</PercentageResult></row>
<row _id="126"><id>126</id><FinancialYear>2011/12</FinancialYear><HBT>5</HBT><HBTQF /><Laboratory>Edinburgh Royal Infirmary</Laboratory><LaboratoryQF /><Results>Mild Dyskaryosis</Results><ResultsQF /><NumberResult>2249</NumberResult><PercentageResult>2.8</PercentageResult></row>
<row _id="127"><id>127</id><FinancialYear>2011/12</FinancialYear><HBT>5</HBT><HBTQF /><Laboratory>Edinburgh Royal Infirmary</Laboratory><LaboratoryQF /><Results>Moderate Dyskaryosis</Results><ResultsQF /><NumberResult>713</NumberResult><PercentageResult>0.9</PercentageResult></row>
<row _id="128"><id>128</id><FinancialYear>2011/12</FinancialYear><HBT>5</HBT><HBTQF /><Laboratory>Edinburgh Royal Infirmary</Laboratory><LaboratoryQF /><Results>Severe Dyskaryosis</Results><ResultsQF /><NumberResult>551</NumberResult><PercentageResult>0.7</PercentageResult></row>
<row _id="129"><id>129</id><FinancialYear>2011/12</FinancialYear><HBT>5</HBT><HBTQF /><Laboratory>Edinburgh Royal Infirmary</Laboratory><LaboratoryQF /><Results>Severe Dyskaryosis (Invasive)</Results><ResultsQF /><NumberResult>8</NumberResult><PercentageResult>0</PercentageResult></row>
<row _id="130"><id>130</id><FinancialYear>2011/12</FinancialYear><HBT>5</HBT><HBTQF /><Laboratory>Edinburgh Royal Infirmary</Laboratory><LaboratoryQF /><Results>Glandular Abnormality</Results><ResultsQF /><NumberResult>14</NumberResult><PercentageResult>0</PercentageResult></row>
<row _id="131"><id>131</id><FinancialYear>2011/12</FinancialYear><HBT>5</HBT><HBTQF /><Laboratory>Edinburgh Royal Infirmary</Laboratory><LaboratoryQF /><Results>Endocervical Adenocarcinoma</Results><ResultsQF /><NumberResult>0</NumberResult><PercentageResult>0</PercentageResult></row>
<row _id="132"><id>132</id><FinancialYear>2011/12</FinancialYear><HBT>5</HBT><HBTQF /><Laboratory>Edinburgh Royal Infirmary</Laboratory><LaboratoryQF /><Results>Endometrial or other cancer</Results><ResultsQF /><NumberResult>3</NumberResult><PercentageResult>0</PercentageResult></row>
<row _id="133"><id>133</id><FinancialYear>2011/12</FinancialYear><HBT>3</HBT><HBTQF /><Laboratory>Ninewells</Laboratory><LaboratoryQF /><Results>Total number of smears</Results><ResultsQF>d</ResultsQF><NumberResult>31233</NumberResult><PercentageResult>100</PercentageResult></row>
<row _id="134"><id>134</id><FinancialYear>2011/12</FinancialYear><HBT>3</HBT><HBTQF /><Laboratory>Ninewells</Laboratory><LaboratoryQF /><Results>Unsatisfactory</Results><ResultsQF /><NumberResult>493</NumberResult><PercentageResult>1.6</PercentageResult></row>
<row _id="135"><id>135</id><FinancialYear>2011/12</FinancialYear><HBT>3</HBT><HBTQF /><Laboratory>Ninewells</Laboratory><LaboratoryQF /><Results>Negative</Results><ResultsQF /><NumberResult>28431</NumberResult><PercentageResult>92.5</PercentageResult></row>
<row _id="136"><id>136</id><FinancialYear>2011/12</FinancialYear><HBT>3</HBT><HBTQF /><Laboratory>Ninewells</Laboratory><LaboratoryQF /><Results>Borderline Squamous Changes</Results><ResultsQF /><NumberResult>1190</NumberResult><PercentageResult>3.9</PercentageResult></row>
<row _id="137"><id>137</id><FinancialYear>2011/12</FinancialYear><HBT>3</HBT><HBTQF /><Laboratory>Ninewells</Laboratory><LaboratoryQF /><Results>Borderline Glandular Changes</Results><ResultsQF /><NumberResult>15</NumberResult><PercentageResult>0</PercentageResult></row>
<row _id="138"><id>138</id><FinancialYear>2011/12</FinancialYear><HBT>3</HBT><HBTQF /><Laboratory>Ninewells</Laboratory><LaboratoryQF /><Results>Mild Dyskaryosis</Results><ResultsQF /><NumberResult>752</NumberResult><PercentageResult>2.4</PercentageResult></row>
<row _id="139"><id>139</id><FinancialYear>2011/12</FinancialYear><HBT>3</HBT><HBTQF /><Laboratory>Ninewells</Laboratory><LaboratoryQF /><Results>Moderate Dyskaryosis</Results><ResultsQF /><NumberResult>177</NumberResult><PercentageResult>0.6</PercentageResult></row>
<row _id="140"><id>140</id><FinancialYear>2011/12</FinancialYear><HBT>3</HBT><HBTQF /><Laboratory>Ninewells</Laboratory><LaboratoryQF /><Results>Severe Dyskaryosis</Results><ResultsQF /><NumberResult>152</NumberResult><PercentageResult>0.5</PercentageResult></row>
<row _id="141"><id>141</id><FinancialYear>2011/12</FinancialYear><HBT>3</HBT><HBTQF /><Laboratory>Ninewells</Laboratory><LaboratoryQF /><Results>Severe Dyskaryosis (Invasive)</Results><ResultsQF /><NumberResult>5</NumberResult><PercentageResult>0</PercentageResult></row>
<row _id="142"><id>142</id><FinancialYear>2011/12</FinancialYear><HBT>3</HBT><HBTQF /><Laboratory>Ninewells</Laboratory><LaboratoryQF /><Results>Glandular Abnormality</Results><ResultsQF /><NumberResult>14</NumberResult><PercentageResult>0</PercentageResult></row>
<row _id="143"><id>143</id><FinancialYear>2011/12</FinancialYear><HBT>3</HBT><HBTQF /><Laboratory>Ninewells</Laboratory><LaboratoryQF /><Results>Endocervical Adenocarcinoma</Results><ResultsQF /><NumberResult>3</NumberResult><PercentageResult>0</PercentageResult></row>
<row _id="144"><id>144</id><FinancialYear>2011/12</FinancialYear><HBT>3</HBT><HBTQF /><Laboratory>Ninewells</Laboratory><LaboratoryQF /><Results>Endometrial or other cancer</Results><ResultsQF /><NumberResult>1</NumberResult><PercentageResult>0</PercentageResult></row>
<row _id="145"><id>145</id><FinancialYear>2010/11</FinancialYear><HBT>S92000003</HBT><HBTQF>d</HBTQF><Laboratory>Scotland</Laboratory><LaboratoryQF>d</LaboratoryQF><Results>Total number of smears</Results><ResultsQF>d</ResultsQF><NumberResult>390194</NumberResult><PercentageResult>100</PercentageResult></row>
<row _id="146"><id>146</id><FinancialYear>2010/11</FinancialYear><HBT>S92000003</HBT><HBTQF>d</HBTQF><Laboratory>Scotland</Laboratory><LaboratoryQF>d</LaboratoryQF><Results>Unsatisfactory</Results><ResultsQF /><NumberResult>10839</NumberResult><PercentageResult>2.8</PercentageResult></row>
<row _id="147"><id>147</id><FinancialYear>2010/11</FinancialYear><HBT>S92000003</HBT><HBTQF>d</HBTQF><Laboratory>Scotland</Laboratory><LaboratoryQF>d</LaboratoryQF><Results>Negative</Results><ResultsQF /><NumberResult>344429</NumberResult><PercentageResult>90.8</PercentageResult></row>
<row _id="148"><id>148</id><FinancialYear>2010/11</FinancialYear><HBT>S92000003</HBT><HBTQF>d</HBTQF><Laboratory>Scotland</Laboratory><LaboratoryQF>d</LaboratoryQF><Results>Borderline Squamous Changes</Results><ResultsQF /><NumberResult>21508</NumberResult><PercentageResult>5.7</PercentageResult></row>
<row _id="149"><id>149</id><FinancialYear>2010/11</FinancialYear><HBT>S92000003</HBT><HBTQF>d</HBTQF><Laboratory>Scotland</Laboratory><LaboratoryQF>d</LaboratoryQF><Results>Borderline Glandular Changes</Results><ResultsQF /><NumberResult>324</NumberResult><PercentageResult>0.1</PercentageResult></row>
<row _id="150"><id>150</id><FinancialYear>2010/11</FinancialYear><HBT>S92000003</HBT><HBTQF>d</HBTQF><Laboratory>Scotland</Laboratory><LaboratoryQF>d</LaboratoryQF><Results>Mild Dyskaryosis</Results><ResultsQF /><NumberResult>8136</NumberResult><PercentageResult>2.1</PercentageResult></row>
<row _id="151"><id>151</id><FinancialYear>2010/11</FinancialYear><HBT>S92000003</HBT><HBTQF>d</HBTQF><Laboratory>Scotland</Laboratory><LaboratoryQF>d</LaboratoryQF><Results>Moderate Dyskaryosis</Results><ResultsQF /><NumberResult>2393</NumberResult><PercentageResult>0.6</PercentageResult></row>
<row _id="152"><id>152</id><FinancialYear>2010/11</FinancialYear><HBT>S92000003</HBT><HBTQF>d</HBTQF><Laboratory>Scotland</Laboratory><LaboratoryQF>d</LaboratoryQF><Results>Severe Dyskaryosis</Results><ResultsQF /><NumberResult>2279</NumberResult><PercentageResult>0.6</PercentageResult></row>
<row _id="153"><id>153</id><FinancialYear>2010/11</FinancialYear><HBT>S92000003</HBT><HBTQF>d</HBTQF><Laboratory>Scotland</Laboratory><LaboratoryQF>d</LaboratoryQF><Results>Severe Dyskaryosis (Invasive)</Results><ResultsQF /><NumberResult>102</NumberResult><PercentageResult>0</PercentageResult></row>
<row _id="154"><id>154</id><FinancialYear>2010/11</FinancialYear><HBT>S92000003</HBT><HBTQF>d</HBTQF><Laboratory>Scotland</Laboratory><LaboratoryQF>d</LaboratoryQF><Results>Glandular Abnormality</Results><ResultsQF /><NumberResult>145</NumberResult><PercentageResult>0</PercentageResult></row>
<row _id="155"><id>155</id><FinancialYear>2010/11</FinancialYear><HBT>S92000003</HBT><HBTQF>d</HBTQF><Laboratory>Scotland</Laboratory><LaboratoryQF>d</LaboratoryQF><Results>Endocervical Adenocarcinoma</Results><ResultsQF /><NumberResult>8</NumberResult><PercentageResult>0</PercentageResult></row>
<row _id="156"><id>156</id><FinancialYear>2010/11</FinancialYear><HBT>S92000003</HBT><HBTQF>d</HBTQF><Laboratory>Scotland</Laboratory><LaboratoryQF>d</LaboratoryQF><Results>Endometrial or other cancer</Results><ResultsQF /><NumberResult>31</NumberResult><PercentageResult>0</PercentageResult></row>
<row _id="157"><id>157</id><FinancialYear>2010/11</FinancialYear><HBT>8</HBT><HBTQF /><Laboratory>Inverclyde</Laboratory><LaboratoryQF /><Results>Total number of smears</Results><ResultsQF>d</ResultsQF><NumberResult>32254</NumberResult><PercentageResult>100</PercentageResult></row>
<row _id="158"><id>158</id><FinancialYear>2010/11</FinancialYear><HBT>8</HBT><HBTQF /><Laboratory>Inverclyde</Laboratory><LaboratoryQF /><Results>Unsatisfactory</Results><ResultsQF /><NumberResult>882</NumberResult><PercentageResult>2.7</PercentageResult></row>
<row _id="159"><id>159</id><FinancialYear>2010/11</FinancialYear><HBT>8</HBT><HBTQF /><Laboratory>Inverclyde</Laboratory><LaboratoryQF /><Results>Negative</Results><ResultsQF /><NumberResult>28294</NumberResult><PercentageResult>90.2</PercentageResult></row>
<row _id="160"><id>160</id><FinancialYear>2010/11</FinancialYear><HBT>8</HBT><HBTQF /><Laboratory>Inverclyde</Laboratory><LaboratoryQF /><Results>Borderline Squamous Changes</Results><ResultsQF /><NumberResult>2470</NumberResult><PercentageResult>7.9</PercentageResult></row>
<row _id="161"><id>161</id><FinancialYear>2010/11</FinancialYear><HBT>8</HBT><HBTQF /><Laboratory>Inverclyde</Laboratory><LaboratoryQF /><Results>Borderline Glandular Changes</Results><ResultsQF /><NumberResult>13</NumberResult><PercentageResult>0</PercentageResult></row>
<row _id="162"><id>162</id><FinancialYear>2010/11</FinancialYear><HBT>8</HBT><HBTQF /><Laboratory>Inverclyde</Laboratory><LaboratoryQF /><Results>Mild Dyskaryosis</Results><ResultsQF /><NumberResult>327</NumberResult><PercentageResult>1</PercentageResult></row>
<row _id="163"><id>163</id><FinancialYear>2010/11</FinancialYear><HBT>8</HBT><HBTQF /><Laboratory>Inverclyde</Laboratory><LaboratoryQF /><Results>Moderate Dyskaryosis</Results><ResultsQF /><NumberResult>130</NumberResult><PercentageResult>0.4</PercentageResult></row>
<row _id="164"><id>164</id><FinancialYear>2010/11</FinancialYear><HBT>8</HBT><HBTQF /><Laboratory>Inverclyde</Laboratory><LaboratoryQF /><Results>Severe Dyskaryosis</Results><ResultsQF /><NumberResult>128</NumberResult><PercentageResult>0.4</PercentageResult></row>
<row _id="165"><id>165</id><FinancialYear>2010/11</FinancialYear><HBT>8</HBT><HBTQF /><Laboratory>Inverclyde</Laboratory><LaboratoryQF /><Results>Severe Dyskaryosis (Invasive)</Results><ResultsQF /><NumberResult>3</NumberResult><PercentageResult>0</PercentageResult></row>
<row _id="166"><id>166</id><FinancialYear>2010/11</FinancialYear><HBT>8</HBT><HBTQF /><Laboratory>Inverclyde</Laboratory><LaboratoryQF /><Results>Glandular Abnormality</Results><ResultsQF /><NumberResult>7</NumberResult><PercentageResult>0</PercentageResult></row>
<row _id="167"><id>167</id><FinancialYear>2010/11</FinancialYear><HBT>8</HBT><HBTQF /><Laboratory>Inverclyde</Laboratory><LaboratoryQF /><Results>Endocervical Adenocarcinoma</Results><ResultsQF /><NumberResult>0</NumberResult><PercentageResult>0</PercentageResult></row>
<row _id="168"><id>168</id><FinancialYear>2010/11</FinancialYear><HBT>8</HBT><HBTQF /><Laboratory>Inverclyde</Laboratory><LaboratoryQF /><Results>Endometrial or other cancer</Results><ResultsQF /><NumberResult>0</NumberResult><PercentageResult>0</PercentageResult></row>
<row _id="169"><id>169</id><FinancialYear>2010/11</FinancialYear><HBT>11</HBT><HBTQF /><Laboratory>Cross House</Laboratory><LaboratoryQF /><Results>Total number of smears</Results><ResultsQF>d</ResultsQF><NumberResult>24800</NumberResult><PercentageResult>100</PercentageResult></row>
<row _id="170"><id>170</id><FinancialYear>2010/11</FinancialYear><HBT>11</HBT><HBTQF /><Laboratory>Cross House</Laboratory><LaboratoryQF /><Results>Unsatisfactory</Results><ResultsQF /><NumberResult>900</NumberResult><PercentageResult>3.6</PercentageResult></row>
<row _id="171"><id>171</id><FinancialYear>2010/11</FinancialYear><HBT>11</HBT><HBTQF /><Laboratory>Cross House</Laboratory><LaboratoryQF /><Results>Negative</Results><ResultsQF /><NumberResult>22198</NumberResult><PercentageResult>92.9</PercentageResult></row>
<row _id="172"><id>172</id><FinancialYear>2010/11</FinancialYear><HBT>11</HBT><HBTQF /><Laboratory>Cross House</Laboratory><LaboratoryQF /><Results>Borderline Squamous Changes</Results><ResultsQF /><NumberResult>1004</NumberResult><PercentageResult>4.2</PercentageResult></row>
<row _id="173"><id>173</id><FinancialYear>2010/11</FinancialYear><HBT>11</HBT><HBTQF /><Laboratory>Cross House</Laboratory><LaboratoryQF /><Results>Borderline Glandular Changes</Results><ResultsQF /><NumberResult>19</NumberResult><PercentageResult>0.1</PercentageResult></row>
<row _id="174"><id>174</id><FinancialYear>2010/11</FinancialYear><HBT>11</HBT><HBTQF /><Laboratory>Cross House</Laboratory><LaboratoryQF /><Results>Mild Dyskaryosis</Results><ResultsQF /><NumberResult>386</NumberResult><PercentageResult>1.6</PercentageResult></row>
<row _id="175"><id>175</id><FinancialYear>2010/11</FinancialYear><HBT>11</HBT><HBTQF /><Laboratory>Cross House</Laboratory><LaboratoryQF /><Results>Moderate Dyskaryosis</Results><ResultsQF /><NumberResult>73</NumberResult><PercentageResult>0.3</PercentageResult></row>
<row _id="176"><id>176</id><FinancialYear>2010/11</FinancialYear><HBT>11</HBT><HBTQF /><Laboratory>Cross House</Laboratory><LaboratoryQF /><Results>Severe Dyskaryosis</Results><ResultsQF /><NumberResult>206</NumberResult><PercentageResult>0.9</PercentageResult></row>
<row _id="177"><id>177</id><FinancialYear>2010/11</FinancialYear><HBT>11</HBT><HBTQF /><Laboratory>Cross House</Laboratory><LaboratoryQF /><Results>Severe Dyskaryosis (Invasive)</Results><ResultsQF /><NumberResult>8</NumberResult><PercentageResult>0</PercentageResult></row>
<row _id="178"><id>178</id><FinancialYear>2010/11</FinancialYear><HBT>11</HBT><HBTQF /><Laboratory>Cross House</Laboratory><LaboratoryQF /><Results>Glandular Abnormality</Results><ResultsQF /><NumberResult>5</NumberResult><PercentageResult>0</PercentageResult></row>
<row _id="179"><id>179</id><FinancialYear>2010/11</FinancialYear><HBT>11</HBT><HBTQF /><Laboratory>Cross House</Laboratory><LaboratoryQF /><Results>Endocervical Adenocarcinoma</Results><ResultsQF /><NumberResult>0</NumberResult><PercentageResult>0</PercentageResult></row>
<row _id="180"><id>180</id><FinancialYear>2010/11</FinancialYear><HBT>11</HBT><HBTQF /><Laboratory>Cross House</Laboratory><LaboratoryQF /><Results>Endometrial or other cancer</Results><ResultsQF /><NumberResult>1</NumberResult><PercentageResult>0</PercentageResult></row>
<row _id="181"><id>181</id><FinancialYear>2010/11</FinancialYear><HBT>4</HBT><HBTQF /><Laboratory>Forth Park</Laboratory><LaboratoryQF /><Results>Total number of smears</Results><ResultsQF>d</ResultsQF><NumberResult>24140</NumberResult><PercentageResult>100</PercentageResult></row>
<row _id="182"><id>182</id><FinancialYear>2010/11</FinancialYear><HBT>4</HBT><HBTQF /><Laboratory>Forth Park</Laboratory><LaboratoryQF /><Results>Unsatisfactory</Results><ResultsQF /><NumberResult>657</NumberResult><PercentageResult>2.7</PercentageResult></row>
<row _id="183"><id>183</id><FinancialYear>2010/11</FinancialYear><HBT>4</HBT><HBTQF /><Laboratory>Forth Park</Laboratory><LaboratoryQF /><Results>Negative</Results><ResultsQF /><NumberResult>21636</NumberResult><PercentageResult>92.1</PercentageResult></row>
<row _id="184"><id>184</id><FinancialYear>2010/11</FinancialYear><HBT>4</HBT><HBTQF /><Laboratory>Forth Park</Laboratory><LaboratoryQF /><Results>Borderline Squamous Changes</Results><ResultsQF /><NumberResult>843</NumberResult><PercentageResult>3.6</PercentageResult></row>
<row _id="185"><id>185</id><FinancialYear>2010/11</FinancialYear><HBT>4</HBT><HBTQF /><Laboratory>Forth Park</Laboratory><LaboratoryQF /><Results>Borderline Glandular Changes</Results><ResultsQF /><NumberResult>13</NumberResult><PercentageResult>0.1</PercentageResult></row>
<row _id="186"><id>186</id><FinancialYear>2010/11</FinancialYear><HBT>4</HBT><HBTQF /><Laboratory>Forth Park</Laboratory><LaboratoryQF /><Results>Mild Dyskaryosis</Results><ResultsQF /><NumberResult>679</NumberResult><PercentageResult>2.9</PercentageResult></row>
<row _id="187"><id>187</id><FinancialYear>2010/11</FinancialYear><HBT>4</HBT><HBTQF /><Laboratory>Forth Park</Laboratory><LaboratoryQF /><Results>Moderate Dyskaryosis</Results><ResultsQF /><NumberResult>177</NumberResult><PercentageResult>0.8</PercentageResult></row>
<row _id="188"><id>188</id><FinancialYear>2010/11</FinancialYear><HBT>4</HBT><HBTQF /><Laboratory>Forth Park</Laboratory><LaboratoryQF /><Results>Severe Dyskaryosis</Results><ResultsQF /><NumberResult>122</NumberResult><PercentageResult>0.5</PercentageResult></row>
<row _id="189"><id>189</id><FinancialYear>2010/11</FinancialYear><HBT>4</HBT><HBTQF /><Laboratory>Forth Park</Laboratory><LaboratoryQF /><Results>Severe Dyskaryosis (Invasive)</Results><ResultsQF /><NumberResult>6</NumberResult><PercentageResult>0</PercentageResult></row>
<row _id="190"><id>190</id><FinancialYear>2010/11</FinancialYear><HBT>4</HBT><HBTQF /><Laboratory>Forth Park</Laboratory><LaboratoryQF /><Results>Glandular Abnormality</Results><ResultsQF /><NumberResult>6</NumberResult><PercentageResult>0</PercentageResult></row>
<row _id="191"><id>191</id><FinancialYear>2010/11</FinancialYear><HBT>4</HBT><HBTQF /><Laboratory>Forth Park</Laboratory><LaboratoryQF /><Results>Endocervical Adenocarcinoma</Results><ResultsQF /><NumberResult>0</NumberResult><PercentageResult>0</PercentageResult></row>
<row _id="192"><id>192</id><FinancialYear>2010/11</FinancialYear><HBT>4</HBT><HBTQF /><Laboratory>Forth Park</Laboratory><LaboratoryQF /><Results>Endometrial or other cancer</Results><ResultsQF /><NumberResult>1</NumberResult><PercentageResult>0</PercentageResult></row>
<row _id="193"><id>193</id><FinancialYear>2010/11</FinancialYear><HBT>7</HBT><HBTQF /><Laboratory>Stirling Royal Infirmary</Laboratory><LaboratoryQF /><Results>Total number of smears</Results><ResultsQF>d</ResultsQF><NumberResult>22972</NumberResult><PercentageResult>100</PercentageResult></row>
<row _id="194"><id>194</id><FinancialYear>2010/11</FinancialYear><HBT>7</HBT><HBTQF /><Laboratory>Stirling Royal Infirmary</Laboratory><LaboratoryQF /><Results>Unsatisfactory</Results><ResultsQF /><NumberResult>633</NumberResult><PercentageResult>2.8</PercentageResult></row>
<row _id="195"><id>195</id><FinancialYear>2010/11</FinancialYear><HBT>7</HBT><HBTQF /><Laboratory>Stirling Royal Infirmary</Laboratory><LaboratoryQF /><Results>Negative</Results><ResultsQF /><NumberResult>20421</NumberResult><PercentageResult>91.4</PercentageResult></row>
<row _id="196"><id>196</id><FinancialYear>2010/11</FinancialYear><HBT>7</HBT><HBTQF /><Laboratory>Stirling Royal Infirmary</Laboratory><LaboratoryQF /><Results>Borderline Squamous Changes</Results><ResultsQF /><NumberResult>1150</NumberResult><PercentageResult>5.1</PercentageResult></row>
<row _id="197"><id>197</id><FinancialYear>2010/11</FinancialYear><HBT>7</HBT><HBTQF /><Laboratory>Stirling Royal Infirmary</Laboratory><LaboratoryQF /><Results>Borderline Glandular Changes</Results><ResultsQF /><NumberResult>47</NumberResult><PercentageResult>0.2</PercentageResult></row>
<row _id="198"><id>198</id><FinancialYear>2010/11</FinancialYear><HBT>7</HBT><HBTQF /><Laboratory>Stirling Royal Infirmary</Laboratory><LaboratoryQF /><Results>Mild Dyskaryosis</Results><ResultsQF /><NumberResult>441</NumberResult><PercentageResult>2</PercentageResult></row>
<row _id="199"><id>199</id><FinancialYear>2010/11</FinancialYear><HBT>7</HBT><HBTQF /><Laboratory>Stirling Royal Infirmary</Laboratory><LaboratoryQF /><Results>Moderate Dyskaryosis</Results><ResultsQF /><NumberResult>177</NumberResult><PercentageResult>0.8</PercentageResult></row>
<row _id="200"><id>200</id><FinancialYear>2010/11</FinancialYear><HBT>7</HBT><HBTQF /><Laboratory>Stirling Royal Infirmary</Laboratory><LaboratoryQF /><Results>Severe Dyskaryosis</Results><ResultsQF /><NumberResult>76</NumberResult><PercentageResult>0.3</PercentageResult></row>
<row _id="201"><id>201</id><FinancialYear>2010/11</FinancialYear><HBT>7</HBT><HBTQF /><Laboratory>Stirling Royal Infirmary</Laboratory><LaboratoryQF /><Results>Severe Dyskaryosis (Invasive)</Results><ResultsQF /><NumberResult>14</NumberResult><PercentageResult>0.1</PercentageResult></row>
<row _id="202"><id>202</id><FinancialYear>2010/11</FinancialYear><HBT>7</HBT><HBTQF /><Laboratory>Stirling Royal Infirmary</Laboratory><LaboratoryQF /><Results>Glandular Abnormality</Results><ResultsQF /><NumberResult>12</NumberResult><PercentageResult>0.1</PercentageResult></row>
<row _id="203"><id>203</id><FinancialYear>2010/11</FinancialYear><HBT>7</HBT><HBTQF /><Laboratory>Stirling Royal Infirmary</Laboratory><LaboratoryQF /><Results>Endocervical Adenocarcinoma</Results><ResultsQF /><NumberResult>0</NumberResult><PercentageResult>0</PercentageResult></row>
<row _id="204"><id>204</id><FinancialYear>2010/11</FinancialYear><HBT>7</HBT><HBTQF /><Laboratory>Stirling Royal Infirmary</Laboratory><LaboratoryQF /><Results>Endometrial or other cancer</Results><ResultsQF /><NumberResult>1</NumberResult><PercentageResult>0</PercentageResult></row>
<row _id="205"><id>205</id><FinancialYear>2010/11</FinancialYear><HBT>2</HBT><HBTQF /><Laboratory>Forester Hill</Laboratory><LaboratoryQF /><Results>Total number of smears</Results><ResultsQF>d</ResultsQF><NumberResult>45103</NumberResult><PercentageResult>100</PercentageResult></row>
<row _id="206"><id>206</id><FinancialYear>2010/11</FinancialYear><HBT>2</HBT><HBTQF /><Laboratory>Forester Hill</Laboratory><LaboratoryQF /><Results>Unsatisfactory</Results><ResultsQF /><NumberResult>1090</NumberResult><PercentageResult>2.4</PercentageResult></row>
<row _id="207"><id>207</id><FinancialYear>2010/11</FinancialYear><HBT>2</HBT><HBTQF /><Laboratory>Forester Hill</Laboratory><LaboratoryQF /><Results>Negative</Results><ResultsQF /><NumberResult>40275</NumberResult><PercentageResult>91.5</PercentageResult></row>
<row _id="208"><id>208</id><FinancialYear>2010/11</FinancialYear><HBT>2</HBT><HBTQF /><Laboratory>Forester Hill</Laboratory><LaboratoryQF /><Results>Borderline Squamous Changes</Results><ResultsQF /><NumberResult>2411</NumberResult><PercentageResult>5.5</PercentageResult></row>
<row _id="209"><id>209</id><FinancialYear>2010/11</FinancialYear><HBT>2</HBT><HBTQF /><Laboratory>Forester Hill</Laboratory><LaboratoryQF /><Results>Borderline Glandular Changes</Results><ResultsQF /><NumberResult>10</NumberResult><PercentageResult>0</PercentageResult></row>
<row _id="210"><id>210</id><FinancialYear>2010/11</FinancialYear><HBT>2</HBT><HBTQF /><Laboratory>Forester Hill</Laboratory><LaboratoryQF /><Results>Mild Dyskaryosis</Results><ResultsQF /><NumberResult>789</NumberResult><PercentageResult>1.8</PercentageResult></row>
<row _id="211"><id>211</id><FinancialYear>2010/11</FinancialYear><HBT>2</HBT><HBTQF /><Laboratory>Forester Hill</Laboratory><LaboratoryQF /><Results>Moderate Dyskaryosis</Results><ResultsQF /><NumberResult>241</NumberResult><PercentageResult>0.5</PercentageResult></row>
<row _id="212"><id>212</id><FinancialYear>2010/11</FinancialYear><HBT>2</HBT><HBTQF /><Laboratory>Forester Hill</Laboratory><LaboratoryQF /><Results>Severe Dyskaryosis</Results><ResultsQF /><NumberResult>252</NumberResult><PercentageResult>0.6</PercentageResult></row>
<row _id="213"><id>213</id><FinancialYear>2010/11</FinancialYear><HBT>2</HBT><HBTQF /><Laboratory>Forester Hill</Laboratory><LaboratoryQF /><Results>Severe Dyskaryosis (Invasive)</Results><ResultsQF /><NumberResult>10</NumberResult><PercentageResult>0</PercentageResult></row>
<row _id="214"><id>214</id><FinancialYear>2010/11</FinancialYear><HBT>2</HBT><HBTQF /><Laboratory>Forester Hill</Laboratory><LaboratoryQF /><Results>Glandular Abnormality</Results><ResultsQF /><NumberResult>19</NumberResult><PercentageResult>0</PercentageResult></row>
<row _id="215"><id>215</id><FinancialYear>2010/11</FinancialYear><HBT>2</HBT><HBTQF /><Laboratory>Forester Hill</Laboratory><LaboratoryQF /><Results>Endocervical Adenocarcinoma</Results><ResultsQF /><NumberResult>1</NumberResult><PercentageResult>0</PercentageResult></row>
<row _id="216"><id>216</id><FinancialYear>2010/11</FinancialYear><HBT>2</HBT><HBTQF /><Laboratory>Forester Hill</Laboratory><LaboratoryQF /><Results>Endometrial or other cancer</Results><ResultsQF /><NumberResult>5</NumberResult><PercentageResult>0</PercentageResult></row>
<row _id="217"><id>217</id><FinancialYear>2010/11</FinancialYear><HBT>9</HBT><HBTQF /><Laboratory>Southern General</Laboratory><LaboratoryQF /><Results>Total number of smears</Results><ResultsQF>d</ResultsQF><NumberResult>25325</NumberResult><PercentageResult>100</PercentageResult></row>
<row _id="218"><id>218</id><FinancialYear>2010/11</FinancialYear><HBT>9</HBT><HBTQF /><Laboratory>Southern General</Laboratory><LaboratoryQF /><Results>Unsatisfactory</Results><ResultsQF /><NumberResult>677</NumberResult><PercentageResult>2.7</PercentageResult></row>
<row _id="219"><id>219</id><FinancialYear>2010/11</FinancialYear><HBT>9</HBT><HBTQF /><Laboratory>Southern General</Laboratory><LaboratoryQF /><Results>Negative</Results><ResultsQF /><NumberResult>22652</NumberResult><PercentageResult>91.9</PercentageResult></row>
<row _id="220"><id>220</id><FinancialYear>2010/11</FinancialYear><HBT>9</HBT><HBTQF /><Laboratory>Southern General</Laboratory><LaboratoryQF /><Results>Borderline Squamous Changes</Results><ResultsQF /><NumberResult>1327</NumberResult><PercentageResult>5.4</PercentageResult></row>
<row _id="221"><id>221</id><FinancialYear>2010/11</FinancialYear><HBT>9</HBT><HBTQF /><Laboratory>Southern General</Laboratory><LaboratoryQF /><Results>Borderline Glandular Changes</Results><ResultsQF /><NumberResult>5</NumberResult><PercentageResult>0</PercentageResult></row>
<row _id="222"><id>222</id><FinancialYear>2010/11</FinancialYear><HBT>9</HBT><HBTQF /><Laboratory>Southern General</Laboratory><LaboratoryQF /><Results>Mild Dyskaryosis</Results><ResultsQF /><NumberResult>463</NumberResult><PercentageResult>1.9</PercentageResult></row>
<row _id="223"><id>223</id><FinancialYear>2010/11</FinancialYear><HBT>9</HBT><HBTQF /><Laboratory>Southern General</Laboratory><LaboratoryQF /><Results>Moderate Dyskaryosis</Results><ResultsQF /><NumberResult>93</NumberResult><PercentageResult>0.4</PercentageResult></row>
<row _id="224"><id>224</id><FinancialYear>2010/11</FinancialYear><HBT>9</HBT><HBTQF /><Laboratory>Southern General</Laboratory><LaboratoryQF /><Results>Severe Dyskaryosis</Results><ResultsQF /><NumberResult>100</NumberResult><PercentageResult>0.4</PercentageResult></row>
<row _id="225"><id>225</id><FinancialYear>2010/11</FinancialYear><HBT>9</HBT><HBTQF /><Laboratory>Southern General</Laboratory><LaboratoryQF /><Results>Severe Dyskaryosis (Invasive)</Results><ResultsQF /><NumberResult>6</NumberResult><PercentageResult>0</PercentageResult></row>
<row _id="226"><id>226</id><FinancialYear>2010/11</FinancialYear><HBT>9</HBT><HBTQF /><Laboratory>Southern General</Laboratory><LaboratoryQF /><Results>Glandular Abnormality</Results><ResultsQF /><NumberResult>2</NumberResult><PercentageResult>0</PercentageResult></row>
<row _id="227"><id>227</id><FinancialYear>2010/11</FinancialYear><HBT>9</HBT><HBTQF /><Laboratory>Southern General</Laboratory><LaboratoryQF /><Results>Endocervical Adenocarcinoma</Results><ResultsQF /><NumberResult>0</NumberResult><PercentageResult>0</PercentageResult></row>
<row _id="228"><id>228</id><FinancialYear>2010/11</FinancialYear><HBT>9</HBT><HBTQF /><Laboratory>Southern General</Laboratory><LaboratoryQF /><Results>Endometrial or other cancer</Results><ResultsQF /><NumberResult>0</NumberResult><PercentageResult>0</PercentageResult></row>
<row _id="229"><id>229</id><FinancialYear>2010/11</FinancialYear><HBT>9</HBT><HBTQF /><Laboratory>Royal Infirmary</Laboratory><LaboratoryQF /><Results>Total number of smears</Results><ResultsQF>d</ResultsQF><NumberResult>42295</NumberResult><PercentageResult>100</PercentageResult></row>
<row _id="230"><id>230</id><FinancialYear>2010/11</FinancialYear><HBT>9</HBT><HBTQF /><Laboratory>Royal Infirmary</Laboratory><LaboratoryQF /><Results>Unsatisfactory</Results><ResultsQF /><NumberResult>951</NumberResult><PercentageResult>2.2</PercentageResult></row>
<row _id="231"><id>231</id><FinancialYear>2010/11</FinancialYear><HBT>9</HBT><HBTQF /><Laboratory>Royal Infirmary</Laboratory><LaboratoryQF /><Results>Negative</Results><ResultsQF /><NumberResult>35900</NumberResult><PercentageResult>86.8</PercentageResult></row>
<row _id="232"><id>232</id><FinancialYear>2010/11</FinancialYear><HBT>9</HBT><HBTQF /><Laboratory>Royal Infirmary</Laboratory><LaboratoryQF /><Results>Borderline Squamous Changes</Results><ResultsQF /><NumberResult>3232</NumberResult><PercentageResult>7.8</PercentageResult></row>
<row _id="233"><id>233</id><FinancialYear>2010/11</FinancialYear><HBT>9</HBT><HBTQF /><Laboratory>Royal Infirmary</Laboratory><LaboratoryQF /><Results>Borderline Glandular Changes</Results><ResultsQF /><NumberResult>26</NumberResult><PercentageResult>0.1</PercentageResult></row>
<row _id="234"><id>234</id><FinancialYear>2010/11</FinancialYear><HBT>9</HBT><HBTQF /><Laboratory>Royal Infirmary</Laboratory><LaboratoryQF /><Results>Mild Dyskaryosis</Results><ResultsQF /><NumberResult>1436</NumberResult><PercentageResult>3.5</PercentageResult></row>
<row _id="235"><id>235</id><FinancialYear>2010/11</FinancialYear><HBT>9</HBT><HBTQF /><Laboratory>Royal Infirmary</Laboratory><LaboratoryQF /><Results>Moderate Dyskaryosis</Results><ResultsQF /><NumberResult>422</NumberResult><PercentageResult>1</PercentageResult></row>
<row _id="236"><id>236</id><FinancialYear>2010/11</FinancialYear><HBT>9</HBT><HBTQF /><Laboratory>Royal Infirmary</Laboratory><LaboratoryQF /><Results>Severe Dyskaryosis</Results><ResultsQF /><NumberResult>296</NumberResult><PercentageResult>0.7</PercentageResult></row>
<row _id="237"><id>237</id><FinancialYear>2010/11</FinancialYear><HBT>9</HBT><HBTQF /><Laboratory>Royal Infirmary</Laboratory><LaboratoryQF /><Results>Severe Dyskaryosis (Invasive)</Results><ResultsQF /><NumberResult>8</NumberResult><PercentageResult>0</PercentageResult></row>
<row _id="238"><id>238</id><FinancialYear>2010/11</FinancialYear><HBT>9</HBT><HBTQF /><Laboratory>Royal Infirmary</Laboratory><LaboratoryQF /><Results>Glandular Abnormality</Results><ResultsQF /><NumberResult>18</NumberResult><PercentageResult>0</PercentageResult></row>
<row _id="239"><id>239</id><FinancialYear>2010/11</FinancialYear><HBT>9</HBT><HBTQF /><Laboratory>Royal Infirmary</Laboratory><LaboratoryQF /><Results>Endocervical Adenocarcinoma</Results><ResultsQF /><NumberResult>0</NumberResult><PercentageResult>0</PercentageResult></row>
<row _id="240"><id>240</id><FinancialYear>2010/11</FinancialYear><HBT>9</HBT><HBTQF /><Laboratory>Royal Infirmary</Laboratory><LaboratoryQF /><Results>Endometrial or other cancer</Results><ResultsQF /><NumberResult>6</NumberResult><PercentageResult>0</PercentageResult></row>
<row _id="241"><id>241</id><FinancialYear>2010/11</FinancialYear><HBT>1</HBT><HBTQF /><Laboratory>Raigmore</Laboratory><LaboratoryQF /><Results>Total number of smears</Results><ResultsQF>d</ResultsQF><NumberResult>17102</NumberResult><PercentageResult>100</PercentageResult></row>
<row _id="242"><id>242</id><FinancialYear>2010/11</FinancialYear><HBT>1</HBT><HBTQF /><Laboratory>Raigmore</Laboratory><LaboratoryQF /><Results>Unsatisfactory</Results><ResultsQF /><NumberResult>398</NumberResult><PercentageResult>2.3</PercentageResult></row>
<row _id="243"><id>243</id><FinancialYear>2010/11</FinancialYear><HBT>1</HBT><HBTQF /><Laboratory>Raigmore</Laboratory><LaboratoryQF /><Results>Negative</Results><ResultsQF /><NumberResult>15599</NumberResult><PercentageResult>93.4</PercentageResult></row>
<row _id="244"><id>244</id><FinancialYear>2010/11</FinancialYear><HBT>1</HBT><HBTQF /><Laboratory>Raigmore</Laboratory><LaboratoryQF /><Results>Borderline Squamous Changes</Results><ResultsQF /><NumberResult>477</NumberResult><PercentageResult>2.9</PercentageResult></row>
<row _id="245"><id>245</id><FinancialYear>2010/11</FinancialYear><HBT>1</HBT><HBTQF /><Laboratory>Raigmore</Laboratory><LaboratoryQF /><Results>Borderline Glandular Changes</Results><ResultsQF /><NumberResult>14</NumberResult><PercentageResult>0.1</PercentageResult></row>
<row _id="246"><id>246</id><FinancialYear>2010/11</FinancialYear><HBT>1</HBT><HBTQF /><Laboratory>Raigmore</Laboratory><LaboratoryQF /><Results>Mild Dyskaryosis</Results><ResultsQF /><NumberResult>297</NumberResult><PercentageResult>1.8</PercentageResult></row>
<row _id="247"><id>247</id><FinancialYear>2010/11</FinancialYear><HBT>1</HBT><HBTQF /><Laboratory>Raigmore</Laboratory><LaboratoryQF /><Results>Moderate Dyskaryosis</Results><ResultsQF /><NumberResult>144</NumberResult><PercentageResult>0.9</PercentageResult></row>
<row _id="248"><id>248</id><FinancialYear>2010/11</FinancialYear><HBT>1</HBT><HBTQF /><Laboratory>Raigmore</Laboratory><LaboratoryQF /><Results>Severe Dyskaryosis</Results><ResultsQF /><NumberResult>153</NumberResult><PercentageResult>0.9</PercentageResult></row>
<row _id="249"><id>249</id><FinancialYear>2010/11</FinancialYear><HBT>1</HBT><HBTQF /><Laboratory>Raigmore</Laboratory><LaboratoryQF /><Results>Severe Dyskaryosis (Invasive)</Results><ResultsQF /><NumberResult>8</NumberResult><PercentageResult>0</PercentageResult></row>
<row _id="250"><id>250</id><FinancialYear>2010/11</FinancialYear><HBT>1</HBT><HBTQF /><Laboratory>Raigmore</Laboratory><LaboratoryQF /><Results>Glandular Abnormality</Results><ResultsQF /><NumberResult>8</NumberResult><PercentageResult>0</PercentageResult></row>
<row _id="251"><id>251</id><FinancialYear>2010/11</FinancialYear><HBT>1</HBT><HBTQF /><Laboratory>Raigmore</Laboratory><LaboratoryQF /><Results>Endocervical Adenocarcinoma</Results><ResultsQF /><NumberResult>0</NumberResult><PercentageResult>0</PercentageResult></row>
<row _id="252"><id>252</id><FinancialYear>2010/11</FinancialYear><HBT>1</HBT><HBTQF /><Laboratory>Raigmore</Laboratory><LaboratoryQF /><Results>Endometrial or other cancer</Results><ResultsQF /><NumberResult>4</NumberResult><PercentageResult>0</PercentageResult></row>
<row _id="253"><id>253</id><FinancialYear>2010/11</FinancialYear><HBT>10</HBT><HBTQF /><Laboratory>Monklands</Laboratory><LaboratoryQF /><Results>Total number of smears</Results><ResultsQF>d</ResultsQF><NumberResult>50921</NumberResult><PercentageResult>100</PercentageResult></row>
<row _id="254"><id>254</id><FinancialYear>2010/11</FinancialYear><HBT>10</HBT><HBTQF /><Laboratory>Monklands</Laboratory><LaboratoryQF /><Results>Unsatisfactory</Results><ResultsQF /><NumberResult>1543</NumberResult><PercentageResult>3</PercentageResult></row>
<row _id="255"><id>255</id><FinancialYear>2010/11</FinancialYear><HBT>10</HBT><HBTQF /><Laboratory>Monklands</Laboratory><LaboratoryQF /><Results>Negative</Results><ResultsQF /><NumberResult>45805</NumberResult><PercentageResult>92.8</PercentageResult></row>
<row _id="256"><id>256</id><FinancialYear>2010/11</FinancialYear><HBT>10</HBT><HBTQF /><Laboratory>Monklands</Laboratory><LaboratoryQF /><Results>Borderline Squamous Changes</Results><ResultsQF /><NumberResult>2370</NumberResult><PercentageResult>4.8</PercentageResult></row>
<row _id="257"><id>257</id><FinancialYear>2010/11</FinancialYear><HBT>10</HBT><HBTQF /><Laboratory>Monklands</Laboratory><LaboratoryQF /><Results>Borderline Glandular Changes</Results><ResultsQF /><NumberResult>18</NumberResult><PercentageResult>0</PercentageResult></row>
<row _id="258"><id>258</id><FinancialYear>2010/11</FinancialYear><HBT>10</HBT><HBTQF /><Laboratory>Monklands</Laboratory><LaboratoryQF /><Results>Mild Dyskaryosis</Results><ResultsQF /><NumberResult>646</NumberResult><PercentageResult>1.3</PercentageResult></row>
<row _id="259"><id>259</id><FinancialYear>2010/11</FinancialYear><HBT>10</HBT><HBTQF /><Laboratory>Monklands</Laboratory><LaboratoryQF /><Results>Moderate Dyskaryosis</Results><ResultsQF /><NumberResult>233</NumberResult><PercentageResult>0.5</PercentageResult></row>
<row _id="260"><id>260</id><FinancialYear>2010/11</FinancialYear><HBT>10</HBT><HBTQF /><Laboratory>Monklands</Laboratory><LaboratoryQF /><Results>Severe Dyskaryosis</Results><ResultsQF /><NumberResult>261</NumberResult><PercentageResult>0.5</PercentageResult></row>
<row _id="261"><id>261</id><FinancialYear>2010/11</FinancialYear><HBT>10</HBT><HBTQF /><Laboratory>Monklands</Laboratory><LaboratoryQF /><Results>Severe Dyskaryosis (Invasive)</Results><ResultsQF /><NumberResult>12</NumberResult><PercentageResult>0</PercentageResult></row>
<row _id="262"><id>262</id><FinancialYear>2010/11</FinancialYear><HBT>10</HBT><HBTQF /><Laboratory>Monklands</Laboratory><LaboratoryQF /><Results>Glandular Abnormality</Results><ResultsQF /><NumberResult>25</NumberResult><PercentageResult>0.1</PercentageResult></row>
<row _id="263"><id>263</id><FinancialYear>2010/11</FinancialYear><HBT>10</HBT><HBTQF /><Laboratory>Monklands</Laboratory><LaboratoryQF /><Results>Endocervical Adenocarcinoma</Results><ResultsQF /><NumberResult>4</NumberResult><PercentageResult>0</PercentageResult></row>
<row _id="264"><id>264</id><FinancialYear>2010/11</FinancialYear><HBT>10</HBT><HBTQF /><Laboratory>Monklands</Laboratory><LaboratoryQF /><Results>Endometrial or other cancer</Results><ResultsQF /><NumberResult>4</NumberResult><PercentageResult>0</PercentageResult></row>
<row _id="265"><id>265</id><FinancialYear>2010/11</FinancialYear><HBT>5</HBT><HBTQF /><Laboratory>Edinburgh Royal Infirmary</Laboratory><LaboratoryQF /><Results>Total number of smears</Results><ResultsQF>d</ResultsQF><NumberResult>76840</NumberResult><PercentageResult>100</PercentageResult></row>
<row _id="266"><id>266</id><FinancialYear>2010/11</FinancialYear><HBT>5</HBT><HBTQF /><Laboratory>Edinburgh Royal Infirmary</Laboratory><LaboratoryQF /><Results>Unsatisfactory</Results><ResultsQF /><NumberResult>2490</NumberResult><PercentageResult>3.2</PercentageResult></row>
<row _id="267"><id>267</id><FinancialYear>2010/11</FinancialYear><HBT>5</HBT><HBTQF /><Laboratory>Edinburgh Royal Infirmary</Laboratory><LaboratoryQF /><Results>Negative</Results><ResultsQF /><NumberResult>65841</NumberResult><PercentageResult>88.6</PercentageResult></row>
<row _id="268"><id>268</id><FinancialYear>2010/11</FinancialYear><HBT>5</HBT><HBTQF /><Laboratory>Edinburgh Royal Infirmary</Laboratory><LaboratoryQF /><Results>Borderline Squamous Changes</Results><ResultsQF /><NumberResult>5114</NumberResult><PercentageResult>6.9</PercentageResult></row>
<row _id="269"><id>269</id><FinancialYear>2010/11</FinancialYear><HBT>5</HBT><HBTQF /><Laboratory>Edinburgh Royal Infirmary</Laboratory><LaboratoryQF /><Results>Borderline Glandular Changes</Results><ResultsQF /><NumberResult>135</NumberResult><PercentageResult>0.2</PercentageResult></row>
<row _id="270"><id>270</id><FinancialYear>2010/11</FinancialYear><HBT>5</HBT><HBTQF /><Laboratory>Edinburgh Royal Infirmary</Laboratory><LaboratoryQF /><Results>Mild Dyskaryosis</Results><ResultsQF /><NumberResult>2113</NumberResult><PercentageResult>2.8</PercentageResult></row>
<row _id="271"><id>271</id><FinancialYear>2010/11</FinancialYear><HBT>5</HBT><HBTQF /><Laboratory>Edinburgh Royal Infirmary</Laboratory><LaboratoryQF /><Results>Moderate Dyskaryosis</Results><ResultsQF /><NumberResult>569</NumberResult><PercentageResult>0.8</PercentageResult></row>
<row _id="272"><id>272</id><FinancialYear>2010/11</FinancialYear><HBT>5</HBT><HBTQF /><Laboratory>Edinburgh Royal Infirmary</Laboratory><LaboratoryQF /><Results>Severe Dyskaryosis</Results><ResultsQF /><NumberResult>520</NumberResult><PercentageResult>0.7</PercentageResult></row>
<row _id="273"><id>273</id><FinancialYear>2010/11</FinancialYear><HBT>5</HBT><HBTQF /><Laboratory>Edinburgh Royal Infirmary</Laboratory><LaboratoryQF /><Results>Severe Dyskaryosis (Invasive)</Results><ResultsQF /><NumberResult>17</NumberResult><PercentageResult>0</PercentageResult></row>
<row _id="274"><id>274</id><FinancialYear>2010/11</FinancialYear><HBT>5</HBT><HBTQF /><Laboratory>Edinburgh Royal Infirmary</Laboratory><LaboratoryQF /><Results>Glandular Abnormality</Results><ResultsQF /><NumberResult>31</NumberResult><PercentageResult>0</PercentageResult></row>
<row _id="275"><id>275</id><FinancialYear>2010/11</FinancialYear><HBT>5</HBT><HBTQF /><Laboratory>Edinburgh Royal Infirmary</Laboratory><LaboratoryQF /><Results>Endocervical Adenocarcinoma</Results><ResultsQF /><NumberResult>2</NumberResult><PercentageResult>0</PercentageResult></row>
<row _id="276"><id>276</id><FinancialYear>2010/11</FinancialYear><HBT>5</HBT><HBTQF /><Laboratory>Edinburgh Royal Infirmary</Laboratory><LaboratoryQF /><Results>Endometrial or other cancer</Results><ResultsQF /><NumberResult>8</NumberResult><PercentageResult>0</PercentageResult></row>
<row _id="277"><id>277</id><FinancialYear>2010/11</FinancialYear><HBT>3</HBT><HBTQF /><Laboratory>Dundee Royal Infirmary</Laboratory><LaboratoryQF /><Results>Total number of smears</Results><ResultsQF>d</ResultsQF><NumberResult>28442</NumberResult><PercentageResult>100</PercentageResult></row>
<row _id="278"><id>278</id><FinancialYear>2010/11</FinancialYear><HBT>3</HBT><HBTQF /><Laboratory>Dundee Royal Infirmary</Laboratory><LaboratoryQF /><Results>Unsatisfactory</Results><ResultsQF /><NumberResult>618</NumberResult><PercentageResult>2.2</PercentageResult></row>
<row _id="279"><id>279</id><FinancialYear>2010/11</FinancialYear><HBT>3</HBT><HBTQF /><Laboratory>Dundee Royal Infirmary</Laboratory><LaboratoryQF /><Results>Negative</Results><ResultsQF /><NumberResult>25808</NumberResult><PercentageResult>92.8</PercentageResult></row>
<row _id="280"><id>280</id><FinancialYear>2010/11</FinancialYear><HBT>3</HBT><HBTQF /><Laboratory>Dundee Royal Infirmary</Laboratory><LaboratoryQF /><Results>Borderline Squamous Changes</Results><ResultsQF /><NumberResult>1110</NumberResult><PercentageResult>4</PercentageResult></row>
<row _id="281"><id>281</id><FinancialYear>2010/11</FinancialYear><HBT>3</HBT><HBTQF /><Laboratory>Dundee Royal Infirmary</Laboratory><LaboratoryQF /><Results>Borderline Glandular Changes</Results><ResultsQF /><NumberResult>24</NumberResult><PercentageResult>0.1</PercentageResult></row>
<row _id="282"><id>282</id><FinancialYear>2010/11</FinancialYear><HBT>3</HBT><HBTQF /><Laboratory>Dundee Royal Infirmary</Laboratory><LaboratoryQF /><Results>Mild Dyskaryosis</Results><ResultsQF /><NumberResult>559</NumberResult><PercentageResult>2</PercentageResult></row>
<row _id="283"><id>283</id><FinancialYear>2010/11</FinancialYear><HBT>3</HBT><HBTQF /><Laboratory>Dundee Royal Infirmary</Laboratory><LaboratoryQF /><Results>Moderate Dyskaryosis</Results><ResultsQF /><NumberResult>134</NumberResult><PercentageResult>0.5</PercentageResult></row>
<row _id="284"><id>284</id><FinancialYear>2010/11</FinancialYear><HBT>3</HBT><HBTQF /><Laboratory>Dundee Royal Infirmary</Laboratory><LaboratoryQF /><Results>Severe Dyskaryosis</Results><ResultsQF /><NumberResult>165</NumberResult><PercentageResult>0.6</PercentageResult></row>
<row _id="285"><id>285</id><FinancialYear>2010/11</FinancialYear><HBT>3</HBT><HBTQF /><Laboratory>Dundee Royal Infirmary</Laboratory><LaboratoryQF /><Results>Severe Dyskaryosis (Invasive)</Results><ResultsQF /><NumberResult>10</NumberResult><PercentageResult>0</PercentageResult></row>
<row _id="286"><id>286</id><FinancialYear>2010/11</FinancialYear><HBT>3</HBT><HBTQF /><Laboratory>Dundee Royal Infirmary</Laboratory><LaboratoryQF /><Results>Glandular Abnormality</Results><ResultsQF /><NumberResult>12</NumberResult><PercentageResult>0</PercentageResult></row>
<row _id="287"><id>287</id><FinancialYear>2010/11</FinancialYear><HBT>3</HBT><HBTQF /><Laboratory>Dundee Royal Infirmary</Laboratory><LaboratoryQF /><Results>Endocervical Adenocarcinoma</Results><ResultsQF /><NumberResult>1</NumberResult><PercentageResult>0</PercentageResult></row>
<row _id="288"><id>288</id><FinancialYear>2010/11</FinancialYear><HBT>3</HBT><HBTQF /><Laboratory>Dundee Royal Infirmary</Laboratory><LaboratoryQF /><Results>Endometrial or other cancer</Results><ResultsQF /><NumberResult>1</NumberResult><PercentageResult>0</PercentageResult></row>
<row _id="289"><id>289</id><FinancialYear>2009/10</FinancialYear><HBT>S92000003</HBT><HBTQF>d</HBTQF><Laboratory>Scotland</Laboratory><LaboratoryQF>d</LaboratoryQF><Results>Total number of smears</Results><ResultsQF>d</ResultsQF><NumberResult>415497</NumberResult><PercentageResult>100</PercentageResult></row>
<row _id="290"><id>290</id><FinancialYear>2009/10</FinancialYear><HBT>S92000003</HBT><HBTQF>d</HBTQF><Laboratory>Scotland</Laboratory><LaboratoryQF>d</LaboratoryQF><Results>Unsatisfactory</Results><ResultsQF /><NumberResult>12592</NumberResult><PercentageResult>3</PercentageResult></row>
<row _id="291"><id>291</id><FinancialYear>2009/10</FinancialYear><HBT>S92000003</HBT><HBTQF>d</HBTQF><Laboratory>Scotland</Laboratory><LaboratoryQF>d</LaboratoryQF><Results>Negative</Results><ResultsQF /><NumberResult>367937</NumberResult><PercentageResult>91.3</PercentageResult></row>
<row _id="292"><id>292</id><FinancialYear>2009/10</FinancialYear><HBT>S92000003</HBT><HBTQF>d</HBTQF><Laboratory>Scotland</Laboratory><LaboratoryQF>d</LaboratoryQF><Results>Borderline Squamous Changes</Results><ResultsQF /><NumberResult>20804</NumberResult><PercentageResult>5.2</PercentageResult></row>
<row _id="293"><id>293</id><FinancialYear>2009/10</FinancialYear><HBT>S92000003</HBT><HBTQF>d</HBTQF><Laboratory>Scotland</Laboratory><LaboratoryQF>d</LaboratoryQF><Results>Borderline Glandular Changes</Results><ResultsQF /><NumberResult>302</NumberResult><PercentageResult>0.1</PercentageResult></row>
<row _id="294"><id>294</id><FinancialYear>2009/10</FinancialYear><HBT>S92000003</HBT><HBTQF>d</HBTQF><Laboratory>Scotland</Laboratory><LaboratoryQF>d</LaboratoryQF><Results>Mild Dyskaryosis</Results><ResultsQF /><NumberResult>8694</NumberResult><PercentageResult>2.2</PercentageResult></row>
<row _id="295"><id>295</id><FinancialYear>2009/10</FinancialYear><HBT>S92000003</HBT><HBTQF>d</HBTQF><Laboratory>Scotland</Laboratory><LaboratoryQF>d</LaboratoryQF><Results>Moderate Dyskaryosis</Results><ResultsQF /><NumberResult>2502</NumberResult><PercentageResult>0.6</PercentageResult></row>
<row _id="296"><id>296</id><FinancialYear>2009/10</FinancialYear><HBT>S92000003</HBT><HBTQF>d</HBTQF><Laboratory>Scotland</Laboratory><LaboratoryQF>d</LaboratoryQF><Results>Severe Dyskaryosis</Results><ResultsQF /><NumberResult>2415</NumberResult><PercentageResult>0.6</PercentageResult></row>
<row _id="297"><id>297</id><FinancialYear>2009/10</FinancialYear><HBT>S92000003</HBT><HBTQF>d</HBTQF><Laboratory>Scotland</Laboratory><LaboratoryQF>d</LaboratoryQF><Results>Severe Dyskaryosis (Invasive)</Results><ResultsQF /><NumberResult>95</NumberResult><PercentageResult>0</PercentageResult></row>
<row _id="298"><id>298</id><FinancialYear>2009/10</FinancialYear><HBT>S92000003</HBT><HBTQF>d</HBTQF><Laboratory>Scotland</Laboratory><LaboratoryQF>d</LaboratoryQF><Results>Glandular Abnormality</Results><ResultsQF /><NumberResult>133</NumberResult><PercentageResult>0</PercentageResult></row>
<row _id="299"><id>299</id><FinancialYear>2009/10</FinancialYear><HBT>S92000003</HBT><HBTQF>d</HBTQF><Laboratory>Scotland</Laboratory><LaboratoryQF>d</LaboratoryQF><Results>Endocervical Adenocarcinoma</Results><ResultsQF /><NumberResult>5</NumberResult><PercentageResult>0</PercentageResult></row>
<row _id="300"><id>300</id><FinancialYear>2009/10</FinancialYear><HBT>S92000003</HBT><HBTQF>d</HBTQF><Laboratory>Scotland</Laboratory><LaboratoryQF>d</LaboratoryQF><Results>Endometrial or other cancer</Results><ResultsQF /><NumberResult>18</NumberResult><PercentageResult>0</PercentageResult></row>
<row _id="301"><id>301</id><FinancialYear>2009/10</FinancialYear><HBT>8</HBT><HBTQF /><Laboratory>Inverclyde</Laboratory><LaboratoryQF /><Results>Total number of smears</Results><ResultsQF>d</ResultsQF><NumberResult>34166</NumberResult><PercentageResult>100</PercentageResult></row>
<row _id="302"><id>302</id><FinancialYear>2009/10</FinancialYear><HBT>8</HBT><HBTQF /><Laboratory>Inverclyde</Laboratory><LaboratoryQF /><Results>Unsatisfactory</Results><ResultsQF /><NumberResult>899</NumberResult><PercentageResult>2.6</PercentageResult></row>
<row _id="303"><id>303</id><FinancialYear>2009/10</FinancialYear><HBT>8</HBT><HBTQF /><Laboratory>Inverclyde</Laboratory><LaboratoryQF /><Results>Negative</Results><ResultsQF /><NumberResult>30298</NumberResult><PercentageResult>91.1</PercentageResult></row>
<row _id="304"><id>304</id><FinancialYear>2009/10</FinancialYear><HBT>8</HBT><HBTQF /><Laboratory>Inverclyde</Laboratory><LaboratoryQF /><Results>Borderline Squamous Changes</Results><ResultsQF /><NumberResult>2250</NumberResult><PercentageResult>6.8</PercentageResult></row>
<row _id="305"><id>305</id><FinancialYear>2009/10</FinancialYear><HBT>8</HBT><HBTQF /><Laboratory>Inverclyde</Laboratory><LaboratoryQF /><Results>Borderline Glandular Changes</Results><ResultsQF /><NumberResult>16</NumberResult><PercentageResult>0</PercentageResult></row>
<row _id="306"><id>306</id><FinancialYear>2009/10</FinancialYear><HBT>8</HBT><HBTQF /><Laboratory>Inverclyde</Laboratory><LaboratoryQF /><Results>Mild Dyskaryosis</Results><ResultsQF /><NumberResult>372</NumberResult><PercentageResult>1.1</PercentageResult></row>
<row _id="307"><id>307</id><FinancialYear>2009/10</FinancialYear><HBT>8</HBT><HBTQF /><Laboratory>Inverclyde</Laboratory><LaboratoryQF /><Results>Moderate Dyskaryosis</Results><ResultsQF /><NumberResult>133</NumberResult><PercentageResult>0.4</PercentageResult></row>
<row _id="308"><id>308</id><FinancialYear>2009/10</FinancialYear><HBT>8</HBT><HBTQF /><Laboratory>Inverclyde</Laboratory><LaboratoryQF /><Results>Severe Dyskaryosis</Results><ResultsQF /><NumberResult>189</NumberResult><PercentageResult>0.6</PercentageResult></row>
<row _id="309"><id>309</id><FinancialYear>2009/10</FinancialYear><HBT>8</HBT><HBTQF /><Laboratory>Inverclyde</Laboratory><LaboratoryQF /><Results>Severe Dyskaryosis (Invasive)</Results><ResultsQF /><NumberResult>2</NumberResult><PercentageResult>0</PercentageResult></row>
<row _id="310"><id>310</id><FinancialYear>2009/10</FinancialYear><HBT>8</HBT><HBTQF /><Laboratory>Inverclyde</Laboratory><LaboratoryQF /><Results>Glandular Abnormality</Results><ResultsQF /><NumberResult>6</NumberResult><PercentageResult>0</PercentageResult></row>
<row _id="311"><id>311</id><FinancialYear>2009/10</FinancialYear><HBT>8</HBT><HBTQF /><Laboratory>Inverclyde</Laboratory><LaboratoryQF /><Results>Endocervical Adenocarcinoma</Results><ResultsQF /><NumberResult>0</NumberResult><PercentageResult>0</PercentageResult></row>
<row _id="312"><id>312</id><FinancialYear>2009/10</FinancialYear><HBT>8</HBT><HBTQF /><Laboratory>Inverclyde</Laboratory><LaboratoryQF /><Results>Endometrial or other cancer</Results><ResultsQF /><NumberResult>1</NumberResult><PercentageResult>0</PercentageResult></row>
<row _id="313"><id>313</id><FinancialYear>2009/10</FinancialYear><HBT>11</HBT><HBTQF /><Laboratory>Cross House</Laboratory><LaboratoryQF /><Results>Total number of smears</Results><ResultsQF>d</ResultsQF><NumberResult>26440</NumberResult><PercentageResult>100</PercentageResult></row>
<row _id="314"><id>314</id><FinancialYear>2009/10</FinancialYear><HBT>11</HBT><HBTQF /><Laboratory>Cross House</Laboratory><LaboratoryQF /><Results>Unsatisfactory</Results><ResultsQF /><NumberResult>866</NumberResult><PercentageResult>3.3</PercentageResult></row>
<row _id="315"><id>315</id><FinancialYear>2009/10</FinancialYear><HBT>11</HBT><HBTQF /><Laboratory>Cross House</Laboratory><LaboratoryQF /><Results>Negative</Results><ResultsQF /><NumberResult>24035</NumberResult><PercentageResult>94</PercentageResult></row>
<row _id="316"><id>316</id><FinancialYear>2009/10</FinancialYear><HBT>11</HBT><HBTQF /><Laboratory>Cross House</Laboratory><LaboratoryQF /><Results>Borderline Squamous Changes</Results><ResultsQF /><NumberResult>869</NumberResult><PercentageResult>3.4</PercentageResult></row>
<row _id="317"><id>317</id><FinancialYear>2009/10</FinancialYear><HBT>11</HBT><HBTQF /><Laboratory>Cross House</Laboratory><LaboratoryQF /><Results>Borderline Glandular Changes</Results><ResultsQF /><NumberResult>13</NumberResult><PercentageResult>0.1</PercentageResult></row>
<row _id="318"><id>318</id><FinancialYear>2009/10</FinancialYear><HBT>11</HBT><HBTQF /><Laboratory>Cross House</Laboratory><LaboratoryQF /><Results>Mild Dyskaryosis</Results><ResultsQF /><NumberResult>381</NumberResult><PercentageResult>1.5</PercentageResult></row>
<row _id="319"><id>319</id><FinancialYear>2009/10</FinancialYear><HBT>11</HBT><HBTQF /><Laboratory>Cross House</Laboratory><LaboratoryQF /><Results>Moderate Dyskaryosis</Results><ResultsQF /><NumberResult>107</NumberResult><PercentageResult>0.4</PercentageResult></row>
<row _id="320"><id>320</id><FinancialYear>2009/10</FinancialYear><HBT>11</HBT><HBTQF /><Laboratory>Cross House</Laboratory><LaboratoryQF /><Results>Severe Dyskaryosis</Results><ResultsQF /><NumberResult>153</NumberResult><PercentageResult>0.6</PercentageResult></row>
<row _id="321"><id>321</id><FinancialYear>2009/10</FinancialYear><HBT>11</HBT><HBTQF /><Laboratory>Cross House</Laboratory><LaboratoryQF /><Results>Severe Dyskaryosis (Invasive)</Results><ResultsQF /><NumberResult>3</NumberResult><PercentageResult>0</PercentageResult></row>
<row _id="322"><id>322</id><FinancialYear>2009/10</FinancialYear><HBT>11</HBT><HBTQF /><Laboratory>Cross House</Laboratory><LaboratoryQF /><Results>Glandular Abnormality</Results><ResultsQF /><NumberResult>12</NumberResult><PercentageResult>0</PercentageResult></row>
<row _id="323"><id>323</id><FinancialYear>2009/10</FinancialYear><HBT>11</HBT><HBTQF /><Laboratory>Cross House</Laboratory><LaboratoryQF /><Results>Endocervical Adenocarcinoma</Results><ResultsQF /><NumberResult>1</NumberResult><PercentageResult>0</PercentageResult></row>
<row _id="324"><id>324</id><FinancialYear>2009/10</FinancialYear><HBT>11</HBT><HBTQF /><Laboratory>Cross House</Laboratory><LaboratoryQF /><Results>Endometrial or other cancer</Results><ResultsQF /><NumberResult>0</NumberResult><PercentageResult>0</PercentageResult></row>
<row _id="325"><id>325</id><FinancialYear>2009/10</FinancialYear><HBT>4</HBT><HBTQF /><Laboratory>Forth Park</Laboratory><LaboratoryQF /><Results>Total number of smears</Results><ResultsQF>d</ResultsQF><NumberResult>26541</NumberResult><PercentageResult>100</PercentageResult></row>
<row _id="326"><id>326</id><FinancialYear>2009/10</FinancialYear><HBT>4</HBT><HBTQF /><Laboratory>Forth Park</Laboratory><LaboratoryQF /><Results>Unsatisfactory</Results><ResultsQF /><NumberResult>793</NumberResult><PercentageResult>3</PercentageResult></row>
<row _id="327"><id>327</id><FinancialYear>2009/10</FinancialYear><HBT>4</HBT><HBTQF /><Laboratory>Forth Park</Laboratory><LaboratoryQF /><Results>Negative</Results><ResultsQF /><NumberResult>24008</NumberResult><PercentageResult>93.2</PercentageResult></row>
<row _id="328"><id>328</id><FinancialYear>2009/10</FinancialYear><HBT>4</HBT><HBTQF /><Laboratory>Forth Park</Laboratory><LaboratoryQF /><Results>Borderline Squamous Changes</Results><ResultsQF /><NumberResult>962</NumberResult><PercentageResult>3.7</PercentageResult></row>
<row _id="329"><id>329</id><FinancialYear>2009/10</FinancialYear><HBT>4</HBT><HBTQF /><Laboratory>Forth Park</Laboratory><LaboratoryQF /><Results>Borderline Glandular Changes</Results><ResultsQF /><NumberResult>7</NumberResult><PercentageResult>0</PercentageResult></row>
<row _id="330"><id>330</id><FinancialYear>2009/10</FinancialYear><HBT>4</HBT><HBTQF /><Laboratory>Forth Park</Laboratory><LaboratoryQF /><Results>Mild Dyskaryosis</Results><ResultsQF /><NumberResult>530</NumberResult><PercentageResult>2.1</PercentageResult></row>
<row _id="331"><id>331</id><FinancialYear>2009/10</FinancialYear><HBT>4</HBT><HBTQF /><Laboratory>Forth Park</Laboratory><LaboratoryQF /><Results>Moderate Dyskaryosis</Results><ResultsQF /><NumberResult>120</NumberResult><PercentageResult>0.5</PercentageResult></row>
<row _id="332"><id>332</id><FinancialYear>2009/10</FinancialYear><HBT>4</HBT><HBTQF /><Laboratory>Forth Park</Laboratory><LaboratoryQF /><Results>Severe Dyskaryosis</Results><ResultsQF /><NumberResult>107</NumberResult><PercentageResult>0.4</PercentageResult></row>
<row _id="333"><id>333</id><FinancialYear>2009/10</FinancialYear><HBT>4</HBT><HBTQF /><Laboratory>Forth Park</Laboratory><LaboratoryQF /><Results>Severe Dyskaryosis (Invasive)</Results><ResultsQF /><NumberResult>6</NumberResult><PercentageResult>0</PercentageResult></row>
<row _id="334"><id>334</id><FinancialYear>2009/10</FinancialYear><HBT>4</HBT><HBTQF /><Laboratory>Forth Park</Laboratory><LaboratoryQF /><Results>Glandular Abnormality</Results><ResultsQF /><NumberResult>7</NumberResult><PercentageResult>0</PercentageResult></row>
<row _id="335"><id>335</id><FinancialYear>2009/10</FinancialYear><HBT>4</HBT><HBTQF /><Laboratory>Forth Park</Laboratory><LaboratoryQF /><Results>Endocervical Adenocarcinoma</Results><ResultsQF /><NumberResult>0</NumberResult><PercentageResult>0</PercentageResult></row>
<row _id="336"><id>336</id><FinancialYear>2009/10</FinancialYear><HBT>4</HBT><HBTQF /><Laboratory>Forth Park</Laboratory><LaboratoryQF /><Results>Endometrial or other cancer</Results><ResultsQF /><NumberResult>1</NumberResult><PercentageResult>0</PercentageResult></row>
<row _id="337"><id>337</id><FinancialYear>2009/10</FinancialYear><HBT>7</HBT><HBTQF /><Laboratory>Stirling Royal Infirmary</Laboratory><LaboratoryQF /><Results>Total number of smears</Results><ResultsQF>d</ResultsQF><NumberResult>24199</NumberResult><PercentageResult>100</PercentageResult></row>
<row _id="338"><id>338</id><FinancialYear>2009/10</FinancialYear><HBT>7</HBT><HBTQF /><Laboratory>Stirling Royal Infirmary</Laboratory><LaboratoryQF /><Results>Unsatisfactory</Results><ResultsQF /><NumberResult>540</NumberResult><PercentageResult>2.2</PercentageResult></row>
<row _id="339"><id>339</id><FinancialYear>2009/10</FinancialYear><HBT>7</HBT><HBTQF /><Laboratory>Stirling Royal Infirmary</Laboratory><LaboratoryQF /><Results>Negative</Results><ResultsQF /><NumberResult>21698</NumberResult><PercentageResult>91.7</PercentageResult></row>
<row _id="340"><id>340</id><FinancialYear>2009/10</FinancialYear><HBT>7</HBT><HBTQF /><Laboratory>Stirling Royal Infirmary</Laboratory><LaboratoryQF /><Results>Borderline Squamous Changes</Results><ResultsQF /><NumberResult>1010</NumberResult><PercentageResult>4.3</PercentageResult></row>
<row _id="341"><id>341</id><FinancialYear>2009/10</FinancialYear><HBT>7</HBT><HBTQF /><Laboratory>Stirling Royal Infirmary</Laboratory><LaboratoryQF /><Results>Borderline Glandular Changes</Results><ResultsQF /><NumberResult>48</NumberResult><PercentageResult>0.2</PercentageResult></row>
<row _id="342"><id>342</id><FinancialYear>2009/10</FinancialYear><HBT>7</HBT><HBTQF /><Laboratory>Stirling Royal Infirmary</Laboratory><LaboratoryQF /><Results>Mild Dyskaryosis</Results><ResultsQF /><NumberResult>551</NumberResult><PercentageResult>2.3</PercentageResult></row>
<row _id="343"><id>343</id><FinancialYear>2009/10</FinancialYear><HBT>7</HBT><HBTQF /><Laboratory>Stirling Royal Infirmary</Laboratory><LaboratoryQF /><Results>Moderate Dyskaryosis</Results><ResultsQF /><NumberResult>214</NumberResult><PercentageResult>0.9</PercentageResult></row>
<row _id="344"><id>344</id><FinancialYear>2009/10</FinancialYear><HBT>7</HBT><HBTQF /><Laboratory>Stirling Royal Infirmary</Laboratory><LaboratoryQF /><Results>Severe Dyskaryosis</Results><ResultsQF /><NumberResult>105</NumberResult><PercentageResult>0.4</PercentageResult></row>
<row _id="345"><id>345</id><FinancialYear>2009/10</FinancialYear><HBT>7</HBT><HBTQF /><Laboratory>Stirling Royal Infirmary</Laboratory><LaboratoryQF /><Results>Severe Dyskaryosis (Invasive)</Results><ResultsQF /><NumberResult>17</NumberResult><PercentageResult>0.1</PercentageResult></row>
<row _id="346"><id>346</id><FinancialYear>2009/10</FinancialYear><HBT>7</HBT><HBTQF /><Laboratory>Stirling Royal Infirmary</Laboratory><LaboratoryQF /><Results>Glandular Abnormality</Results><ResultsQF /><NumberResult>16</NumberResult><PercentageResult>0.1</PercentageResult></row>
<row _id="347"><id>347</id><FinancialYear>2009/10</FinancialYear><HBT>7</HBT><HBTQF /><Laboratory>Stirling Royal Infirmary</Laboratory><LaboratoryQF /><Results>Endocervical Adenocarcinoma</Results><ResultsQF /><NumberResult>0</NumberResult><PercentageResult>0</PercentageResult></row>
<row _id="348"><id>348</id><FinancialYear>2009/10</FinancialYear><HBT>7</HBT><HBTQF /><Laboratory>Stirling Royal Infirmary</Laboratory><LaboratoryQF /><Results>Endometrial or other cancer</Results><ResultsQF /><NumberResult>0</NumberResult><PercentageResult>0</PercentageResult></row>
<row _id="349"><id>349</id><FinancialYear>2009/10</FinancialYear><HBT>2</HBT><HBTQF /><Laboratory>Forester Hill</Laboratory><LaboratoryQF /><Results>Total number of smears</Results><ResultsQF>d</ResultsQF><NumberResult>47569</NumberResult><PercentageResult>100</PercentageResult></row>
<row _id="350"><id>350</id><FinancialYear>2009/10</FinancialYear><HBT>2</HBT><HBTQF /><Laboratory>Forester Hill</Laboratory><LaboratoryQF /><Results>Unsatisfactory</Results><ResultsQF /><NumberResult>1127</NumberResult><PercentageResult>2.4</PercentageResult></row>
<row _id="351"><id>351</id><FinancialYear>2009/10</FinancialYear><HBT>2</HBT><HBTQF /><Laboratory>Forester Hill</Laboratory><LaboratoryQF /><Results>Negative</Results><ResultsQF /><NumberResult>42622</NumberResult><PercentageResult>91.8</PercentageResult></row>
<row _id="352"><id>352</id><FinancialYear>2009/10</FinancialYear><HBT>2</HBT><HBTQF /><Laboratory>Forester Hill</Laboratory><LaboratoryQF /><Results>Borderline Squamous Changes</Results><ResultsQF /><NumberResult>2559</NumberResult><PercentageResult>5.5</PercentageResult></row>
<row _id="353"><id>353</id><FinancialYear>2009/10</FinancialYear><HBT>2</HBT><HBTQF /><Laboratory>Forester Hill</Laboratory><LaboratoryQF /><Results>Borderline Glandular Changes</Results><ResultsQF /><NumberResult>5</NumberResult><PercentageResult>0</PercentageResult></row>
<row _id="354"><id>354</id><FinancialYear>2009/10</FinancialYear><HBT>2</HBT><HBTQF /><Laboratory>Forester Hill</Laboratory><LaboratoryQF /><Results>Mild Dyskaryosis</Results><ResultsQF /><NumberResult>727</NumberResult><PercentageResult>1.6</PercentageResult></row>
<row _id="355"><id>355</id><FinancialYear>2009/10</FinancialYear><HBT>2</HBT><HBTQF /><Laboratory>Forester Hill</Laboratory><LaboratoryQF /><Results>Moderate Dyskaryosis</Results><ResultsQF /><NumberResult>243</NumberResult><PercentageResult>0.5</PercentageResult></row>
<row _id="356"><id>356</id><FinancialYear>2009/10</FinancialYear><HBT>2</HBT><HBTQF /><Laboratory>Forester Hill</Laboratory><LaboratoryQF /><Results>Severe Dyskaryosis</Results><ResultsQF /><NumberResult>262</NumberResult><PercentageResult>0.6</PercentageResult></row>
<row _id="357"><id>357</id><FinancialYear>2009/10</FinancialYear><HBT>2</HBT><HBTQF /><Laboratory>Forester Hill</Laboratory><LaboratoryQF /><Results>Severe Dyskaryosis (Invasive)</Results><ResultsQF /><NumberResult>14</NumberResult><PercentageResult>0</PercentageResult></row>
<row _id="358"><id>358</id><FinancialYear>2009/10</FinancialYear><HBT>2</HBT><HBTQF /><Laboratory>Forester Hill</Laboratory><LaboratoryQF /><Results>Glandular Abnormality</Results><ResultsQF /><NumberResult>9</NumberResult><PercentageResult>0</PercentageResult></row>
<row _id="359"><id>359</id><FinancialYear>2009/10</FinancialYear><HBT>2</HBT><HBTQF /><Laboratory>Forester Hill</Laboratory><LaboratoryQF /><Results>Endocervical Adenocarcinoma</Results><ResultsQF /><NumberResult>0</NumberResult><PercentageResult>0</PercentageResult></row>
<row _id="360"><id>360</id><FinancialYear>2009/10</FinancialYear><HBT>2</HBT><HBTQF /><Laboratory>Forester Hill</Laboratory><LaboratoryQF /><Results>Endometrial or other cancer</Results><ResultsQF /><NumberResult>1</NumberResult><PercentageResult>0</PercentageResult></row>
<row _id="361"><id>361</id><FinancialYear>2009/10</FinancialYear><HBT>9</HBT><HBTQF /><Laboratory>Southern General</Laboratory><LaboratoryQF /><Results>Total number of smears</Results><ResultsQF>d</ResultsQF><NumberResult>25138</NumberResult><PercentageResult>100</PercentageResult></row>
<row _id="362"><id>362</id><FinancialYear>2009/10</FinancialYear><HBT>9</HBT><HBTQF /><Laboratory>Southern General</Laboratory><LaboratoryQF /><Results>Unsatisfactory</Results><ResultsQF /><NumberResult>727</NumberResult><PercentageResult>2.9</PercentageResult></row>
<row _id="363"><id>363</id><FinancialYear>2009/10</FinancialYear><HBT>9</HBT><HBTQF /><Laboratory>Southern General</Laboratory><LaboratoryQF /><Results>Negative</Results><ResultsQF /><NumberResult>22129</NumberResult><PercentageResult>90.7</PercentageResult></row>
<row _id="364"><id>364</id><FinancialYear>2009/10</FinancialYear><HBT>9</HBT><HBTQF /><Laboratory>Southern General</Laboratory><LaboratoryQF /><Results>Borderline Squamous Changes</Results><ResultsQF /><NumberResult>1186</NumberResult><PercentageResult>4.9</PercentageResult></row>
<row _id="365"><id>365</id><FinancialYear>2009/10</FinancialYear><HBT>9</HBT><HBTQF /><Laboratory>Southern General</Laboratory><LaboratoryQF /><Results>Borderline Glandular Changes</Results><ResultsQF /><NumberResult>11</NumberResult><PercentageResult>0</PercentageResult></row>
<row _id="366"><id>366</id><FinancialYear>2009/10</FinancialYear><HBT>9</HBT><HBTQF /><Laboratory>Southern General</Laboratory><LaboratoryQF /><Results>Mild Dyskaryosis</Results><ResultsQF /><NumberResult>787</NumberResult><PercentageResult>3.2</PercentageResult></row>
<row _id="367"><id>367</id><FinancialYear>2009/10</FinancialYear><HBT>9</HBT><HBTQF /><Laboratory>Southern General</Laboratory><LaboratoryQF /><Results>Moderate Dyskaryosis</Results><ResultsQF /><NumberResult>134</NumberResult><PercentageResult>0.5</PercentageResult></row>
<row _id="368"><id>368</id><FinancialYear>2009/10</FinancialYear><HBT>9</HBT><HBTQF /><Laboratory>Southern General</Laboratory><LaboratoryQF /><Results>Severe Dyskaryosis</Results><ResultsQF /><NumberResult>154</NumberResult><PercentageResult>0.6</PercentageResult></row>
<row _id="369"><id>369</id><FinancialYear>2009/10</FinancialYear><HBT>9</HBT><HBTQF /><Laboratory>Southern General</Laboratory><LaboratoryQF /><Results>Severe Dyskaryosis (Invasive)</Results><ResultsQF /><NumberResult>4</NumberResult><PercentageResult>0</PercentageResult></row>
<row _id="370"><id>370</id><FinancialYear>2009/10</FinancialYear><HBT>9</HBT><HBTQF /><Laboratory>Southern General</Laboratory><LaboratoryQF /><Results>Glandular Abnormality</Results><ResultsQF /><NumberResult>5</NumberResult><PercentageResult>0</PercentageResult></row>
<row _id="371"><id>371</id><FinancialYear>2009/10</FinancialYear><HBT>9</HBT><HBTQF /><Laboratory>Southern General</Laboratory><LaboratoryQF /><Results>Endocervical Adenocarcinoma</Results><ResultsQF /><NumberResult>0</NumberResult><PercentageResult>0</PercentageResult></row>
<row _id="372"><id>372</id><FinancialYear>2009/10</FinancialYear><HBT>9</HBT><HBTQF /><Laboratory>Southern General</Laboratory><LaboratoryQF /><Results>Endometrial or other cancer</Results><ResultsQF /><NumberResult>1</NumberResult><PercentageResult>0</PercentageResult></row>
<row _id="373"><id>373</id><FinancialYear>2009/10</FinancialYear><HBT>9</HBT><HBTQF /><Laboratory>Royal Infirmary</Laboratory><LaboratoryQF /><Results>Total number of smears</Results><ResultsQF>d</ResultsQF><NumberResult>46025</NumberResult><PercentageResult>100</PercentageResult></row>
<row _id="374"><id>374</id><FinancialYear>2009/10</FinancialYear><HBT>9</HBT><HBTQF /><Laboratory>Royal Infirmary</Laboratory><LaboratoryQF /><Results>Unsatisfactory</Results><ResultsQF /><NumberResult>1317</NumberResult><PercentageResult>2.9</PercentageResult></row>
<row _id="375"><id>375</id><FinancialYear>2009/10</FinancialYear><HBT>9</HBT><HBTQF /><Laboratory>Royal Infirmary</Laboratory><LaboratoryQF /><Results>Negative</Results><ResultsQF /><NumberResult>39433</NumberResult><PercentageResult>88.2</PercentageResult></row>
<row _id="376"><id>376</id><FinancialYear>2009/10</FinancialYear><HBT>9</HBT><HBTQF /><Laboratory>Royal Infirmary</Laboratory><LaboratoryQF /><Results>Borderline Squamous Changes</Results><ResultsQF /><NumberResult>2997</NumberResult><PercentageResult>6.7</PercentageResult></row>
<row _id="377"><id>377</id><FinancialYear>2009/10</FinancialYear><HBT>9</HBT><HBTQF /><Laboratory>Royal Infirmary</Laboratory><LaboratoryQF /><Results>Borderline Glandular Changes</Results><ResultsQF /><NumberResult>12</NumberResult><PercentageResult>0</PercentageResult></row>
<row _id="378"><id>378</id><FinancialYear>2009/10</FinancialYear><HBT>9</HBT><HBTQF /><Laboratory>Royal Infirmary</Laboratory><LaboratoryQF /><Results>Mild Dyskaryosis</Results><ResultsQF /><NumberResult>1497</NumberResult><PercentageResult>3.3</PercentageResult></row>
<row _id="379"><id>379</id><FinancialYear>2009/10</FinancialYear><HBT>9</HBT><HBTQF /><Laboratory>Royal Infirmary</Laboratory><LaboratoryQF /><Results>Moderate Dyskaryosis</Results><ResultsQF /><NumberResult>436</NumberResult><PercentageResult>1</PercentageResult></row>
<row _id="380"><id>380</id><FinancialYear>2009/10</FinancialYear><HBT>9</HBT><HBTQF /><Laboratory>Royal Infirmary</Laboratory><LaboratoryQF /><Results>Severe Dyskaryosis</Results><ResultsQF /><NumberResult>304</NumberResult><PercentageResult>0.7</PercentageResult></row>
<row _id="381"><id>381</id><FinancialYear>2009/10</FinancialYear><HBT>9</HBT><HBTQF /><Laboratory>Royal Infirmary</Laboratory><LaboratoryQF /><Results>Severe Dyskaryosis (Invasive)</Results><ResultsQF /><NumberResult>2</NumberResult><PercentageResult>0</PercentageResult></row>
<row _id="382"><id>382</id><FinancialYear>2009/10</FinancialYear><HBT>9</HBT><HBTQF /><Laboratory>Royal Infirmary</Laboratory><LaboratoryQF /><Results>Glandular Abnormality</Results><ResultsQF /><NumberResult>24</NumberResult><PercentageResult>0.1</PercentageResult></row>
<row _id="383"><id>383</id><FinancialYear>2009/10</FinancialYear><HBT>9</HBT><HBTQF /><Laboratory>Royal Infirmary</Laboratory><LaboratoryQF /><Results>Endocervical Adenocarcinoma</Results><ResultsQF /><NumberResult>0</NumberResult><PercentageResult>0</PercentageResult></row>
<row _id="384"><id>384</id><FinancialYear>2009/10</FinancialYear><HBT>9</HBT><HBTQF /><Laboratory>Royal Infirmary</Laboratory><LaboratoryQF /><Results>Endometrial or other cancer</Results><ResultsQF /><NumberResult>3</NumberResult><PercentageResult>0</PercentageResult></row>
<row _id="385"><id>385</id><FinancialYear>2009/10</FinancialYear><HBT>1</HBT><HBTQF /><Laboratory>Raigmore</Laboratory><LaboratoryQF /><Results>Total number of smears</Results><ResultsQF>d</ResultsQF><NumberResult>18389</NumberResult><PercentageResult>100</PercentageResult></row>
<row _id="386"><id>386</id><FinancialYear>2009/10</FinancialYear><HBT>1</HBT><HBTQF /><Laboratory>Raigmore</Laboratory><LaboratoryQF /><Results>Unsatisfactory</Results><ResultsQF /><NumberResult>439</NumberResult><PercentageResult>2.4</PercentageResult></row>
<row _id="387"><id>387</id><FinancialYear>2009/10</FinancialYear><HBT>1</HBT><HBTQF /><Laboratory>Raigmore</Laboratory><LaboratoryQF /><Results>Negative</Results><ResultsQF /><NumberResult>16871</NumberResult><PercentageResult>94</PercentageResult></row>
<row _id="388"><id>388</id><FinancialYear>2009/10</FinancialYear><HBT>1</HBT><HBTQF /><Laboratory>Raigmore</Laboratory><LaboratoryQF /><Results>Borderline Squamous Changes</Results><ResultsQF /><NumberResult>609</NumberResult><PercentageResult>3.4</PercentageResult></row>
<row _id="389"><id>389</id><FinancialYear>2009/10</FinancialYear><HBT>1</HBT><HBTQF /><Laboratory>Raigmore</Laboratory><LaboratoryQF /><Results>Borderline Glandular Changes</Results><ResultsQF /><NumberResult>10</NumberResult><PercentageResult>0.1</PercentageResult></row>
<row _id="390"><id>390</id><FinancialYear>2009/10</FinancialYear><HBT>1</HBT><HBTQF /><Laboratory>Raigmore</Laboratory><LaboratoryQF /><Results>Mild Dyskaryosis</Results><ResultsQF /><NumberResult>264</NumberResult><PercentageResult>1.5</PercentageResult></row>
<row _id="391"><id>391</id><FinancialYear>2009/10</FinancialYear><HBT>1</HBT><HBTQF /><Laboratory>Raigmore</Laboratory><LaboratoryQF /><Results>Moderate Dyskaryosis</Results><ResultsQF /><NumberResult>79</NumberResult><PercentageResult>0.4</PercentageResult></row>
<row _id="392"><id>392</id><FinancialYear>2009/10</FinancialYear><HBT>1</HBT><HBTQF /><Laboratory>Raigmore</Laboratory><LaboratoryQF /><Results>Severe Dyskaryosis</Results><ResultsQF /><NumberResult>102</NumberResult><PercentageResult>0.6</PercentageResult></row>
<row _id="393"><id>393</id><FinancialYear>2009/10</FinancialYear><HBT>1</HBT><HBTQF /><Laboratory>Raigmore</Laboratory><LaboratoryQF /><Results>Severe Dyskaryosis (Invasive)</Results><ResultsQF /><NumberResult>4</NumberResult><PercentageResult>0</PercentageResult></row>
<row _id="394"><id>394</id><FinancialYear>2009/10</FinancialYear><HBT>1</HBT><HBTQF /><Laboratory>Raigmore</Laboratory><LaboratoryQF /><Results>Glandular Abnormality</Results><ResultsQF /><NumberResult>8</NumberResult><PercentageResult>0</PercentageResult></row>
<row _id="395"><id>395</id><FinancialYear>2009/10</FinancialYear><HBT>1</HBT><HBTQF /><Laboratory>Raigmore</Laboratory><LaboratoryQF /><Results>Endocervical Adenocarcinoma</Results><ResultsQF /><NumberResult>2</NumberResult><PercentageResult>0</PercentageResult></row>
<row _id="396"><id>396</id><FinancialYear>2009/10</FinancialYear><HBT>1</HBT><HBTQF /><Laboratory>Raigmore</Laboratory><LaboratoryQF /><Results>Endometrial or other cancer</Results><ResultsQF /><NumberResult>1</NumberResult><PercentageResult>0</PercentageResult></row>
<row _id="397"><id>397</id><FinancialYear>2009/10</FinancialYear><HBT>10</HBT><HBTQF /><Laboratory>Monklands</Laboratory><LaboratoryQF /><Results>Total number of smears</Results><ResultsQF>d</ResultsQF><NumberResult>55259</NumberResult><PercentageResult>100</PercentageResult></row>
<row _id="398"><id>398</id><FinancialYear>2009/10</FinancialYear><HBT>10</HBT><HBTQF /><Laboratory>Monklands</Laboratory><LaboratoryQF /><Results>Unsatisfactory</Results><ResultsQF /><NumberResult>2012</NumberResult><PercentageResult>3.6</PercentageResult></row>
<row _id="399"><id>399</id><FinancialYear>2009/10</FinancialYear><HBT>10</HBT><HBTQF /><Laboratory>Monklands</Laboratory><LaboratoryQF /><Results>Negative</Results><ResultsQF /><NumberResult>49877</NumberResult><PercentageResult>93.7</PercentageResult></row>
<row _id="400"><id>400</id><FinancialYear>2009/10</FinancialYear><HBT>10</HBT><HBTQF /><Laboratory>Monklands</Laboratory><LaboratoryQF /><Results>Borderline Squamous Changes</Results><ResultsQF /><NumberResult>2110</NumberResult><PercentageResult>4</PercentageResult></row>
<row _id="401"><id>401</id><FinancialYear>2009/10</FinancialYear><HBT>10</HBT><HBTQF /><Laboratory>Monklands</Laboratory><LaboratoryQF /><Results>Borderline Glandular Changes</Results><ResultsQF /><NumberResult>16</NumberResult><PercentageResult>0</PercentageResult></row>
<row _id="402"><id>402</id><FinancialYear>2009/10</FinancialYear><HBT>10</HBT><HBTQF /><Laboratory>Monklands</Laboratory><LaboratoryQF /><Results>Mild Dyskaryosis</Results><ResultsQF /><NumberResult>703</NumberResult><PercentageResult>1.3</PercentageResult></row>
<row _id="403"><id>403</id><FinancialYear>2009/10</FinancialYear><HBT>10</HBT><HBTQF /><Laboratory>Monklands</Laboratory><LaboratoryQF /><Results>Moderate Dyskaryosis</Results><ResultsQF /><NumberResult>258</NumberResult><PercentageResult>0.5</PercentageResult></row>
<row _id="404"><id>404</id><FinancialYear>2009/10</FinancialYear><HBT>10</HBT><HBTQF /><Laboratory>Monklands</Laboratory><LaboratoryQF /><Results>Severe Dyskaryosis</Results><ResultsQF /><NumberResult>262</NumberResult><PercentageResult>0.5</PercentageResult></row>
<row _id="405"><id>405</id><FinancialYear>2009/10</FinancialYear><HBT>10</HBT><HBTQF /><Laboratory>Monklands</Laboratory><LaboratoryQF /><Results>Severe Dyskaryosis (Invasive)</Results><ResultsQF /><NumberResult>7</NumberResult><PercentageResult>0</PercentageResult></row>
<row _id="406"><id>406</id><FinancialYear>2009/10</FinancialYear><HBT>10</HBT><HBTQF /><Laboratory>Monklands</Laboratory><LaboratoryQF /><Results>Glandular Abnormality</Results><ResultsQF /><NumberResult>11</NumberResult><PercentageResult>0</PercentageResult></row>
<row _id="407"><id>407</id><FinancialYear>2009/10</FinancialYear><HBT>10</HBT><HBTQF /><Laboratory>Monklands</Laboratory><LaboratoryQF /><Results>Endocervical Adenocarcinoma</Results><ResultsQF /><NumberResult>1</NumberResult><PercentageResult>0</PercentageResult></row>
<row _id="408"><id>408</id><FinancialYear>2009/10</FinancialYear><HBT>10</HBT><HBTQF /><Laboratory>Monklands</Laboratory><LaboratoryQF /><Results>Endometrial or other cancer</Results><ResultsQF /><NumberResult>2</NumberResult><PercentageResult>0</PercentageResult></row>
<row _id="409"><id>409</id><FinancialYear>2009/10</FinancialYear><HBT>5</HBT><HBTQF /><Laboratory>Edinburgh Royal Infirmary</Laboratory><LaboratoryQF /><Results>Total number of smears</Results><ResultsQF>d</ResultsQF><NumberResult>81633</NumberResult><PercentageResult>100</PercentageResult></row>
<row _id="410"><id>410</id><FinancialYear>2009/10</FinancialYear><HBT>5</HBT><HBTQF /><Laboratory>Edinburgh Royal Infirmary</Laboratory><LaboratoryQF /><Results>Unsatisfactory</Results><ResultsQF /><NumberResult>3275</NumberResult><PercentageResult>4</PercentageResult></row>
<row _id="411"><id>411</id><FinancialYear>2009/10</FinancialYear><HBT>5</HBT><HBTQF /><Laboratory>Edinburgh Royal Infirmary</Laboratory><LaboratoryQF /><Results>Negative</Results><ResultsQF /><NumberResult>69778</NumberResult><PercentageResult>89.1</PercentageResult></row>
<row _id="412"><id>412</id><FinancialYear>2009/10</FinancialYear><HBT>5</HBT><HBTQF /><Laboratory>Edinburgh Royal Infirmary</Laboratory><LaboratoryQF /><Results>Borderline Squamous Changes</Results><ResultsQF /><NumberResult>5136</NumberResult><PercentageResult>6.6</PercentageResult></row>
<row _id="413"><id>413</id><FinancialYear>2009/10</FinancialYear><HBT>5</HBT><HBTQF /><Laboratory>Edinburgh Royal Infirmary</Laboratory><LaboratoryQF /><Results>Borderline Glandular Changes</Results><ResultsQF /><NumberResult>133</NumberResult><PercentageResult>0.2</PercentageResult></row>
<row _id="414"><id>414</id><FinancialYear>2009/10</FinancialYear><HBT>5</HBT><HBTQF /><Laboratory>Edinburgh Royal Infirmary</Laboratory><LaboratoryQF /><Results>Mild Dyskaryosis</Results><ResultsQF /><NumberResult>2200</NumberResult><PercentageResult>2.8</PercentageResult></row>
<row _id="415"><id>415</id><FinancialYear>2009/10</FinancialYear><HBT>5</HBT><HBTQF /><Laboratory>Edinburgh Royal Infirmary</Laboratory><LaboratoryQF /><Results>Moderate Dyskaryosis</Results><ResultsQF /><NumberResult>533</NumberResult><PercentageResult>0.7</PercentageResult></row>
<row _id="416"><id>416</id><FinancialYear>2009/10</FinancialYear><HBT>5</HBT><HBTQF /><Laboratory>Edinburgh Royal Infirmary</Laboratory><LaboratoryQF /><Results>Severe Dyskaryosis</Results><ResultsQF /><NumberResult>516</NumberResult><PercentageResult>0.7</PercentageResult></row>
<row _id="417"><id>417</id><FinancialYear>2009/10</FinancialYear><HBT>5</HBT><HBTQF /><Laboratory>Edinburgh Royal Infirmary</Laboratory><LaboratoryQF /><Results>Severe Dyskaryosis (Invasive)</Results><ResultsQF /><NumberResult>28</NumberResult><PercentageResult>0</PercentageResult></row>
<row _id="418"><id>418</id><FinancialYear>2009/10</FinancialYear><HBT>5</HBT><HBTQF /><Laboratory>Edinburgh Royal Infirmary</Laboratory><LaboratoryQF /><Results>Glandular Abnormality</Results><ResultsQF /><NumberResult>27</NumberResult><PercentageResult>0</PercentageResult></row>
<row _id="419"><id>419</id><FinancialYear>2009/10</FinancialYear><HBT>5</HBT><HBTQF /><Laboratory>Edinburgh Royal Infirmary</Laboratory><LaboratoryQF /><Results>Endocervical Adenocarcinoma</Results><ResultsQF /><NumberResult>0</NumberResult><PercentageResult>0</PercentageResult></row>
<row _id="420"><id>420</id><FinancialYear>2009/10</FinancialYear><HBT>5</HBT><HBTQF /><Laboratory>Edinburgh Royal Infirmary</Laboratory><LaboratoryQF /><Results>Endometrial or other cancer</Results><ResultsQF /><NumberResult>7</NumberResult><PercentageResult>0</PercentageResult></row>
<row _id="421"><id>421</id><FinancialYear>2009/10</FinancialYear><HBT>3</HBT><HBTQF /><Laboratory>Dundee Royal Infirmary</Laboratory><LaboratoryQF /><Results>Total number of smears</Results><ResultsQF>d</ResultsQF><NumberResult>30138</NumberResult><PercentageResult>100</PercentageResult></row>
<row _id="422"><id>422</id><FinancialYear>2009/10</FinancialYear><HBT>3</HBT><HBTQF /><Laboratory>Dundee Royal Infirmary</Laboratory><LaboratoryQF /><Results>Unsatisfactory</Results><ResultsQF /><NumberResult>597</NumberResult><PercentageResult>2</PercentageResult></row>
<row _id="423"><id>423</id><FinancialYear>2009/10</FinancialYear><HBT>3</HBT><HBTQF /><Laboratory>Dundee Royal Infirmary</Laboratory><LaboratoryQF /><Results>Negative</Results><ResultsQF /><NumberResult>27188</NumberResult><PercentageResult>92</PercentageResult></row>
<row _id="424"><id>424</id><FinancialYear>2009/10</FinancialYear><HBT>3</HBT><HBTQF /><Laboratory>Dundee Royal Infirmary</Laboratory><LaboratoryQF /><Results>Borderline Squamous Changes</Results><ResultsQF /><NumberResult>1116</NumberResult><PercentageResult>3.8</PercentageResult></row>
<row _id="425"><id>425</id><FinancialYear>2009/10</FinancialYear><HBT>3</HBT><HBTQF /><Laboratory>Dundee Royal Infirmary</Laboratory><LaboratoryQF /><Results>Borderline Glandular Changes</Results><ResultsQF /><NumberResult>31</NumberResult><PercentageResult>0.1</PercentageResult></row>
<row _id="426"><id>426</id><FinancialYear>2009/10</FinancialYear><HBT>3</HBT><HBTQF /><Laboratory>Dundee Royal Infirmary</Laboratory><LaboratoryQF /><Results>Mild Dyskaryosis</Results><ResultsQF /><NumberResult>682</NumberResult><PercentageResult>2.3</PercentageResult></row>
<row _id="427"><id>427</id><FinancialYear>2009/10</FinancialYear><HBT>3</HBT><HBTQF /><Laboratory>Dundee Royal Infirmary</Laboratory><LaboratoryQF /><Results>Moderate Dyskaryosis</Results><ResultsQF /><NumberResult>245</NumberResult><PercentageResult>0.8</PercentageResult></row>
<row _id="428"><id>428</id><FinancialYear>2009/10</FinancialYear><HBT>3</HBT><HBTQF /><Laboratory>Dundee Royal Infirmary</Laboratory><LaboratoryQF /><Results>Severe Dyskaryosis</Results><ResultsQF /><NumberResult>261</NumberResult><PercentageResult>0.9</PercentageResult></row>
<row _id="429"><id>429</id><FinancialYear>2009/10</FinancialYear><HBT>3</HBT><HBTQF /><Laboratory>Dundee Royal Infirmary</Laboratory><LaboratoryQF /><Results>Severe Dyskaryosis (Invasive)</Results><ResultsQF /><NumberResult>8</NumberResult><PercentageResult>0</PercentageResult></row>
<row _id="430"><id>430</id><FinancialYear>2009/10</FinancialYear><HBT>3</HBT><HBTQF /><Laboratory>Dundee Royal Infirmary</Laboratory><LaboratoryQF /><Results>Glandular Abnormality</Results><ResultsQF /><NumberResult>8</NumberResult><PercentageResult>0</PercentageResult></row>
<row _id="431"><id>431</id><FinancialYear>2009/10</FinancialYear><HBT>3</HBT><HBTQF /><Laboratory>Dundee Royal Infirmary</Laboratory><LaboratoryQF /><Results>Endocervical Adenocarcinoma</Results><ResultsQF /><NumberResult>1</NumberResult><PercentageResult>0</PercentageResult></row>
<row _id="432"><id>432</id><FinancialYear>2009/10</FinancialYear><HBT>3</HBT><HBTQF /><Laboratory>Dundee Royal Infirmary</Laboratory><LaboratoryQF /><Results>Endometrial or other cancer</Results><ResultsQF /><NumberResult>1</NumberResult><PercentageResult>0</PercentageResult></row>
<row _id="433"><id>433</id><FinancialYear>2008/09</FinancialYear><HBT>S92000003</HBT><HBTQF>d</HBTQF><Laboratory>Scotland</Laboratory><LaboratoryQF>d</LaboratoryQF><Results>Total number of smears</Results><ResultsQF>d</ResultsQF><NumberResult>450522</NumberResult><PercentageResult>100</PercentageResult></row>
<row _id="434"><id>434</id><FinancialYear>2008/09</FinancialYear><HBT>S92000003</HBT><HBTQF>d</HBTQF><Laboratory>Scotland</Laboratory><LaboratoryQF>d</LaboratoryQF><Results>Unsatisfactory</Results><ResultsQF /><NumberResult>13641</NumberResult><PercentageResult>3</PercentageResult></row>
<row _id="435"><id>435</id><FinancialYear>2008/09</FinancialYear><HBT>S92000003</HBT><HBTQF>d</HBTQF><Laboratory>Scotland</Laboratory><LaboratoryQF>d</LaboratoryQF><Results>Negative</Results><ResultsQF /><NumberResult>400108</NumberResult><PercentageResult>91.6</PercentageResult></row>
<row _id="436"><id>436</id><FinancialYear>2008/09</FinancialYear><HBT>S92000003</HBT><HBTQF>d</HBTQF><Laboratory>Scotland</Laboratory><LaboratoryQF>d</LaboratoryQF><Results>Borderline Squamous Changes</Results><ResultsQF /><NumberResult>20959</NumberResult><PercentageResult>4.8</PercentageResult></row>
<row _id="437"><id>437</id><FinancialYear>2008/09</FinancialYear><HBT>S92000003</HBT><HBTQF>d</HBTQF><Laboratory>Scotland</Laboratory><LaboratoryQF>d</LaboratoryQF><Results>Borderline Glandular Changes</Results><ResultsQF /><NumberResult>362</NumberResult><PercentageResult>0.1</PercentageResult></row>
<row _id="438"><id>438</id><FinancialYear>2008/09</FinancialYear><HBT>S92000003</HBT><HBTQF>d</HBTQF><Laboratory>Scotland</Laboratory><LaboratoryQF>d</LaboratoryQF><Results>Mild Dyskaryosis</Results><ResultsQF /><NumberResult>9149</NumberResult><PercentageResult>2.1</PercentageResult></row>
<row _id="439"><id>439</id><FinancialYear>2008/09</FinancialYear><HBT>S92000003</HBT><HBTQF>d</HBTQF><Laboratory>Scotland</Laboratory><LaboratoryQF>d</LaboratoryQF><Results>Moderate Dyskaryosis</Results><ResultsQF /><NumberResult>2942</NumberResult><PercentageResult>0.7</PercentageResult></row>
<row _id="440"><id>440</id><FinancialYear>2008/09</FinancialYear><HBT>S92000003</HBT><HBTQF>d</HBTQF><Laboratory>Scotland</Laboratory><LaboratoryQF>d</LaboratoryQF><Results>Severe Dyskaryosis</Results><ResultsQF /><NumberResult>3043</NumberResult><PercentageResult>0.7</PercentageResult></row>
<row _id="441"><id>441</id><FinancialYear>2008/09</FinancialYear><HBT>S92000003</HBT><HBTQF>d</HBTQF><Laboratory>Scotland</Laboratory><LaboratoryQF>d</LaboratoryQF><Results>Severe Dyskaryosis (Invasive)</Results><ResultsQF /><NumberResult>109</NumberResult><PercentageResult>0</PercentageResult></row>
<row _id="442"><id>442</id><FinancialYear>2008/09</FinancialYear><HBT>S92000003</HBT><HBTQF>d</HBTQF><Laboratory>Scotland</Laboratory><LaboratoryQF>d</LaboratoryQF><Results>Glandular Abnormality</Results><ResultsQF /><NumberResult>185</NumberResult><PercentageResult>0</PercentageResult></row>
<row _id="443"><id>443</id><FinancialYear>2008/09</FinancialYear><HBT>S92000003</HBT><HBTQF>d</HBTQF><Laboratory>Scotland</Laboratory><LaboratoryQF>d</LaboratoryQF><Results>Endocervical Adenocarcinoma</Results><ResultsQF /><NumberResult>9</NumberResult><PercentageResult>0</PercentageResult></row>
<row _id="444"><id>444</id><FinancialYear>2008/09</FinancialYear><HBT>S92000003</HBT><HBTQF>d</HBTQF><Laboratory>Scotland</Laboratory><LaboratoryQF>d</LaboratoryQF><Results>Endometrial or other cancer</Results><ResultsQF /><NumberResult>15</NumberResult><PercentageResult>0</PercentageResult></row>
<row _id="445"><id>445</id><FinancialYear>2008/09</FinancialYear><HBT>8</HBT><HBTQF /><Laboratory>Inverclyde</Laboratory><LaboratoryQF /><Results>Total number of smears</Results><ResultsQF>d</ResultsQF><NumberResult>38363</NumberResult><PercentageResult>100</PercentageResult></row>
<row _id="446"><id>446</id><FinancialYear>2008/09</FinancialYear><HBT>8</HBT><HBTQF /><Laboratory>Inverclyde</Laboratory><LaboratoryQF /><Results>Unsatisfactory</Results><ResultsQF /><NumberResult>784</NumberResult><PercentageResult>2</PercentageResult></row>
<row _id="447"><id>447</id><FinancialYear>2008/09</FinancialYear><HBT>8</HBT><HBTQF /><Laboratory>Inverclyde</Laboratory><LaboratoryQF /><Results>Negative</Results><ResultsQF /><NumberResult>33977</NumberResult><PercentageResult>90.4</PercentageResult></row>
<row _id="448"><id>448</id><FinancialYear>2008/09</FinancialYear><HBT>8</HBT><HBTQF /><Laboratory>Inverclyde</Laboratory><LaboratoryQF /><Results>Borderline Squamous Changes</Results><ResultsQF /><NumberResult>2803</NumberResult><PercentageResult>7.5</PercentageResult></row>
<row _id="449"><id>449</id><FinancialYear>2008/09</FinancialYear><HBT>8</HBT><HBTQF /><Laboratory>Inverclyde</Laboratory><LaboratoryQF /><Results>Borderline Glandular Changes</Results><ResultsQF /><NumberResult>20</NumberResult><PercentageResult>0.1</PercentageResult></row>
<row _id="450"><id>450</id><FinancialYear>2008/09</FinancialYear><HBT>8</HBT><HBTQF /><Laboratory>Inverclyde</Laboratory><LaboratoryQF /><Results>Mild Dyskaryosis</Results><ResultsQF /><NumberResult>370</NumberResult><PercentageResult>1</PercentageResult></row>
<row _id="451"><id>451</id><FinancialYear>2008/09</FinancialYear><HBT>8</HBT><HBTQF /><Laboratory>Inverclyde</Laboratory><LaboratoryQF /><Results>Moderate Dyskaryosis</Results><ResultsQF /><NumberResult>177</NumberResult><PercentageResult>0.5</PercentageResult></row>
<row _id="452"><id>452</id><FinancialYear>2008/09</FinancialYear><HBT>8</HBT><HBTQF /><Laboratory>Inverclyde</Laboratory><LaboratoryQF /><Results>Severe Dyskaryosis</Results><ResultsQF /><NumberResult>217</NumberResult><PercentageResult>0.6</PercentageResult></row>
<row _id="453"><id>453</id><FinancialYear>2008/09</FinancialYear><HBT>8</HBT><HBTQF /><Laboratory>Inverclyde</Laboratory><LaboratoryQF /><Results>Severe Dyskaryosis (Invasive)</Results><ResultsQF /><NumberResult>4</NumberResult><PercentageResult>0</PercentageResult></row>
<row _id="454"><id>454</id><FinancialYear>2008/09</FinancialYear><HBT>8</HBT><HBTQF /><Laboratory>Inverclyde</Laboratory><LaboratoryQF /><Results>Glandular Abnormality</Results><ResultsQF /><NumberResult>11</NumberResult><PercentageResult>0</PercentageResult></row>
<row _id="455"><id>455</id><FinancialYear>2008/09</FinancialYear><HBT>8</HBT><HBTQF /><Laboratory>Inverclyde</Laboratory><LaboratoryQF /><Results>Endocervical Adenocarcinoma</Results><ResultsQF /><NumberResult>0</NumberResult><PercentageResult>0</PercentageResult></row>
<row _id="456"><id>456</id><FinancialYear>2008/09</FinancialYear><HBT>8</HBT><HBTQF /><Laboratory>Inverclyde</Laboratory><LaboratoryQF /><Results>Endometrial or other cancer</Results><ResultsQF /><NumberResult>0</NumberResult><PercentageResult>0</PercentageResult></row>
<row _id="457"><id>457</id><FinancialYear>2008/09</FinancialYear><HBT>11</HBT><HBTQF /><Laboratory>Cross House</Laboratory><LaboratoryQF /><Results>Total number of smears</Results><ResultsQF>d</ResultsQF><NumberResult>30522</NumberResult><PercentageResult>100</PercentageResult></row>
<row _id="458"><id>458</id><FinancialYear>2008/09</FinancialYear><HBT>11</HBT><HBTQF /><Laboratory>Cross House</Laboratory><LaboratoryQF /><Results>Unsatisfactory</Results><ResultsQF /><NumberResult>1290</NumberResult><PercentageResult>4.2</PercentageResult></row>
<row _id="459"><id>459</id><FinancialYear>2008/09</FinancialYear><HBT>11</HBT><HBTQF /><Laboratory>Cross House</Laboratory><LaboratoryQF /><Results>Negative</Results><ResultsQF /><NumberResult>27262</NumberResult><PercentageResult>93.3</PercentageResult></row>
<row _id="460"><id>460</id><FinancialYear>2008/09</FinancialYear><HBT>11</HBT><HBTQF /><Laboratory>Cross House</Laboratory><LaboratoryQF /><Results>Borderline Squamous Changes</Results><ResultsQF /><NumberResult>1056</NumberResult><PercentageResult>3.6</PercentageResult></row>
<row _id="461"><id>461</id><FinancialYear>2008/09</FinancialYear><HBT>11</HBT><HBTQF /><Laboratory>Cross House</Laboratory><LaboratoryQF /><Results>Borderline Glandular Changes</Results><ResultsQF /><NumberResult>27</NumberResult><PercentageResult>0.1</PercentageResult></row>
<row _id="462"><id>462</id><FinancialYear>2008/09</FinancialYear><HBT>11</HBT><HBTQF /><Laboratory>Cross House</Laboratory><LaboratoryQF /><Results>Mild Dyskaryosis</Results><ResultsQF /><NumberResult>482</NumberResult><PercentageResult>1.6</PercentageResult></row>
<row _id="463"><id>463</id><FinancialYear>2008/09</FinancialYear><HBT>11</HBT><HBTQF /><Laboratory>Cross House</Laboratory><LaboratoryQF /><Results>Moderate Dyskaryosis</Results><ResultsQF /><NumberResult>143</NumberResult><PercentageResult>0.5</PercentageResult></row>
<row _id="464"><id>464</id><FinancialYear>2008/09</FinancialYear><HBT>11</HBT><HBTQF /><Laboratory>Cross House</Laboratory><LaboratoryQF /><Results>Severe Dyskaryosis</Results><ResultsQF /><NumberResult>235</NumberResult><PercentageResult>0.8</PercentageResult></row>
<row _id="465"><id>465</id><FinancialYear>2008/09</FinancialYear><HBT>11</HBT><HBTQF /><Laboratory>Cross House</Laboratory><LaboratoryQF /><Results>Severe Dyskaryosis (Invasive)</Results><ResultsQF /><NumberResult>5</NumberResult><PercentageResult>0</PercentageResult></row>
<row _id="466"><id>466</id><FinancialYear>2008/09</FinancialYear><HBT>11</HBT><HBTQF /><Laboratory>Cross House</Laboratory><LaboratoryQF /><Results>Glandular Abnormality</Results><ResultsQF /><NumberResult>18</NumberResult><PercentageResult>0.1</PercentageResult></row>
<row _id="467"><id>467</id><FinancialYear>2008/09</FinancialYear><HBT>11</HBT><HBTQF /><Laboratory>Cross House</Laboratory><LaboratoryQF /><Results>Endocervical Adenocarcinoma</Results><ResultsQF /><NumberResult>2</NumberResult><PercentageResult>0</PercentageResult></row>
<row _id="468"><id>468</id><FinancialYear>2008/09</FinancialYear><HBT>11</HBT><HBTQF /><Laboratory>Cross House</Laboratory><LaboratoryQF /><Results>Endometrial or other cancer</Results><ResultsQF /><NumberResult>2</NumberResult><PercentageResult>0</PercentageResult></row>
<row _id="469"><id>469</id><FinancialYear>2008/09</FinancialYear><HBT>4</HBT><HBTQF /><Laboratory>Forth Park</Laboratory><LaboratoryQF /><Results>Total number of smears</Results><ResultsQF>d</ResultsQF><NumberResult>28726</NumberResult><PercentageResult>100</PercentageResult></row>
<row _id="470"><id>470</id><FinancialYear>2008/09</FinancialYear><HBT>4</HBT><HBTQF /><Laboratory>Forth Park</Laboratory><LaboratoryQF /><Results>Unsatisfactory</Results><ResultsQF /><NumberResult>584</NumberResult><PercentageResult>2</PercentageResult></row>
<row _id="471"><id>471</id><FinancialYear>2008/09</FinancialYear><HBT>4</HBT><HBTQF /><Laboratory>Forth Park</Laboratory><LaboratoryQF /><Results>Negative</Results><ResultsQF /><NumberResult>26204</NumberResult><PercentageResult>93.1</PercentageResult></row>
<row _id="472"><id>472</id><FinancialYear>2008/09</FinancialYear><HBT>4</HBT><HBTQF /><Laboratory>Forth Park</Laboratory><LaboratoryQF /><Results>Borderline Squamous Changes</Results><ResultsQF /><NumberResult>900</NumberResult><PercentageResult>3.2</PercentageResult></row>
<row _id="473"><id>473</id><FinancialYear>2008/09</FinancialYear><HBT>4</HBT><HBTQF /><Laboratory>Forth Park</Laboratory><LaboratoryQF /><Results>Borderline Glandular Changes</Results><ResultsQF /><NumberResult>2</NumberResult><PercentageResult>0</PercentageResult></row>
<row _id="474"><id>474</id><FinancialYear>2008/09</FinancialYear><HBT>4</HBT><HBTQF /><Laboratory>Forth Park</Laboratory><LaboratoryQF /><Results>Mild Dyskaryosis</Results><ResultsQF /><NumberResult>661</NumberResult><PercentageResult>2.3</PercentageResult></row>
<row _id="475"><id>475</id><FinancialYear>2008/09</FinancialYear><HBT>4</HBT><HBTQF /><Laboratory>Forth Park</Laboratory><LaboratoryQF /><Results>Moderate Dyskaryosis</Results><ResultsQF /><NumberResult>171</NumberResult><PercentageResult>0.6</PercentageResult></row>
<row _id="476"><id>476</id><FinancialYear>2008/09</FinancialYear><HBT>4</HBT><HBTQF /><Laboratory>Forth Park</Laboratory><LaboratoryQF /><Results>Severe Dyskaryosis</Results><ResultsQF /><NumberResult>181</NumberResult><PercentageResult>0.6</PercentageResult></row>
<row _id="477"><id>477</id><FinancialYear>2008/09</FinancialYear><HBT>4</HBT><HBTQF /><Laboratory>Forth Park</Laboratory><LaboratoryQF /><Results>Severe Dyskaryosis (Invasive)</Results><ResultsQF /><NumberResult>10</NumberResult><PercentageResult>0</PercentageResult></row>
<row _id="478"><id>478</id><FinancialYear>2008/09</FinancialYear><HBT>4</HBT><HBTQF /><Laboratory>Forth Park</Laboratory><LaboratoryQF /><Results>Glandular Abnormality</Results><ResultsQF /><NumberResult>12</NumberResult><PercentageResult>0</PercentageResult></row>
<row _id="479"><id>479</id><FinancialYear>2008/09</FinancialYear><HBT>4</HBT><HBTQF /><Laboratory>Forth Park</Laboratory><LaboratoryQF /><Results>Endocervical Adenocarcinoma</Results><ResultsQF /><NumberResult>0</NumberResult><PercentageResult>0</PercentageResult></row>
<row _id="480"><id>480</id><FinancialYear>2008/09</FinancialYear><HBT>4</HBT><HBTQF /><Laboratory>Forth Park</Laboratory><LaboratoryQF /><Results>Endometrial or other cancer</Results><ResultsQF /><NumberResult>1</NumberResult><PercentageResult>0</PercentageResult></row>
<row _id="481"><id>481</id><FinancialYear>2008/09</FinancialYear><HBT>7</HBT><HBTQF /><Laboratory>Stirling Royal Infirmary</Laboratory><LaboratoryQF /><Results>Total number of smears</Results><ResultsQF>d</ResultsQF><NumberResult>25192</NumberResult><PercentageResult>100</PercentageResult></row>
<row _id="482"><id>482</id><FinancialYear>2008/09</FinancialYear><HBT>7</HBT><HBTQF /><Laboratory>Stirling Royal Infirmary</Laboratory><LaboratoryQF /><Results>Unsatisfactory</Results><ResultsQF /><NumberResult>436</NumberResult><PercentageResult>1.7</PercentageResult></row>
<row _id="483"><id>483</id><FinancialYear>2008/09</FinancialYear><HBT>7</HBT><HBTQF /><Laboratory>Stirling Royal Infirmary</Laboratory><LaboratoryQF /><Results>Negative</Results><ResultsQF /><NumberResult>22377</NumberResult><PercentageResult>90.4</PercentageResult></row>
<row _id="484"><id>484</id><FinancialYear>2008/09</FinancialYear><HBT>7</HBT><HBTQF /><Laboratory>Stirling Royal Infirmary</Laboratory><LaboratoryQF /><Results>Borderline Squamous Changes</Results><ResultsQF /><NumberResult>1189</NumberResult><PercentageResult>4.8</PercentageResult></row>
<row _id="485"><id>485</id><FinancialYear>2008/09</FinancialYear><HBT>7</HBT><HBTQF /><Laboratory>Stirling Royal Infirmary</Laboratory><LaboratoryQF /><Results>Borderline Glandular Changes</Results><ResultsQF /><NumberResult>69</NumberResult><PercentageResult>0.3</PercentageResult></row>
<row _id="486"><id>486</id><FinancialYear>2008/09</FinancialYear><HBT>7</HBT><HBTQF /><Laboratory>Stirling Royal Infirmary</Laboratory><LaboratoryQF /><Results>Mild Dyskaryosis</Results><ResultsQF /><NumberResult>597</NumberResult><PercentageResult>2.4</PercentageResult></row>
<row _id="487"><id>487</id><FinancialYear>2008/09</FinancialYear><HBT>7</HBT><HBTQF /><Laboratory>Stirling Royal Infirmary</Laboratory><LaboratoryQF /><Results>Moderate Dyskaryosis</Results><ResultsQF /><NumberResult>292</NumberResult><PercentageResult>1.2</PercentageResult></row>
<row _id="488"><id>488</id><FinancialYear>2008/09</FinancialYear><HBT>7</HBT><HBTQF /><Laboratory>Stirling Royal Infirmary</Laboratory><LaboratoryQF /><Results>Severe Dyskaryosis</Results><ResultsQF /><NumberResult>186</NumberResult><PercentageResult>0.8</PercentageResult></row>
<row _id="489"><id>489</id><FinancialYear>2008/09</FinancialYear><HBT>7</HBT><HBTQF /><Laboratory>Stirling Royal Infirmary</Laboratory><LaboratoryQF /><Results>Severe Dyskaryosis (Invasive)</Results><ResultsQF /><NumberResult>16</NumberResult><PercentageResult>0.1</PercentageResult></row>
<row _id="490"><id>490</id><FinancialYear>2008/09</FinancialYear><HBT>7</HBT><HBTQF /><Laboratory>Stirling Royal Infirmary</Laboratory><LaboratoryQF /><Results>Glandular Abnormality</Results><ResultsQF /><NumberResult>27</NumberResult><PercentageResult>0.1</PercentageResult></row>
<row _id="491"><id>491</id><FinancialYear>2008/09</FinancialYear><HBT>7</HBT><HBTQF /><Laboratory>Stirling Royal Infirmary</Laboratory><LaboratoryQF /><Results>Endocervical Adenocarcinoma</Results><ResultsQF /><NumberResult>2</NumberResult><PercentageResult>0</PercentageResult></row>
<row _id="492"><id>492</id><FinancialYear>2008/09</FinancialYear><HBT>7</HBT><HBTQF /><Laboratory>Stirling Royal Infirmary</Laboratory><LaboratoryQF /><Results>Endometrial or other cancer</Results><ResultsQF /><NumberResult>1</NumberResult><PercentageResult>0</PercentageResult></row>
<row _id="493"><id>493</id><FinancialYear>2008/09</FinancialYear><HBT>2</HBT><HBTQF /><Laboratory>Forester Hill</Laboratory><LaboratoryQF /><Results>Total number of smears</Results><ResultsQF>d</ResultsQF><NumberResult>50938</NumberResult><PercentageResult>100</PercentageResult></row>
<row _id="494"><id>494</id><FinancialYear>2008/09</FinancialYear><HBT>2</HBT><HBTQF /><Laboratory>Forester Hill</Laboratory><LaboratoryQF /><Results>Unsatisfactory</Results><ResultsQF /><NumberResult>1000</NumberResult><PercentageResult>2</PercentageResult></row>
<row _id="495"><id>495</id><FinancialYear>2008/09</FinancialYear><HBT>2</HBT><HBTQF /><Laboratory>Forester Hill</Laboratory><LaboratoryQF /><Results>Negative</Results><ResultsQF /><NumberResult>45687</NumberResult><PercentageResult>91.5</PercentageResult></row>
<row _id="496"><id>496</id><FinancialYear>2008/09</FinancialYear><HBT>2</HBT><HBTQF /><Laboratory>Forester Hill</Laboratory><LaboratoryQF /><Results>Borderline Squamous Changes</Results><ResultsQF /><NumberResult>2649</NumberResult><PercentageResult>5.3</PercentageResult></row>
<row _id="497"><id>497</id><FinancialYear>2008/09</FinancialYear><HBT>2</HBT><HBTQF /><Laboratory>Forester Hill</Laboratory><LaboratoryQF /><Results>Borderline Glandular Changes</Results><ResultsQF /><NumberResult>18</NumberResult><PercentageResult>0</PercentageResult></row>
<row _id="498"><id>498</id><FinancialYear>2008/09</FinancialYear><HBT>2</HBT><HBTQF /><Laboratory>Forester Hill</Laboratory><LaboratoryQF /><Results>Mild Dyskaryosis</Results><ResultsQF /><NumberResult>904</NumberResult><PercentageResult>1.8</PercentageResult></row>
<row _id="499"><id>499</id><FinancialYear>2008/09</FinancialYear><HBT>2</HBT><HBTQF /><Laboratory>Forester Hill</Laboratory><LaboratoryQF /><Results>Moderate Dyskaryosis</Results><ResultsQF /><NumberResult>357</NumberResult><PercentageResult>0.7</PercentageResult></row>
<row _id="500"><id>500</id><FinancialYear>2008/09</FinancialYear><HBT>2</HBT><HBTQF /><Laboratory>Forester Hill</Laboratory><LaboratoryQF /><Results>Severe Dyskaryosis</Results><ResultsQF /><NumberResult>300</NumberResult><PercentageResult>0.6</PercentageResult></row>
<row _id="501"><id>501</id><FinancialYear>2008/09</FinancialYear><HBT>2</HBT><HBTQF /><Laboratory>Forester Hill</Laboratory><LaboratoryQF /><Results>Severe Dyskaryosis (Invasive)</Results><ResultsQF /><NumberResult>6</NumberResult><PercentageResult>0</PercentageResult></row>
<row _id="502"><id>502</id><FinancialYear>2008/09</FinancialYear><HBT>2</HBT><HBTQF /><Laboratory>Forester Hill</Laboratory><LaboratoryQF /><Results>Glandular Abnormality</Results><ResultsQF /><NumberResult>16</NumberResult><PercentageResult>0</PercentageResult></row>
<row _id="503"><id>503</id><FinancialYear>2008/09</FinancialYear><HBT>2</HBT><HBTQF /><Laboratory>Forester Hill</Laboratory><LaboratoryQF /><Results>Endocervical Adenocarcinoma</Results><ResultsQF /><NumberResult>0</NumberResult><PercentageResult>0</PercentageResult></row>
<row _id="504"><id>504</id><FinancialYear>2008/09</FinancialYear><HBT>2</HBT><HBTQF /><Laboratory>Forester Hill</Laboratory><LaboratoryQF /><Results>Endometrial or other cancer</Results><ResultsQF /><NumberResult>1</NumberResult><PercentageResult>0</PercentageResult></row>
<row _id="505"><id>505</id><FinancialYear>2008/09</FinancialYear><HBT>9</HBT><HBTQF /><Laboratory>Southern General</Laboratory><LaboratoryQF /><Results>Total number of smears</Results><ResultsQF>d</ResultsQF><NumberResult>28190</NumberResult><PercentageResult>100</PercentageResult></row>
<row _id="506"><id>506</id><FinancialYear>2008/09</FinancialYear><HBT>9</HBT><HBTQF /><Laboratory>Southern General</Laboratory><LaboratoryQF /><Results>Unsatisfactory</Results><ResultsQF /><NumberResult>753</NumberResult><PercentageResult>2.7</PercentageResult></row>
<row _id="507"><id>507</id><FinancialYear>2008/09</FinancialYear><HBT>9</HBT><HBTQF /><Laboratory>Southern General</Laboratory><LaboratoryQF /><Results>Negative</Results><ResultsQF /><NumberResult>25094</NumberResult><PercentageResult>91.5</PercentageResult></row>
<row _id="508"><id>508</id><FinancialYear>2008/09</FinancialYear><HBT>9</HBT><HBTQF /><Laboratory>Southern General</Laboratory><LaboratoryQF /><Results>Borderline Squamous Changes</Results><ResultsQF /><NumberResult>1208</NumberResult><PercentageResult>4.4</PercentageResult></row>
<row _id="509"><id>509</id><FinancialYear>2008/09</FinancialYear><HBT>9</HBT><HBTQF /><Laboratory>Southern General</Laboratory><LaboratoryQF /><Results>Borderline Glandular Changes</Results><ResultsQF /><NumberResult>14</NumberResult><PercentageResult>0.1</PercentageResult></row>
<row _id="510"><id>510</id><FinancialYear>2008/09</FinancialYear><HBT>9</HBT><HBTQF /><Laboratory>Southern General</Laboratory><LaboratoryQF /><Results>Mild Dyskaryosis</Results><ResultsQF /><NumberResult>821</NumberResult><PercentageResult>3</PercentageResult></row>
<row _id="511"><id>511</id><FinancialYear>2008/09</FinancialYear><HBT>9</HBT><HBTQF /><Laboratory>Southern General</Laboratory><LaboratoryQF /><Results>Moderate Dyskaryosis</Results><ResultsQF /><NumberResult>155</NumberResult><PercentageResult>0.6</PercentageResult></row>
<row _id="512"><id>512</id><FinancialYear>2008/09</FinancialYear><HBT>9</HBT><HBTQF /><Laboratory>Southern General</Laboratory><LaboratoryQF /><Results>Severe Dyskaryosis</Results><ResultsQF /><NumberResult>131</NumberResult><PercentageResult>0.5</PercentageResult></row>
<row _id="513"><id>513</id><FinancialYear>2008/09</FinancialYear><HBT>9</HBT><HBTQF /><Laboratory>Southern General</Laboratory><LaboratoryQF /><Results>Severe Dyskaryosis (Invasive)</Results><ResultsQF /><NumberResult>6</NumberResult><PercentageResult>0</PercentageResult></row>
<row _id="514"><id>514</id><FinancialYear>2008/09</FinancialYear><HBT>9</HBT><HBTQF /><Laboratory>Southern General</Laboratory><LaboratoryQF /><Results>Glandular Abnormality</Results><ResultsQF /><NumberResult>7</NumberResult><PercentageResult>0</PercentageResult></row>
<row _id="515"><id>515</id><FinancialYear>2008/09</FinancialYear><HBT>9</HBT><HBTQF /><Laboratory>Southern General</Laboratory><LaboratoryQF /><Results>Endocervical Adenocarcinoma</Results><ResultsQF /><NumberResult>1</NumberResult><PercentageResult>0</PercentageResult></row>
<row _id="516"><id>516</id><FinancialYear>2008/09</FinancialYear><HBT>9</HBT><HBTQF /><Laboratory>Southern General</Laboratory><LaboratoryQF /><Results>Endometrial or other cancer</Results><ResultsQF /><NumberResult>0</NumberResult><PercentageResult>0</PercentageResult></row>
<row _id="517"><id>517</id><FinancialYear>2008/09</FinancialYear><HBT>9</HBT><HBTQF /><Laboratory>Royal Infirmary</Laboratory><LaboratoryQF /><Results>Total number of smears</Results><ResultsQF>d</ResultsQF><NumberResult>49502</NumberResult><PercentageResult>100</PercentageResult></row>
<row _id="518"><id>518</id><FinancialYear>2008/09</FinancialYear><HBT>9</HBT><HBTQF /><Laboratory>Royal Infirmary</Laboratory><LaboratoryQF /><Results>Unsatisfactory</Results><ResultsQF /><NumberResult>1540</NumberResult><PercentageResult>3.1</PercentageResult></row>
<row _id="519"><id>519</id><FinancialYear>2008/09</FinancialYear><HBT>9</HBT><HBTQF /><Laboratory>Royal Infirmary</Laboratory><LaboratoryQF /><Results>Negative</Results><ResultsQF /><NumberResult>42744</NumberResult><PercentageResult>89.1</PercentageResult></row>
<row _id="520"><id>520</id><FinancialYear>2008/09</FinancialYear><HBT>9</HBT><HBTQF /><Laboratory>Royal Infirmary</Laboratory><LaboratoryQF /><Results>Borderline Squamous Changes</Results><ResultsQF /><NumberResult>3060</NumberResult><PercentageResult>6.4</PercentageResult></row>
<row _id="521"><id>521</id><FinancialYear>2008/09</FinancialYear><HBT>9</HBT><HBTQF /><Laboratory>Royal Infirmary</Laboratory><LaboratoryQF /><Results>Borderline Glandular Changes</Results><ResultsQF /><NumberResult>20</NumberResult><PercentageResult>0</PercentageResult></row>
<row _id="522"><id>522</id><FinancialYear>2008/09</FinancialYear><HBT>9</HBT><HBTQF /><Laboratory>Royal Infirmary</Laboratory><LaboratoryQF /><Results>Mild Dyskaryosis</Results><ResultsQF /><NumberResult>1395</NumberResult><PercentageResult>2.9</PercentageResult></row>
<row _id="523"><id>523</id><FinancialYear>2008/09</FinancialYear><HBT>9</HBT><HBTQF /><Laboratory>Royal Infirmary</Laboratory><LaboratoryQF /><Results>Moderate Dyskaryosis</Results><ResultsQF /><NumberResult>408</NumberResult><PercentageResult>0.9</PercentageResult></row>
<row _id="524"><id>524</id><FinancialYear>2008/09</FinancialYear><HBT>9</HBT><HBTQF /><Laboratory>Royal Infirmary</Laboratory><LaboratoryQF /><Results>Severe Dyskaryosis</Results><ResultsQF /><NumberResult>297</NumberResult><PercentageResult>0.6</PercentageResult></row>
<row _id="525"><id>525</id><FinancialYear>2008/09</FinancialYear><HBT>9</HBT><HBTQF /><Laboratory>Royal Infirmary</Laboratory><LaboratoryQF /><Results>Severe Dyskaryosis (Invasive)</Results><ResultsQF /><NumberResult>5</NumberResult><PercentageResult>0</PercentageResult></row>
<row _id="526"><id>526</id><FinancialYear>2008/09</FinancialYear><HBT>9</HBT><HBTQF /><Laboratory>Royal Infirmary</Laboratory><LaboratoryQF /><Results>Glandular Abnormality</Results><ResultsQF /><NumberResult>33</NumberResult><PercentageResult>0.1</PercentageResult></row>
<row _id="527"><id>527</id><FinancialYear>2008/09</FinancialYear><HBT>9</HBT><HBTQF /><Laboratory>Royal Infirmary</Laboratory><LaboratoryQF /><Results>Endocervical Adenocarcinoma</Results><ResultsQF /><NumberResult>0</NumberResult><PercentageResult>0</PercentageResult></row>
<row _id="528"><id>528</id><FinancialYear>2008/09</FinancialYear><HBT>9</HBT><HBTQF /><Laboratory>Royal Infirmary</Laboratory><LaboratoryQF /><Results>Endometrial or other cancer</Results><ResultsQF /><NumberResult>0</NumberResult><PercentageResult>0</PercentageResult></row>
<row _id="529"><id>529</id><FinancialYear>2008/09</FinancialYear><HBT>1</HBT><HBTQF /><Laboratory>Raigmore</Laboratory><LaboratoryQF /><Results>Total number of smears</Results><ResultsQF>d</ResultsQF><NumberResult>20867</NumberResult><PercentageResult>100</PercentageResult></row>
<row _id="530"><id>530</id><FinancialYear>2008/09</FinancialYear><HBT>1</HBT><HBTQF /><Laboratory>Raigmore</Laboratory><LaboratoryQF /><Results>Unsatisfactory</Results><ResultsQF /><NumberResult>716</NumberResult><PercentageResult>3.4</PercentageResult></row>
<row _id="531"><id>531</id><FinancialYear>2008/09</FinancialYear><HBT>1</HBT><HBTQF /><Laboratory>Raigmore</Laboratory><LaboratoryQF /><Results>Negative</Results><ResultsQF /><NumberResult>18826</NumberResult><PercentageResult>93.4</PercentageResult></row>
<row _id="532"><id>532</id><FinancialYear>2008/09</FinancialYear><HBT>1</HBT><HBTQF /><Laboratory>Raigmore</Laboratory><LaboratoryQF /><Results>Borderline Squamous Changes</Results><ResultsQF /><NumberResult>589</NumberResult><PercentageResult>2.9</PercentageResult></row>
<row _id="533"><id>533</id><FinancialYear>2008/09</FinancialYear><HBT>1</HBT><HBTQF /><Laboratory>Raigmore</Laboratory><LaboratoryQF /><Results>Borderline Glandular Changes</Results><ResultsQF /><NumberResult>15</NumberResult><PercentageResult>0.1</PercentageResult></row>
<row _id="534"><id>534</id><FinancialYear>2008/09</FinancialYear><HBT>1</HBT><HBTQF /><Laboratory>Raigmore</Laboratory><LaboratoryQF /><Results>Mild Dyskaryosis</Results><ResultsQF /><NumberResult>281</NumberResult><PercentageResult>1.4</PercentageResult></row>
<row _id="535"><id>535</id><FinancialYear>2008/09</FinancialYear><HBT>1</HBT><HBTQF /><Laboratory>Raigmore</Laboratory><LaboratoryQF /><Results>Moderate Dyskaryosis</Results><ResultsQF /><NumberResult>146</NumberResult><PercentageResult>0.7</PercentageResult></row>
<row _id="536"><id>536</id><FinancialYear>2008/09</FinancialYear><HBT>1</HBT><HBTQF /><Laboratory>Raigmore</Laboratory><LaboratoryQF /><Results>Severe Dyskaryosis</Results><ResultsQF /><NumberResult>280</NumberResult><PercentageResult>1.4</PercentageResult></row>
<row _id="537"><id>537</id><FinancialYear>2008/09</FinancialYear><HBT>1</HBT><HBTQF /><Laboratory>Raigmore</Laboratory><LaboratoryQF /><Results>Severe Dyskaryosis (Invasive)</Results><ResultsQF /><NumberResult>6</NumberResult><PercentageResult>0</PercentageResult></row>
<row _id="538"><id>538</id><FinancialYear>2008/09</FinancialYear><HBT>1</HBT><HBTQF /><Laboratory>Raigmore</Laboratory><LaboratoryQF /><Results>Glandular Abnormality</Results><ResultsQF /><NumberResult>5</NumberResult><PercentageResult>0</PercentageResult></row>
<row _id="539"><id>539</id><FinancialYear>2008/09</FinancialYear><HBT>1</HBT><HBTQF /><Laboratory>Raigmore</Laboratory><LaboratoryQF /><Results>Endocervical Adenocarcinoma</Results><ResultsQF /><NumberResult>1</NumberResult><PercentageResult>0</PercentageResult></row>
<row _id="540"><id>540</id><FinancialYear>2008/09</FinancialYear><HBT>1</HBT><HBTQF /><Laboratory>Raigmore</Laboratory><LaboratoryQF /><Results>Endometrial or other cancer</Results><ResultsQF /><NumberResult>2</NumberResult><PercentageResult>0</PercentageResult></row>
<row _id="541"><id>541</id><FinancialYear>2008/09</FinancialYear><HBT>10</HBT><HBTQF /><Laboratory>Monklands</Laboratory><LaboratoryQF /><Results>Total number of smears</Results><ResultsQF>d</ResultsQF><NumberResult>59318</NumberResult><PercentageResult>100</PercentageResult></row>
<row _id="542"><id>542</id><FinancialYear>2008/09</FinancialYear><HBT>10</HBT><HBTQF /><Laboratory>Monklands</Laboratory><LaboratoryQF /><Results>Unsatisfactory</Results><ResultsQF /><NumberResult>1761</NumberResult><PercentageResult>3</PercentageResult></row>
<row _id="543"><id>543</id><FinancialYear>2008/09</FinancialYear><HBT>10</HBT><HBTQF /><Laboratory>Monklands</Laboratory><LaboratoryQF /><Results>Negative</Results><ResultsQF /><NumberResult>54141</NumberResult><PercentageResult>94.1</PercentageResult></row>
<row _id="544"><id>544</id><FinancialYear>2008/09</FinancialYear><HBT>10</HBT><HBTQF /><Laboratory>Monklands</Laboratory><LaboratoryQF /><Results>Borderline Squamous Changes</Results><ResultsQF /><NumberResult>2045</NumberResult><PercentageResult>3.6</PercentageResult></row>
<row _id="545"><id>545</id><FinancialYear>2008/09</FinancialYear><HBT>10</HBT><HBTQF /><Laboratory>Monklands</Laboratory><LaboratoryQF /><Results>Borderline Glandular Changes</Results><ResultsQF /><NumberResult>12</NumberResult><PercentageResult>0</PercentageResult></row>
<row _id="546"><id>546</id><FinancialYear>2008/09</FinancialYear><HBT>10</HBT><HBTQF /><Laboratory>Monklands</Laboratory><LaboratoryQF /><Results>Mild Dyskaryosis</Results><ResultsQF /><NumberResult>720</NumberResult><PercentageResult>1.3</PercentageResult></row>
<row _id="547"><id>547</id><FinancialYear>2008/09</FinancialYear><HBT>10</HBT><HBTQF /><Laboratory>Monklands</Laboratory><LaboratoryQF /><Results>Moderate Dyskaryosis</Results><ResultsQF /><NumberResult>273</NumberResult><PercentageResult>0.5</PercentageResult></row>
<row _id="548"><id>548</id><FinancialYear>2008/09</FinancialYear><HBT>10</HBT><HBTQF /><Laboratory>Monklands</Laboratory><LaboratoryQF /><Results>Severe Dyskaryosis</Results><ResultsQF /><NumberResult>340</NumberResult><PercentageResult>0.6</PercentageResult></row>
<row _id="549"><id>549</id><FinancialYear>2008/09</FinancialYear><HBT>10</HBT><HBTQF /><Laboratory>Monklands</Laboratory><LaboratoryQF /><Results>Severe Dyskaryosis (Invasive)</Results><ResultsQF /><NumberResult>9</NumberResult><PercentageResult>0</PercentageResult></row>
<row _id="550"><id>550</id><FinancialYear>2008/09</FinancialYear><HBT>10</HBT><HBTQF /><Laboratory>Monklands</Laboratory><LaboratoryQF /><Results>Glandular Abnormality</Results><ResultsQF /><NumberResult>15</NumberResult><PercentageResult>0</PercentageResult></row>
<row _id="551"><id>551</id><FinancialYear>2008/09</FinancialYear><HBT>10</HBT><HBTQF /><Laboratory>Monklands</Laboratory><LaboratoryQF /><Results>Endocervical Adenocarcinoma</Results><ResultsQF /><NumberResult>0</NumberResult><PercentageResult>0</PercentageResult></row>
<row _id="552"><id>552</id><FinancialYear>2008/09</FinancialYear><HBT>10</HBT><HBTQF /><Laboratory>Monklands</Laboratory><LaboratoryQF /><Results>Endometrial or other cancer</Results><ResultsQF /><NumberResult>2</NumberResult><PercentageResult>0</PercentageResult></row>
<row _id="553"><id>553</id><FinancialYear>2008/09</FinancialYear><HBT>5</HBT><HBTQF /><Laboratory>Edinburgh Royal Infirmary</Laboratory><LaboratoryQF /><Results>Total number of smears</Results><ResultsQF>d</ResultsQF><NumberResult>86083</NumberResult><PercentageResult>100</PercentageResult></row>
<row _id="554"><id>554</id><FinancialYear>2008/09</FinancialYear><HBT>5</HBT><HBTQF /><Laboratory>Edinburgh Royal Infirmary</Laboratory><LaboratoryQF /><Results>Unsatisfactory</Results><ResultsQF /><NumberResult>4233</NumberResult><PercentageResult>4.9</PercentageResult></row>
<row _id="555"><id>555</id><FinancialYear>2008/09</FinancialYear><HBT>5</HBT><HBTQF /><Laboratory>Edinburgh Royal Infirmary</Laboratory><LaboratoryQF /><Results>Negative</Results><ResultsQF /><NumberResult>73622</NumberResult><PercentageResult>89.9</PercentageResult></row>
<row _id="556"><id>556</id><FinancialYear>2008/09</FinancialYear><HBT>5</HBT><HBTQF /><Laboratory>Edinburgh Royal Infirmary</Laboratory><LaboratoryQF /><Results>Borderline Squamous Changes</Results><ResultsQF /><NumberResult>4463</NumberResult><PercentageResult>5.5</PercentageResult></row>
<row _id="557"><id>557</id><FinancialYear>2008/09</FinancialYear><HBT>5</HBT><HBTQF /><Laboratory>Edinburgh Royal Infirmary</Laboratory><LaboratoryQF /><Results>Borderline Glandular Changes</Results><ResultsQF /><NumberResult>139</NumberResult><PercentageResult>0.2</PercentageResult></row>
<row _id="558"><id>558</id><FinancialYear>2008/09</FinancialYear><HBT>5</HBT><HBTQF /><Laboratory>Edinburgh Royal Infirmary</Laboratory><LaboratoryQF /><Results>Mild Dyskaryosis</Results><ResultsQF /><NumberResult>2307</NumberResult><PercentageResult>2.8</PercentageResult></row>
<row _id="559"><id>559</id><FinancialYear>2008/09</FinancialYear><HBT>5</HBT><HBTQF /><Laboratory>Edinburgh Royal Infirmary</Laboratory><LaboratoryQF /><Results>Moderate Dyskaryosis</Results><ResultsQF /><NumberResult>614</NumberResult><PercentageResult>0.8</PercentageResult></row>
<row _id="560"><id>560</id><FinancialYear>2008/09</FinancialYear><HBT>5</HBT><HBTQF /><Laboratory>Edinburgh Royal Infirmary</Laboratory><LaboratoryQF /><Results>Severe Dyskaryosis</Results><ResultsQF /><NumberResult>634</NumberResult><PercentageResult>0.8</PercentageResult></row>
<row _id="561"><id>561</id><FinancialYear>2008/09</FinancialYear><HBT>5</HBT><HBTQF /><Laboratory>Edinburgh Royal Infirmary</Laboratory><LaboratoryQF /><Results>Severe Dyskaryosis (Invasive)</Results><ResultsQF /><NumberResult>36</NumberResult><PercentageResult>0</PercentageResult></row>
<row _id="562"><id>562</id><FinancialYear>2008/09</FinancialYear><HBT>5</HBT><HBTQF /><Laboratory>Edinburgh Royal Infirmary</Laboratory><LaboratoryQF /><Results>Glandular Abnormality</Results><ResultsQF /><NumberResult>29</NumberResult><PercentageResult>0</PercentageResult></row>
<row _id="563"><id>563</id><FinancialYear>2008/09</FinancialYear><HBT>5</HBT><HBTQF /><Laboratory>Edinburgh Royal Infirmary</Laboratory><LaboratoryQF /><Results>Endocervical Adenocarcinoma</Results><ResultsQF /><NumberResult>1</NumberResult><PercentageResult>0</PercentageResult></row>
<row _id="564"><id>564</id><FinancialYear>2008/09</FinancialYear><HBT>5</HBT><HBTQF /><Laboratory>Edinburgh Royal Infirmary</Laboratory><LaboratoryQF /><Results>Endometrial or other cancer</Results><ResultsQF /><NumberResult>5</NumberResult><PercentageResult>0</PercentageResult></row>
<row _id="565"><id>565</id><FinancialYear>2008/09</FinancialYear><HBT>3</HBT><HBTQF /><Laboratory>Dundee Royal Infirmary</Laboratory><LaboratoryQF /><Results>Total number of smears</Results><ResultsQF>d</ResultsQF><NumberResult>32821</NumberResult><PercentageResult>100</PercentageResult></row>
<row _id="566"><id>566</id><FinancialYear>2008/09</FinancialYear><HBT>3</HBT><HBTQF /><Laboratory>Dundee Royal Infirmary</Laboratory><LaboratoryQF /><Results>Unsatisfactory</Results><ResultsQF /><NumberResult>544</NumberResult><PercentageResult>1.7</PercentageResult></row>
<row _id="567"><id>567</id><FinancialYear>2008/09</FinancialYear><HBT>3</HBT><HBTQF /><Laboratory>Dundee Royal Infirmary</Laboratory><LaboratoryQF /><Results>Negative</Results><ResultsQF /><NumberResult>30174</NumberResult><PercentageResult>93.5</PercentageResult></row>
<row _id="568"><id>568</id><FinancialYear>2008/09</FinancialYear><HBT>3</HBT><HBTQF /><Laboratory>Dundee Royal Infirmary</Laboratory><LaboratoryQF /><Results>Borderline Squamous Changes</Results><ResultsQF /><NumberResult>997</NumberResult><PercentageResult>3.1</PercentageResult></row>
<row _id="569"><id>569</id><FinancialYear>2008/09</FinancialYear><HBT>3</HBT><HBTQF /><Laboratory>Dundee Royal Infirmary</Laboratory><LaboratoryQF /><Results>Borderline Glandular Changes</Results><ResultsQF /><NumberResult>26</NumberResult><PercentageResult>0.1</PercentageResult></row>
<row _id="570"><id>570</id><FinancialYear>2008/09</FinancialYear><HBT>3</HBT><HBTQF /><Laboratory>Dundee Royal Infirmary</Laboratory><LaboratoryQF /><Results>Mild Dyskaryosis</Results><ResultsQF /><NumberResult>611</NumberResult><PercentageResult>1.9</PercentageResult></row>
<row _id="571"><id>571</id><FinancialYear>2008/09</FinancialYear><HBT>3</HBT><HBTQF /><Laboratory>Dundee Royal Infirmary</Laboratory><LaboratoryQF /><Results>Moderate Dyskaryosis</Results><ResultsQF /><NumberResult>206</NumberResult><PercentageResult>0.6</PercentageResult></row>
<row _id="572"><id>572</id><FinancialYear>2008/09</FinancialYear><HBT>3</HBT><HBTQF /><Laboratory>Dundee Royal Infirmary</Laboratory><LaboratoryQF /><Results>Severe Dyskaryosis</Results><ResultsQF /><NumberResult>242</NumberResult><PercentageResult>0.7</PercentageResult></row>
<row _id="573"><id>573</id><FinancialYear>2008/09</FinancialYear><HBT>3</HBT><HBTQF /><Laboratory>Dundee Royal Infirmary</Laboratory><LaboratoryQF /><Results>Severe Dyskaryosis (Invasive)</Results><ResultsQF /><NumberResult>6</NumberResult><PercentageResult>0</PercentageResult></row>
<row _id="574"><id>574</id><FinancialYear>2008/09</FinancialYear><HBT>3</HBT><HBTQF /><Laboratory>Dundee Royal Infirmary</Laboratory><LaboratoryQF /><Results>Glandular Abnormality</Results><ResultsQF /><NumberResult>12</NumberResult><PercentageResult>0</PercentageResult></row>
<row _id="575"><id>575</id><FinancialYear>2008/09</FinancialYear><HBT>3</HBT><HBTQF /><Laboratory>Dundee Royal Infirmary</Laboratory><LaboratoryQF /><Results>Endocervical Adenocarcinoma</Results><ResultsQF /><NumberResult>2</NumberResult><PercentageResult>0</PercentageResult></row>
<row _id="576"><id>576</id><FinancialYear>2008/09</FinancialYear><HBT>3</HBT><HBTQF /><Laboratory>Dundee Royal Infirmary</Laboratory><LaboratoryQF /><Results>Endometrial or other cancer</Results><ResultsQF /><NumberResult>1</NumberResult><PercentageResult>0</PercentageResult></row>
<row _id="577"><id>577</id><FinancialYear>2007/08</FinancialYear><HBT>S92000003</HBT><HBTQF>d</HBTQF><Laboratory>Scotland</Laboratory><LaboratoryQF>d</LaboratoryQF><Results>Total number of smears</Results><ResultsQF>d</ResultsQF><NumberResult>375451</NumberResult><PercentageResult>100</PercentageResult></row>
<row _id="578"><id>578</id><FinancialYear>2007/08</FinancialYear><HBT>S92000003</HBT><HBTQF>d</HBTQF><Laboratory>Scotland</Laboratory><LaboratoryQF>d</LaboratoryQF><Results>Unsatisfactory</Results><ResultsQF /><NumberResult>10609</NumberResult><PercentageResult>2.8</PercentageResult></row>
<row _id="579"><id>579</id><FinancialYear>2007/08</FinancialYear><HBT>S92000003</HBT><HBTQF>d</HBTQF><Laboratory>Scotland</Laboratory><LaboratoryQF>d</LaboratoryQF><Results>Negative</Results><ResultsQF /><NumberResult>336824</NumberResult><PercentageResult>92.3</PercentageResult></row>
<row _id="580"><id>580</id><FinancialYear>2007/08</FinancialYear><HBT>S92000003</HBT><HBTQF>d</HBTQF><Laboratory>Scotland</Laboratory><LaboratoryQF>d</LaboratoryQF><Results>Borderline Squamous Changes</Results><ResultsQF /><NumberResult>16032</NumberResult><PercentageResult>4.4</PercentageResult></row>
<row _id="581"><id>581</id><FinancialYear>2007/08</FinancialYear><HBT>S92000003</HBT><HBTQF>d</HBTQF><Laboratory>Scotland</Laboratory><LaboratoryQF>d</LaboratoryQF><Results>Borderline Glandular Changes</Results><ResultsQF /><NumberResult>187</NumberResult><PercentageResult>0.1</PercentageResult></row>
<row _id="582"><id>582</id><FinancialYear>2007/08</FinancialYear><HBT>S92000003</HBT><HBTQF>d</HBTQF><Laboratory>Scotland</Laboratory><LaboratoryQF>d</LaboratoryQF><Results>Mild Dyskaryosis</Results><ResultsQF /><NumberResult>7019</NumberResult><PercentageResult>1.9</PercentageResult></row>
<row _id="583"><id>583</id><FinancialYear>2007/08</FinancialYear><HBT>S92000003</HBT><HBTQF>d</HBTQF><Laboratory>Scotland</Laboratory><LaboratoryQF>d</LaboratoryQF><Results>Moderate Dyskaryosis</Results><ResultsQF /><NumberResult>2332</NumberResult><PercentageResult>0.6</PercentageResult></row>
<row _id="584"><id>584</id><FinancialYear>2007/08</FinancialYear><HBT>S92000003</HBT><HBTQF>d</HBTQF><Laboratory>Scotland</Laboratory><LaboratoryQF>d</LaboratoryQF><Results>Severe Dyskaryosis</Results><ResultsQF /><NumberResult>2187</NumberResult><PercentageResult>0.6</PercentageResult></row>
<row _id="585"><id>585</id><FinancialYear>2007/08</FinancialYear><HBT>S92000003</HBT><HBTQF>d</HBTQF><Laboratory>Scotland</Laboratory><LaboratoryQF>d</LaboratoryQF><Results>Severe Dyskaryosis (Invasive)</Results><ResultsQF /><NumberResult>86</NumberResult><PercentageResult>0</PercentageResult></row>
<row _id="586"><id>586</id><FinancialYear>2007/08</FinancialYear><HBT>S92000003</HBT><HBTQF>d</HBTQF><Laboratory>Scotland</Laboratory><LaboratoryQF>d</LaboratoryQF><Results>Glandular Abnormality</Results><ResultsQF /><NumberResult>136</NumberResult><PercentageResult>0</PercentageResult></row>
<row _id="587"><id>587</id><FinancialYear>2007/08</FinancialYear><HBT>S92000003</HBT><HBTQF>d</HBTQF><Laboratory>Scotland</Laboratory><LaboratoryQF>d</LaboratoryQF><Results>Endocervical Adenocarcinoma</Results><ResultsQF /><NumberResult>11</NumberResult><PercentageResult>0</PercentageResult></row>
<row _id="588"><id>588</id><FinancialYear>2007/08</FinancialYear><HBT>S92000003</HBT><HBTQF>d</HBTQF><Laboratory>Scotland</Laboratory><LaboratoryQF>d</LaboratoryQF><Results>Endometrial or other cancer</Results><ResultsQF /><NumberResult>28</NumberResult><PercentageResult>0</PercentageResult></row>
<row _id="589"><id>589</id><FinancialYear>2007/08</FinancialYear><HBT>8</HBT><HBTQF /><Laboratory>Inverclyde</Laboratory><LaboratoryQF /><Results>Total number of smears</Results><ResultsQF>d</ResultsQF><NumberResult>30437</NumberResult><PercentageResult>100</PercentageResult></row>
<row _id="590"><id>590</id><FinancialYear>2007/08</FinancialYear><HBT>8</HBT><HBTQF /><Laboratory>Inverclyde</Laboratory><LaboratoryQF /><Results>Unsatisfactory</Results><ResultsQF /><NumberResult>537</NumberResult><PercentageResult>0.1</PercentageResult></row>
<row _id="591"><id>591</id><FinancialYear>2007/08</FinancialYear><HBT>8</HBT><HBTQF /><Laboratory>Inverclyde</Laboratory><LaboratoryQF /><Results>Negative</Results><ResultsQF /><NumberResult>27335</NumberResult><PercentageResult>91.4</PercentageResult></row>
<row _id="592"><id>592</id><FinancialYear>2007/08</FinancialYear><HBT>8</HBT><HBTQF /><Laboratory>Inverclyde</Laboratory><LaboratoryQF /><Results>Borderline Squamous Changes</Results><ResultsQF /><NumberResult>2076</NumberResult><PercentageResult>6.9</PercentageResult></row>
<row _id="593"><id>593</id><FinancialYear>2007/08</FinancialYear><HBT>8</HBT><HBTQF /><Laboratory>Inverclyde</Laboratory><LaboratoryQF /><Results>Borderline Glandular Changes</Results><ResultsQF /><NumberResult>14</NumberResult><PercentageResult>0</PercentageResult></row>
<row _id="594"><id>594</id><FinancialYear>2007/08</FinancialYear><HBT>8</HBT><HBTQF /><Laboratory>Inverclyde</Laboratory><LaboratoryQF /><Results>Mild Dyskaryosis</Results><ResultsQF /><NumberResult>242</NumberResult><PercentageResult>0.8</PercentageResult></row>
<row _id="595"><id>595</id><FinancialYear>2007/08</FinancialYear><HBT>8</HBT><HBTQF /><Laboratory>Inverclyde</Laboratory><LaboratoryQF /><Results>Moderate Dyskaryosis</Results><ResultsQF /><NumberResult>87</NumberResult><PercentageResult>0.3</PercentageResult></row>
<row _id="596"><id>596</id><FinancialYear>2007/08</FinancialYear><HBT>8</HBT><HBTQF /><Laboratory>Inverclyde</Laboratory><LaboratoryQF /><Results>Severe Dyskaryosis</Results><ResultsQF /><NumberResult>125</NumberResult><PercentageResult>0.4</PercentageResult></row>
<row _id="597"><id>597</id><FinancialYear>2007/08</FinancialYear><HBT>8</HBT><HBTQF /><Laboratory>Inverclyde</Laboratory><LaboratoryQF /><Results>Severe Dyskaryosis (Invasive)</Results><ResultsQF /><NumberResult>7</NumberResult><PercentageResult>0</PercentageResult></row>
<row _id="598"><id>598</id><FinancialYear>2007/08</FinancialYear><HBT>8</HBT><HBTQF /><Laboratory>Inverclyde</Laboratory><LaboratoryQF /><Results>Glandular Abnormality</Results><ResultsQF /><NumberResult>10</NumberResult><PercentageResult>0</PercentageResult></row>
<row _id="599"><id>599</id><FinancialYear>2007/08</FinancialYear><HBT>8</HBT><HBTQF /><Laboratory>Inverclyde</Laboratory><LaboratoryQF /><Results>Endocervical Adenocarcinoma</Results><ResultsQF /><NumberResult>0</NumberResult><PercentageResult>0</PercentageResult></row>
<row _id="600"><id>600</id><FinancialYear>2007/08</FinancialYear><HBT>8</HBT><HBTQF /><Laboratory>Inverclyde</Laboratory><LaboratoryQF /><Results>Endometrial or other cancer</Results><ResultsQF /><NumberResult>4</NumberResult><PercentageResult>0</PercentageResult></row>
<row _id="601"><id>601</id><FinancialYear>2007/08</FinancialYear><HBT>11</HBT><HBTQF /><Laboratory>Cross House</Laboratory><LaboratoryQF /><Results>Total number of smears</Results><ResultsQF>d</ResultsQF><NumberResult>24477</NumberResult><PercentageResult>100</PercentageResult></row>
<row _id="602"><id>602</id><FinancialYear>2007/08</FinancialYear><HBT>11</HBT><HBTQF /><Laboratory>Cross House</Laboratory><LaboratoryQF /><Results>Unsatisfactory</Results><ResultsQF /><NumberResult>853</NumberResult><PercentageResult>0.2</PercentageResult></row>
<row _id="603"><id>603</id><FinancialYear>2007/08</FinancialYear><HBT>11</HBT><HBTQF /><Laboratory>Cross House</Laboratory><LaboratoryQF /><Results>Negative</Results><ResultsQF /><NumberResult>22190</NumberResult><PercentageResult>93.9</PercentageResult></row>
<row _id="604"><id>604</id><FinancialYear>2007/08</FinancialYear><HBT>11</HBT><HBTQF /><Laboratory>Cross House</Laboratory><LaboratoryQF /><Results>Borderline Squamous Changes</Results><ResultsQF /><NumberResult>731</NumberResult><PercentageResult>3.1</PercentageResult></row>
<row _id="605"><id>605</id><FinancialYear>2007/08</FinancialYear><HBT>11</HBT><HBTQF /><Laboratory>Cross House</Laboratory><LaboratoryQF /><Results>Borderline Glandular Changes</Results><ResultsQF /><NumberResult>22</NumberResult><PercentageResult>0.1</PercentageResult></row>
<row _id="606"><id>606</id><FinancialYear>2007/08</FinancialYear><HBT>11</HBT><HBTQF /><Laboratory>Cross House</Laboratory><LaboratoryQF /><Results>Mild Dyskaryosis</Results><ResultsQF /><NumberResult>384</NumberResult><PercentageResult>1.6</PercentageResult></row>
<row _id="607"><id>607</id><FinancialYear>2007/08</FinancialYear><HBT>11</HBT><HBTQF /><Laboratory>Cross House</Laboratory><LaboratoryQF /><Results>Moderate Dyskaryosis</Results><ResultsQF /><NumberResult>132</NumberResult><PercentageResult>0.6</PercentageResult></row>
<row _id="608"><id>608</id><FinancialYear>2007/08</FinancialYear><HBT>11</HBT><HBTQF /><Laboratory>Cross House</Laboratory><LaboratoryQF /><Results>Severe Dyskaryosis</Results><ResultsQF /><NumberResult>152</NumberResult><PercentageResult>0.6</PercentageResult></row>
<row _id="609"><id>609</id><FinancialYear>2007/08</FinancialYear><HBT>11</HBT><HBTQF /><Laboratory>Cross House</Laboratory><LaboratoryQF /><Results>Severe Dyskaryosis (Invasive)</Results><ResultsQF /><NumberResult>2</NumberResult><PercentageResult>0</PercentageResult></row>
<row _id="610"><id>610</id><FinancialYear>2007/08</FinancialYear><HBT>11</HBT><HBTQF /><Laboratory>Cross House</Laboratory><LaboratoryQF /><Results>Glandular Abnormality</Results><ResultsQF /><NumberResult>9</NumberResult><PercentageResult>0</PercentageResult></row>
<row _id="611"><id>611</id><FinancialYear>2007/08</FinancialYear><HBT>11</HBT><HBTQF /><Laboratory>Cross House</Laboratory><LaboratoryQF /><Results>Endocervical Adenocarcinoma</Results><ResultsQF /><NumberResult>1</NumberResult><PercentageResult>0</PercentageResult></row>
<row _id="612"><id>612</id><FinancialYear>2007/08</FinancialYear><HBT>11</HBT><HBTQF /><Laboratory>Cross House</Laboratory><LaboratoryQF /><Results>Endometrial or other cancer</Results><ResultsQF /><NumberResult>1</NumberResult><PercentageResult>0</PercentageResult></row>
<row _id="613"><id>613</id><FinancialYear>2007/08</FinancialYear><HBT>4</HBT><HBTQF /><Laboratory>Forth Park</Laboratory><LaboratoryQF /><Results>Total number of smears</Results><ResultsQF>d</ResultsQF><NumberResult>23414</NumberResult><PercentageResult>100</PercentageResult></row>
<row _id="614"><id>614</id><FinancialYear>2007/08</FinancialYear><HBT>4</HBT><HBTQF /><Laboratory>Forth Park</Laboratory><LaboratoryQF /><Results>Unsatisfactory</Results><ResultsQF /><NumberResult>356</NumberResult><PercentageResult>0.1</PercentageResult></row>
<row _id="615"><id>615</id><FinancialYear>2007/08</FinancialYear><HBT>4</HBT><HBTQF /><Laboratory>Forth Park</Laboratory><LaboratoryQF /><Results>Negative</Results><ResultsQF /><NumberResult>21575</NumberResult><PercentageResult>93.6</PercentageResult></row>
<row _id="616"><id>616</id><FinancialYear>2007/08</FinancialYear><HBT>4</HBT><HBTQF /><Laboratory>Forth Park</Laboratory><LaboratoryQF /><Results>Borderline Squamous Changes</Results><ResultsQF /><NumberResult>739</NumberResult><PercentageResult>3.2</PercentageResult></row>
<row _id="617"><id>617</id><FinancialYear>2007/08</FinancialYear><HBT>4</HBT><HBTQF /><Laboratory>Forth Park</Laboratory><LaboratoryQF /><Results>Borderline Glandular Changes</Results><ResultsQF /><NumberResult>0</NumberResult><PercentageResult>0</PercentageResult></row>
<row _id="618"><id>618</id><FinancialYear>2007/08</FinancialYear><HBT>4</HBT><HBTQF /><Laboratory>Forth Park</Laboratory><LaboratoryQF /><Results>Mild Dyskaryosis</Results><ResultsQF /><NumberResult>489</NumberResult><PercentageResult>2.1</PercentageResult></row>
<row _id="619"><id>619</id><FinancialYear>2007/08</FinancialYear><HBT>4</HBT><HBTQF /><Laboratory>Forth Park</Laboratory><LaboratoryQF /><Results>Moderate Dyskaryosis</Results><ResultsQF /><NumberResult>148</NumberResult><PercentageResult>0.6</PercentageResult></row>
<row _id="620"><id>620</id><FinancialYear>2007/08</FinancialYear><HBT>4</HBT><HBTQF /><Laboratory>Forth Park</Laboratory><LaboratoryQF /><Results>Severe Dyskaryosis</Results><ResultsQF /><NumberResult>94</NumberResult><PercentageResult>0.4</PercentageResult></row>
<row _id="621"><id>621</id><FinancialYear>2007/08</FinancialYear><HBT>4</HBT><HBTQF /><Laboratory>Forth Park</Laboratory><LaboratoryQF /><Results>Severe Dyskaryosis (Invasive)</Results><ResultsQF /><NumberResult>5</NumberResult><PercentageResult>0</PercentageResult></row>
<row _id="622"><id>622</id><FinancialYear>2007/08</FinancialYear><HBT>4</HBT><HBTQF /><Laboratory>Forth Park</Laboratory><LaboratoryQF /><Results>Glandular Abnormality</Results><ResultsQF /><NumberResult>6</NumberResult><PercentageResult>0</PercentageResult></row>
<row _id="623"><id>623</id><FinancialYear>2007/08</FinancialYear><HBT>4</HBT><HBTQF /><Laboratory>Forth Park</Laboratory><LaboratoryQF /><Results>Endocervical Adenocarcinoma</Results><ResultsQF /><NumberResult>0</NumberResult><PercentageResult>0</PercentageResult></row>
<row _id="624"><id>624</id><FinancialYear>2007/08</FinancialYear><HBT>4</HBT><HBTQF /><Laboratory>Forth Park</Laboratory><LaboratoryQF /><Results>Endometrial or other cancer</Results><ResultsQF /><NumberResult>2</NumberResult><PercentageResult>0</PercentageResult></row>
<row _id="625"><id>625</id><FinancialYear>2007/08</FinancialYear><HBT>7</HBT><HBTQF /><Laboratory>Stirling Royal Infirmary</Laboratory><LaboratoryQF /><Results>Total number of smears</Results><ResultsQF>d</ResultsQF><NumberResult>23026</NumberResult><PercentageResult>100</PercentageResult></row>
<row _id="626"><id>626</id><FinancialYear>2007/08</FinancialYear><HBT>7</HBT><HBTQF /><Laboratory>Stirling Royal Infirmary</Laboratory><LaboratoryQF /><Results>Unsatisfactory</Results><ResultsQF /><NumberResult>410</NumberResult><PercentageResult>0.1</PercentageResult></row>
<row _id="627"><id>627</id><FinancialYear>2007/08</FinancialYear><HBT>7</HBT><HBTQF /><Laboratory>Stirling Royal Infirmary</Laboratory><LaboratoryQF /><Results>Negative</Results><ResultsQF /><NumberResult>20782</NumberResult><PercentageResult>91.9</PercentageResult></row>
<row _id="628"><id>628</id><FinancialYear>2007/08</FinancialYear><HBT>7</HBT><HBTQF /><Laboratory>Stirling Royal Infirmary</Laboratory><LaboratoryQF /><Results>Borderline Squamous Changes</Results><ResultsQF /><NumberResult>974</NumberResult><PercentageResult>4.3</PercentageResult></row>
<row _id="629"><id>629</id><FinancialYear>2007/08</FinancialYear><HBT>7</HBT><HBTQF /><Laboratory>Stirling Royal Infirmary</Laboratory><LaboratoryQF /><Results>Borderline Glandular Changes</Results><ResultsQF /><NumberResult>22</NumberResult><PercentageResult>0.1</PercentageResult></row>
<row _id="630"><id>630</id><FinancialYear>2007/08</FinancialYear><HBT>7</HBT><HBTQF /><Laboratory>Stirling Royal Infirmary</Laboratory><LaboratoryQF /><Results>Mild Dyskaryosis</Results><ResultsQF /><NumberResult>458</NumberResult><PercentageResult>2</PercentageResult></row>
<row _id="631"><id>631</id><FinancialYear>2007/08</FinancialYear><HBT>7</HBT><HBTQF /><Laboratory>Stirling Royal Infirmary</Laboratory><LaboratoryQF /><Results>Moderate Dyskaryosis</Results><ResultsQF /><NumberResult>202</NumberResult><PercentageResult>0.9</PercentageResult></row>
<row _id="632"><id>632</id><FinancialYear>2007/08</FinancialYear><HBT>7</HBT><HBTQF /><Laboratory>Stirling Royal Infirmary</Laboratory><LaboratoryQF /><Results>Severe Dyskaryosis</Results><ResultsQF /><NumberResult>135</NumberResult><PercentageResult>0.6</PercentageResult></row>
<row _id="633"><id>633</id><FinancialYear>2007/08</FinancialYear><HBT>7</HBT><HBTQF /><Laboratory>Stirling Royal Infirmary</Laboratory><LaboratoryQF /><Results>Severe Dyskaryosis (Invasive)</Results><ResultsQF /><NumberResult>11</NumberResult><PercentageResult>0</PercentageResult></row>
<row _id="634"><id>634</id><FinancialYear>2007/08</FinancialYear><HBT>7</HBT><HBTQF /><Laboratory>Stirling Royal Infirmary</Laboratory><LaboratoryQF /><Results>Glandular Abnormality</Results><ResultsQF /><NumberResult>27</NumberResult><PercentageResult>0.1</PercentageResult></row>
<row _id="635"><id>635</id><FinancialYear>2007/08</FinancialYear><HBT>7</HBT><HBTQF /><Laboratory>Stirling Royal Infirmary</Laboratory><LaboratoryQF /><Results>Endocervical Adenocarcinoma</Results><ResultsQF /><NumberResult>2</NumberResult><PercentageResult>0</PercentageResult></row>
<row _id="636"><id>636</id><FinancialYear>2007/08</FinancialYear><HBT>7</HBT><HBTQF /><Laboratory>Stirling Royal Infirmary</Laboratory><LaboratoryQF /><Results>Endometrial or other cancer</Results><ResultsQF /><NumberResult>3</NumberResult><PercentageResult>0</PercentageResult></row>
<row _id="637"><id>637</id><FinancialYear>2007/08</FinancialYear><HBT>2</HBT><HBTQF /><Laboratory>Forester Hill</Laboratory><LaboratoryQF /><Results>Total number of smears</Results><ResultsQF>d</ResultsQF><NumberResult>42870</NumberResult><PercentageResult>100</PercentageResult></row>
<row _id="638"><id>638</id><FinancialYear>2007/08</FinancialYear><HBT>2</HBT><HBTQF /><Laboratory>Forester Hill</Laboratory><LaboratoryQF /><Results>Unsatisfactory</Results><ResultsQF /><NumberResult>1134</NumberResult><PercentageResult>0.3</PercentageResult></row>
<row _id="639"><id>639</id><FinancialYear>2007/08</FinancialYear><HBT>2</HBT><HBTQF /><Laboratory>Forester Hill</Laboratory><LaboratoryQF /><Results>Negative</Results><ResultsQF /><NumberResult>38388</NumberResult><PercentageResult>92</PercentageResult></row>
<row _id="640"><id>640</id><FinancialYear>2007/08</FinancialYear><HBT>2</HBT><HBTQF /><Laboratory>Forester Hill</Laboratory><LaboratoryQF /><Results>Borderline Squamous Changes</Results><ResultsQF /><NumberResult>1982</NumberResult><PercentageResult>4.7</PercentageResult></row>
<row _id="641"><id>641</id><FinancialYear>2007/08</FinancialYear><HBT>2</HBT><HBTQF /><Laboratory>Forester Hill</Laboratory><LaboratoryQF /><Results>Borderline Glandular Changes</Results><ResultsQF /><NumberResult>11</NumberResult><PercentageResult>0</PercentageResult></row>
<row _id="642"><id>642</id><FinancialYear>2007/08</FinancialYear><HBT>2</HBT><HBTQF /><Laboratory>Forester Hill</Laboratory><LaboratoryQF /><Results>Mild Dyskaryosis</Results><ResultsQF /><NumberResult>722</NumberResult><PercentageResult>1.7</PercentageResult></row>
<row _id="643"><id>643</id><FinancialYear>2007/08</FinancialYear><HBT>2</HBT><HBTQF /><Laboratory>Forester Hill</Laboratory><LaboratoryQF /><Results>Moderate Dyskaryosis</Results><ResultsQF /><NumberResult>341</NumberResult><PercentageResult>0.8</PercentageResult></row>
<row _id="644"><id>644</id><FinancialYear>2007/08</FinancialYear><HBT>2</HBT><HBTQF /><Laboratory>Forester Hill</Laboratory><LaboratoryQF /><Results>Severe Dyskaryosis</Results><ResultsQF /><NumberResult>268</NumberResult><PercentageResult>0.6</PercentageResult></row>
<row _id="645"><id>645</id><FinancialYear>2007/08</FinancialYear><HBT>2</HBT><HBTQF /><Laboratory>Forester Hill</Laboratory><LaboratoryQF /><Results>Severe Dyskaryosis (Invasive)</Results><ResultsQF /><NumberResult>6</NumberResult><PercentageResult>0</PercentageResult></row>
<row _id="646"><id>646</id><FinancialYear>2007/08</FinancialYear><HBT>2</HBT><HBTQF /><Laboratory>Forester Hill</Laboratory><LaboratoryQF /><Results>Glandular Abnormality</Results><ResultsQF /><NumberResult>17</NumberResult><PercentageResult>0</PercentageResult></row>
<row _id="647"><id>647</id><FinancialYear>2007/08</FinancialYear><HBT>2</HBT><HBTQF /><Laboratory>Forester Hill</Laboratory><LaboratoryQF /><Results>Endocervical Adenocarcinoma</Results><ResultsQF /><NumberResult>0</NumberResult><PercentageResult>0</PercentageResult></row>
<row _id="648"><id>648</id><FinancialYear>2007/08</FinancialYear><HBT>2</HBT><HBTQF /><Laboratory>Forester Hill</Laboratory><LaboratoryQF /><Results>Endometrial or other cancer</Results><ResultsQF /><NumberResult>1</NumberResult><PercentageResult>0</PercentageResult></row>
<row _id="649"><id>649</id><FinancialYear>2007/08</FinancialYear><HBT>9</HBT><HBTQF /><Laboratory>Southern General</Laboratory><LaboratoryQF /><Results>Total number of smears</Results><ResultsQF>d</ResultsQF><NumberResult>23679</NumberResult><PercentageResult>100</PercentageResult></row>
<row _id="650"><id>650</id><FinancialYear>2007/08</FinancialYear><HBT>9</HBT><HBTQF /><Laboratory>Southern General</Laboratory><LaboratoryQF /><Results>Unsatisfactory</Results><ResultsQF /><NumberResult>628</NumberResult><PercentageResult>1.5</PercentageResult></row>
<row _id="651"><id>651</id><FinancialYear>2007/08</FinancialYear><HBT>9</HBT><HBTQF /><Laboratory>Southern General</Laboratory><LaboratoryQF /><Results>Negative</Results><ResultsQF /><NumberResult>21408</NumberResult><PercentageResult>92.9</PercentageResult></row>
<row _id="652"><id>652</id><FinancialYear>2007/08</FinancialYear><HBT>9</HBT><HBTQF /><Laboratory>Southern General</Laboratory><LaboratoryQF /><Results>Borderline Squamous Changes</Results><ResultsQF /><NumberResult>921</NumberResult><PercentageResult>4</PercentageResult></row>
<row _id="653"><id>653</id><FinancialYear>2007/08</FinancialYear><HBT>9</HBT><HBTQF /><Laboratory>Southern General</Laboratory><LaboratoryQF /><Results>Borderline Glandular Changes</Results><ResultsQF /><NumberResult>6</NumberResult><PercentageResult>0</PercentageResult></row>
<row _id="654"><id>654</id><FinancialYear>2007/08</FinancialYear><HBT>9</HBT><HBTQF /><Laboratory>Southern General</Laboratory><LaboratoryQF /><Results>Mild Dyskaryosis</Results><ResultsQF /><NumberResult>510</NumberResult><PercentageResult>2.2</PercentageResult></row>
<row _id="655"><id>655</id><FinancialYear>2007/08</FinancialYear><HBT>9</HBT><HBTQF /><Laboratory>Southern General</Laboratory><LaboratoryQF /><Results>Moderate Dyskaryosis</Results><ResultsQF /><NumberResult>100</NumberResult><PercentageResult>0.4</PercentageResult></row>
<row _id="656"><id>656</id><FinancialYear>2007/08</FinancialYear><HBT>9</HBT><HBTQF /><Laboratory>Southern General</Laboratory><LaboratoryQF /><Results>Severe Dyskaryosis</Results><ResultsQF /><NumberResult>97</NumberResult><PercentageResult>0.4</PercentageResult></row>
<row _id="657"><id>657</id><FinancialYear>2007/08</FinancialYear><HBT>9</HBT><HBTQF /><Laboratory>Southern General</Laboratory><LaboratoryQF /><Results>Severe Dyskaryosis (Invasive)</Results><ResultsQF /><NumberResult>3</NumberResult><PercentageResult>0</PercentageResult></row>
<row _id="658"><id>658</id><FinancialYear>2007/08</FinancialYear><HBT>9</HBT><HBTQF /><Laboratory>Southern General</Laboratory><LaboratoryQF /><Results>Glandular Abnormality</Results><ResultsQF /><NumberResult>4</NumberResult><PercentageResult>0</PercentageResult></row>
<row _id="659"><id>659</id><FinancialYear>2007/08</FinancialYear><HBT>9</HBT><HBTQF /><Laboratory>Southern General</Laboratory><LaboratoryQF /><Results>Endocervical Adenocarcinoma</Results><ResultsQF /><NumberResult>1</NumberResult><PercentageResult>0</PercentageResult></row>
<row _id="660"><id>660</id><FinancialYear>2007/08</FinancialYear><HBT>9</HBT><HBTQF /><Laboratory>Southern General</Laboratory><LaboratoryQF /><Results>Endometrial or other cancer</Results><ResultsQF /><NumberResult>1</NumberResult><PercentageResult>0</PercentageResult></row>
<row _id="661"><id>661</id><FinancialYear>2007/08</FinancialYear><HBT>9</HBT><HBTQF /><Laboratory>Royal Infirmary</Laboratory><LaboratoryQF /><Results>Total number of smears</Results><ResultsQF>d</ResultsQF><NumberResult>39868</NumberResult><PercentageResult>100</PercentageResult></row>
<row _id="662"><id>662</id><FinancialYear>2007/08</FinancialYear><HBT>9</HBT><HBTQF /><Laboratory>Royal Infirmary</Laboratory><LaboratoryQF /><Results>Unsatisfactory</Results><ResultsQF /><NumberResult>1134</NumberResult><PercentageResult>2.7</PercentageResult></row>
<row _id="663"><id>663</id><FinancialYear>2007/08</FinancialYear><HBT>9</HBT><HBTQF /><Laboratory>Royal Infirmary</Laboratory><LaboratoryQF /><Results>Negative</Results><ResultsQF /><NumberResult>34435</NumberResult><PercentageResult>88.9</PercentageResult></row>
<row _id="664"><id>664</id><FinancialYear>2007/08</FinancialYear><HBT>9</HBT><HBTQF /><Laboratory>Royal Infirmary</Laboratory><LaboratoryQF /><Results>Borderline Squamous Changes</Results><ResultsQF /><NumberResult>2469</NumberResult><PercentageResult>6.4</PercentageResult></row>
<row _id="665"><id>665</id><FinancialYear>2007/08</FinancialYear><HBT>9</HBT><HBTQF /><Laboratory>Royal Infirmary</Laboratory><LaboratoryQF /><Results>Borderline Glandular Changes</Results><ResultsQF /><NumberResult>16</NumberResult><PercentageResult>0</PercentageResult></row>
<row _id="666"><id>666</id><FinancialYear>2007/08</FinancialYear><HBT>9</HBT><HBTQF /><Laboratory>Royal Infirmary</Laboratory><LaboratoryQF /><Results>Mild Dyskaryosis</Results><ResultsQF /><NumberResult>1177</NumberResult><PercentageResult>3</PercentageResult></row>
<row _id="667"><id>667</id><FinancialYear>2007/08</FinancialYear><HBT>9</HBT><HBTQF /><Laboratory>Royal Infirmary</Laboratory><LaboratoryQF /><Results>Moderate Dyskaryosis</Results><ResultsQF /><NumberResult>366</NumberResult><PercentageResult>0.9</PercentageResult></row>
<row _id="668"><id>668</id><FinancialYear>2007/08</FinancialYear><HBT>9</HBT><HBTQF /><Laboratory>Royal Infirmary</Laboratory><LaboratoryQF /><Results>Severe Dyskaryosis</Results><ResultsQF /><NumberResult>243</NumberResult><PercentageResult>0.6</PercentageResult></row>
<row _id="669"><id>669</id><FinancialYear>2007/08</FinancialYear><HBT>9</HBT><HBTQF /><Laboratory>Royal Infirmary</Laboratory><LaboratoryQF /><Results>Severe Dyskaryosis (Invasive)</Results><ResultsQF /><NumberResult>13</NumberResult><PercentageResult>0</PercentageResult></row>
<row _id="670"><id>670</id><FinancialYear>2007/08</FinancialYear><HBT>9</HBT><HBTQF /><Laboratory>Royal Infirmary</Laboratory><LaboratoryQF /><Results>Glandular Abnormality</Results><ResultsQF /><NumberResult>13</NumberResult><PercentageResult>0</PercentageResult></row>
<row _id="671"><id>671</id><FinancialYear>2007/08</FinancialYear><HBT>9</HBT><HBTQF /><Laboratory>Royal Infirmary</Laboratory><LaboratoryQF /><Results>Endocervical Adenocarcinoma</Results><ResultsQF /><NumberResult>0</NumberResult><PercentageResult>0</PercentageResult></row>
<row _id="672"><id>672</id><FinancialYear>2007/08</FinancialYear><HBT>9</HBT><HBTQF /><Laboratory>Royal Infirmary</Laboratory><LaboratoryQF /><Results>Endometrial or other cancer</Results><ResultsQF /><NumberResult>2</NumberResult><PercentageResult>0</PercentageResult></row>
<row _id="673"><id>673</id><FinancialYear>2007/08</FinancialYear><HBT>1</HBT><HBTQF /><Laboratory>Raigmore</Laboratory><LaboratoryQF /><Results>Total number of smears</Results><ResultsQF>d</ResultsQF><NumberResult>17154</NumberResult><PercentageResult>100</PercentageResult></row>
<row _id="674"><id>674</id><FinancialYear>2007/08</FinancialYear><HBT>1</HBT><HBTQF /><Laboratory>Raigmore</Laboratory><LaboratoryQF /><Results>Unsatisfactory</Results><ResultsQF /><NumberResult>547</NumberResult><PercentageResult>1.3</PercentageResult></row>
<row _id="675"><id>675</id><FinancialYear>2007/08</FinancialYear><HBT>1</HBT><HBTQF /><Laboratory>Raigmore</Laboratory><LaboratoryQF /><Results>Negative</Results><ResultsQF /><NumberResult>15628</NumberResult><PercentageResult>94.1</PercentageResult></row>
<row _id="676"><id>676</id><FinancialYear>2007/08</FinancialYear><HBT>1</HBT><HBTQF /><Laboratory>Raigmore</Laboratory><LaboratoryQF /><Results>Borderline Squamous Changes</Results><ResultsQF /><NumberResult>498</NumberResult><PercentageResult>3</PercentageResult></row>
<row _id="677"><id>677</id><FinancialYear>2007/08</FinancialYear><HBT>1</HBT><HBTQF /><Laboratory>Raigmore</Laboratory><LaboratoryQF /><Results>Borderline Glandular Changes</Results><ResultsQF /><NumberResult>7</NumberResult><PercentageResult>0</PercentageResult></row>
<row _id="678"><id>678</id><FinancialYear>2007/08</FinancialYear><HBT>1</HBT><HBTQF /><Laboratory>Raigmore</Laboratory><LaboratoryQF /><Results>Mild Dyskaryosis</Results><ResultsQF /><NumberResult>230</NumberResult><PercentageResult>1.4</PercentageResult></row>
<row _id="679"><id>679</id><FinancialYear>2007/08</FinancialYear><HBT>1</HBT><HBTQF /><Laboratory>Raigmore</Laboratory><LaboratoryQF /><Results>Moderate Dyskaryosis</Results><ResultsQF /><NumberResult>83</NumberResult><PercentageResult>0.5</PercentageResult></row>
<row _id="680"><id>680</id><FinancialYear>2007/08</FinancialYear><HBT>1</HBT><HBTQF /><Laboratory>Raigmore</Laboratory><LaboratoryQF /><Results>Severe Dyskaryosis</Results><ResultsQF /><NumberResult>152</NumberResult><PercentageResult>0.9</PercentageResult></row>
<row _id="681"><id>681</id><FinancialYear>2007/08</FinancialYear><HBT>1</HBT><HBTQF /><Laboratory>Raigmore</Laboratory><LaboratoryQF /><Results>Severe Dyskaryosis (Invasive)</Results><ResultsQF /><NumberResult>3</NumberResult><PercentageResult>0</PercentageResult></row>
<row _id="682"><id>682</id><FinancialYear>2007/08</FinancialYear><HBT>1</HBT><HBTQF /><Laboratory>Raigmore</Laboratory><LaboratoryQF /><Results>Glandular Abnormality</Results><ResultsQF /><NumberResult>2</NumberResult><PercentageResult>0</PercentageResult></row>
<row _id="683"><id>683</id><FinancialYear>2007/08</FinancialYear><HBT>1</HBT><HBTQF /><Laboratory>Raigmore</Laboratory><LaboratoryQF /><Results>Endocervical Adenocarcinoma</Results><ResultsQF /><NumberResult>2</NumberResult><PercentageResult>0</PercentageResult></row>
<row _id="684"><id>684</id><FinancialYear>2007/08</FinancialYear><HBT>1</HBT><HBTQF /><Laboratory>Raigmore</Laboratory><LaboratoryQF /><Results>Endometrial or other cancer</Results><ResultsQF /><NumberResult>2</NumberResult><PercentageResult>0</PercentageResult></row>
<row _id="685"><id>685</id><FinancialYear>2007/08</FinancialYear><HBT>10</HBT><HBTQF /><Laboratory>Monklands</Laboratory><LaboratoryQF /><Results>Total number of smears</Results><ResultsQF>d</ResultsQF><NumberResult>50235</NumberResult><PercentageResult>100</PercentageResult></row>
<row _id="686"><id>686</id><FinancialYear>2007/08</FinancialYear><HBT>10</HBT><HBTQF /><Laboratory>Monklands</Laboratory><LaboratoryQF /><Results>Unsatisfactory</Results><ResultsQF /><NumberResult>1642</NumberResult><PercentageResult>3.9</PercentageResult></row>
<row _id="687"><id>687</id><FinancialYear>2007/08</FinancialYear><HBT>10</HBT><HBTQF /><Laboratory>Monklands</Laboratory><LaboratoryQF /><Results>Negative</Results><ResultsQF /><NumberResult>45448</NumberResult><PercentageResult>93.5</PercentageResult></row>
<row _id="688"><id>688</id><FinancialYear>2007/08</FinancialYear><HBT>10</HBT><HBTQF /><Laboratory>Monklands</Laboratory><LaboratoryQF /><Results>Borderline Squamous Changes</Results><ResultsQF /><NumberResult>1869</NumberResult><PercentageResult>3.8</PercentageResult></row>
<row _id="689"><id>689</id><FinancialYear>2007/08</FinancialYear><HBT>10</HBT><HBTQF /><Laboratory>Monklands</Laboratory><LaboratoryQF /><Results>Borderline Glandular Changes</Results><ResultsQF /><NumberResult>17</NumberResult><PercentageResult>0</PercentageResult></row>
<row _id="690"><id>690</id><FinancialYear>2007/08</FinancialYear><HBT>10</HBT><HBTQF /><Laboratory>Monklands</Laboratory><LaboratoryQF /><Results>Mild Dyskaryosis</Results><ResultsQF /><NumberResult>650</NumberResult><PercentageResult>1.3</PercentageResult></row>
<row _id="691"><id>691</id><FinancialYear>2007/08</FinancialYear><HBT>10</HBT><HBTQF /><Laboratory>Monklands</Laboratory><LaboratoryQF /><Results>Moderate Dyskaryosis</Results><ResultsQF /><NumberResult>251</NumberResult><PercentageResult>0.5</PercentageResult></row>
<row _id="692"><id>692</id><FinancialYear>2007/08</FinancialYear><HBT>10</HBT><HBTQF /><Laboratory>Monklands</Laboratory><LaboratoryQF /><Results>Severe Dyskaryosis</Results><ResultsQF /><NumberResult>327</NumberResult><PercentageResult>0.7</PercentageResult></row>
<row _id="693"><id>693</id><FinancialYear>2007/08</FinancialYear><HBT>10</HBT><HBTQF /><Laboratory>Monklands</Laboratory><LaboratoryQF /><Results>Severe Dyskaryosis (Invasive)</Results><ResultsQF /><NumberResult>11</NumberResult><PercentageResult>0</PercentageResult></row>
<row _id="694"><id>694</id><FinancialYear>2007/08</FinancialYear><HBT>10</HBT><HBTQF /><Laboratory>Monklands</Laboratory><LaboratoryQF /><Results>Glandular Abnormality</Results><ResultsQF /><NumberResult>17</NumberResult><PercentageResult>0</PercentageResult></row>
<row _id="695"><id>695</id><FinancialYear>2007/08</FinancialYear><HBT>10</HBT><HBTQF /><Laboratory>Monklands</Laboratory><LaboratoryQF /><Results>Endocervical Adenocarcinoma</Results><ResultsQF /><NumberResult>1</NumberResult><PercentageResult>0</PercentageResult></row>
<row _id="696"><id>696</id><FinancialYear>2007/08</FinancialYear><HBT>10</HBT><HBTQF /><Laboratory>Monklands</Laboratory><LaboratoryQF /><Results>Endometrial or other cancer</Results><ResultsQF /><NumberResult>2</NumberResult><PercentageResult>0</PercentageResult></row>
<row _id="697"><id>697</id><FinancialYear>2007/08</FinancialYear><HBT>5</HBT><HBTQF /><Laboratory>Edinburgh Royal Infirmary</Laboratory><LaboratoryQF /><Results>Total number of smears</Results><ResultsQF>d</ResultsQF><NumberResult>71629</NumberResult><PercentageResult>100</PercentageResult></row>
<row _id="698"><id>698</id><FinancialYear>2007/08</FinancialYear><HBT>5</HBT><HBTQF /><Laboratory>Edinburgh Royal Infirmary</Laboratory><LaboratoryQF /><Results>Unsatisfactory</Results><ResultsQF /><NumberResult>2858</NumberResult><PercentageResult>6.8</PercentageResult></row>
<row _id="699"><id>699</id><FinancialYear>2007/08</FinancialYear><HBT>5</HBT><HBTQF /><Laboratory>Edinburgh Royal Infirmary</Laboratory><LaboratoryQF /><Results>Negative</Results><ResultsQF /><NumberResult>63073</NumberResult><PercentageResult>91.7</PercentageResult></row>
<row _id="700"><id>700</id><FinancialYear>2007/08</FinancialYear><HBT>5</HBT><HBTQF /><Laboratory>Edinburgh Royal Infirmary</Laboratory><LaboratoryQF /><Results>Borderline Squamous Changes</Results><ResultsQF /><NumberResult>3000</NumberResult><PercentageResult>4.4</PercentageResult></row>
<row _id="701"><id>701</id><FinancialYear>2007/08</FinancialYear><HBT>5</HBT><HBTQF /><Laboratory>Edinburgh Royal Infirmary</Laboratory><LaboratoryQF /><Results>Borderline Glandular Changes</Results><ResultsQF /><NumberResult>55</NumberResult><PercentageResult>0.1</PercentageResult></row>
<row _id="702"><id>702</id><FinancialYear>2007/08</FinancialYear><HBT>5</HBT><HBTQF /><Laboratory>Edinburgh Royal Infirmary</Laboratory><LaboratoryQF /><Results>Mild Dyskaryosis</Results><ResultsQF /><NumberResult>1726</NumberResult><PercentageResult>2.5</PercentageResult></row>
<row _id="703"><id>703</id><FinancialYear>2007/08</FinancialYear><HBT>5</HBT><HBTQF /><Laboratory>Edinburgh Royal Infirmary</Laboratory><LaboratoryQF /><Results>Moderate Dyskaryosis</Results><ResultsQF /><NumberResult>457</NumberResult><PercentageResult>0.7</PercentageResult></row>
<row _id="704"><id>704</id><FinancialYear>2007/08</FinancialYear><HBT>5</HBT><HBTQF /><Laboratory>Edinburgh Royal Infirmary</Laboratory><LaboratoryQF /><Results>Severe Dyskaryosis</Results><ResultsQF /><NumberResult>413</NumberResult><PercentageResult>0.6</PercentageResult></row>
<row _id="705"><id>705</id><FinancialYear>2007/08</FinancialYear><HBT>5</HBT><HBTQF /><Laboratory>Edinburgh Royal Infirmary</Laboratory><LaboratoryQF /><Results>Severe Dyskaryosis (Invasive)</Results><ResultsQF /><NumberResult>17</NumberResult><PercentageResult>0</PercentageResult></row>
<row _id="706"><id>706</id><FinancialYear>2007/08</FinancialYear><HBT>5</HBT><HBTQF /><Laboratory>Edinburgh Royal Infirmary</Laboratory><LaboratoryQF /><Results>Glandular Abnormality</Results><ResultsQF /><NumberResult>21</NumberResult><PercentageResult>0</PercentageResult></row>
<row _id="707"><id>707</id><FinancialYear>2007/08</FinancialYear><HBT>5</HBT><HBTQF /><Laboratory>Edinburgh Royal Infirmary</Laboratory><LaboratoryQF /><Results>Endocervical Adenocarcinoma</Results><ResultsQF /><NumberResult>2</NumberResult><PercentageResult>0</PercentageResult></row>
<row _id="708"><id>708</id><FinancialYear>2007/08</FinancialYear><HBT>5</HBT><HBTQF /><Laboratory>Edinburgh Royal Infirmary</Laboratory><LaboratoryQF /><Results>Endometrial or other cancer</Results><ResultsQF /><NumberResult>7</NumberResult><PercentageResult>0</PercentageResult></row>
<row _id="709"><id>709</id><FinancialYear>2007/08</FinancialYear><HBT>3</HBT><HBTQF /><Laboratory>Dundee Royal Infirmary</Laboratory><LaboratoryQF /><Results>Total number of smears</Results><ResultsQF>d</ResultsQF><NumberResult>28662</NumberResult><PercentageResult>100</PercentageResult></row>
<row _id="710"><id>710</id><FinancialYear>2007/08</FinancialYear><HBT>3</HBT><HBTQF /><Laboratory>Dundee Royal Infirmary</Laboratory><LaboratoryQF /><Results>Unsatisfactory</Results><ResultsQF /><NumberResult>510</NumberResult><PercentageResult>1.2</PercentageResult></row>
<row _id="711"><id>711</id><FinancialYear>2007/08</FinancialYear><HBT>3</HBT><HBTQF /><Laboratory>Dundee Royal Infirmary</Laboratory><LaboratoryQF /><Results>Negative</Results><ResultsQF /><NumberResult>26562</NumberResult><PercentageResult>94.4</PercentageResult></row>
<row _id="712"><id>712</id><FinancialYear>2007/08</FinancialYear><HBT>3</HBT><HBTQF /><Laboratory>Dundee Royal Infirmary</Laboratory><LaboratoryQF /><Results>Borderline Squamous Changes</Results><ResultsQF /><NumberResult>773</NumberResult><PercentageResult>2.7</PercentageResult></row>
<row _id="713"><id>713</id><FinancialYear>2007/08</FinancialYear><HBT>3</HBT><HBTQF /><Laboratory>Dundee Royal Infirmary</Laboratory><LaboratoryQF /><Results>Borderline Glandular Changes</Results><ResultsQF /><NumberResult>17</NumberResult><PercentageResult>0.1</PercentageResult></row>
<row _id="714"><id>714</id><FinancialYear>2007/08</FinancialYear><HBT>3</HBT><HBTQF /><Laboratory>Dundee Royal Infirmary</Laboratory><LaboratoryQF /><Results>Mild Dyskaryosis</Results><ResultsQF /><NumberResult>431</NumberResult><PercentageResult>1.5</PercentageResult></row>
<row _id="715"><id>715</id><FinancialYear>2007/08</FinancialYear><HBT>3</HBT><HBTQF /><Laboratory>Dundee Royal Infirmary</Laboratory><LaboratoryQF /><Results>Moderate Dyskaryosis</Results><ResultsQF /><NumberResult>165</NumberResult><PercentageResult>0.6</PercentageResult></row>
<row _id="716"><id>716</id><FinancialYear>2007/08</FinancialYear><HBT>3</HBT><HBTQF /><Laboratory>Dundee Royal Infirmary</Laboratory><LaboratoryQF /><Results>Severe Dyskaryosis</Results><ResultsQF /><NumberResult>181</NumberResult><PercentageResult>0.6</PercentageResult></row>
<row _id="717"><id>717</id><FinancialYear>2007/08</FinancialYear><HBT>3</HBT><HBTQF /><Laboratory>Dundee Royal Infirmary</Laboratory><LaboratoryQF /><Results>Severe Dyskaryosis (Invasive)</Results><ResultsQF /><NumberResult>8</NumberResult><PercentageResult>0</PercentageResult></row>
<row _id="718"><id>718</id><FinancialYear>2007/08</FinancialYear><HBT>3</HBT><HBTQF /><Laboratory>Dundee Royal Infirmary</Laboratory><LaboratoryQF /><Results>Glandular Abnormality</Results><ResultsQF /><NumberResult>10</NumberResult><PercentageResult>0</PercentageResult></row>
<row _id="719"><id>719</id><FinancialYear>2007/08</FinancialYear><HBT>3</HBT><HBTQF /><Laboratory>Dundee Royal Infirmary</Laboratory><LaboratoryQF /><Results>Endocervical Adenocarcinoma</Results><ResultsQF /><NumberResult>2</NumberResult><PercentageResult>0</PercentageResult></row>
<row _id="720"><id>720</id><FinancialYear>2007/08</FinancialYear><HBT>3</HBT><HBTQF /><Laboratory>Dundee Royal Infirmary</Laboratory><LaboratoryQF /><Results>Endometrial or other cancer</Results><ResultsQF /><NumberResult>3</NumberResult><PercentageResult>0</PercentageResult></row>
</data>
